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ABSTRACT 
Due to the abuse of antibiotics for chicken’s growth promotion and the rapid 
emergence of multi-drug resistant Salmonella infections of animal intestine, there is 
increasing pressure to use nonantibiotics to promote animal health. Bacteriophage use 
is therefore a potential alternative. In this study, a lytic gut phage vB_SenM-PA13076 
(PA13076) infecting Salmonella Enteritidis was isolated from fecal samples of 
chickens, while a temperate gut phage vB_SpuP-BP96115 (BP96115) was induced by 
mitomycin C from a Salmonella Pullorum gut isolate. Transmission electron 
microscopy (TEM) indicated that the isolated lytic phage belonged to the family 
Myoviridae, with an oval head (66±4 nm) and a contractile tail (90±5 nm). However, 
the temperate phage matched the family Podoviridae of the C1 morphotype, 
possessing a small head (diameter, 54±4 nm) and a short tail (10±2 nm) with fibers. 
One-step growth curves under optimal growth conditions revealed the latent periods 
of both phages to be 10 min and burst sizes of 21 and 24 PFU per infected cell, for the 
lytic and temperate phage, respectively. The lytic gut phage PA13076 had a broad host 
range, infecting 222 out of 311 tested Salmonella strains representing different 
serovars. However, the temperate phage BP96115 had a narrow host range with the 
lytic effect on only 34.61% (9/26) of tested Salmonella enterica subsp. enterica 
strains. The complete linear genome sequences of PA13076 and BP96115 comprised 
of 52,474 bp and 41,264 bp and contained 69 and 62 ORFs, respectively. 
Bioinformatic analyses identified 44 and 47 ORFs in the genome of PA13076 and 
BP96115, coding for DNA packaging and morphogenetic proteins, lysis components, 
and proteins necessary for DNA recombination, regulation, modification and 
replication. The temperate phage BP96115 also carried the functional lysogeny 
modules. Furthermore, comparative genome sequence analysis revealed a high 
similarity of gut phage PA13076 with the two Salmonella phages BP63 and UPF_BP2 
(97% sequence identities), while the temperate phage BP96115 showed high 
similarity to several temperate phages, especially enterobacteria phage ST104 with 99% 
sequence identity.  
In order to elucidate the colonization of the gastrointestinal tract of mice by phages, 
the lytic gut phage PA13076 and the temperate gut phage BP96115 were fed to mice. 
Moreover, phage titers in blood and spleen were detected to verify the phage 
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penetration. Both phages were purified to reduce the endotoxin levels of phage 
PA13076 and BP96115 solutions to <1 EU/mL. For the animal experiment, 60 female 
mice were divided into a control group, a lytic group, and a temperate group on the 
basis of body weight. About 4×108 PFU of phages were fed daily to each mouse in the 
lytic or the temperate group via drinking water over 31 days. Results showed that 
phage titers were similar at day 16 and day 31 in different segments of the 
gastrointestinal tract. Both phages survived in the gastrointestinal tract, and highest 
phage titers were detected in the cecum as well as in feces with 104 and 106 PFU/g for 
PA13076 and BP96115. In addition, phages entered the bloodstream and appeared in 
spleen of mice. The phage titer in blood was at 102~103 PFU/mL, while in the spleen 
tissue, the titer of the lytic phage was lower than the temperate phage titer. Oral 
administration of both phages over 31 days induced a slight but not significant 
increase of serum IgG and ileal secretory IgA (sIgA) levels. 
The overuse of antibiotics in livestock has led to a series of threats to public health, 
especially the rapid emergence of gut superbugs. Phages, the most abundant species in 
the mammalian gut, have numerous advantages over antibiotics. In this study, mice 
were orally treated with the lytic gut phage PA13076 (group B), the temperate phage 
BP96115 (group C), no phage (group A) or streptomycin (group D) over 31 days. At 
the end of the experiment, fecal microbiota diversity and composition was determined 
and compared using high-throughput sequencing of the V3-V4 hyper-variable region 
of the 16S rRNA gene and virus-like-particles (VLPs) were quantified in feces. There 
was high diversity and richness of microbiota in the lytic and temperate gut phage 
treated mice, with the lytic gut phage causing an increased alpha diversity based on 
the Chao 1 index (p<0.01). However, the streptomycin treatment reduced the 
microbiota diversity and richness (p=0.0299). Both phage and streptomycin 
treatments reduced the abundance of Bacteroidetes at the phylum level and increased 
the abundance of the phylum Firmicutes. Interestingly, two beneficial genera, 
Lactobacillus and Bifidobacterium, were enhanced by treatment with the lytic and 
temperate gut phage. The abundance of the genus Escherichia/Shigella was higher in 
mice after temperate phage administration than in the control group, but lower than in 
the streptomycin group. Moreover, streptomycin treatment increased the abundance of 
the genera Klebsiella and Escherichia/Shigella. In terms of the gut virome, fecal 
VLPs did not change significantly after phage treatment. This study showed that lytic 
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and temperate gut phage treatment modulated the composition and diversity of gut 
microbiota and the lytic gut phage promoted a beneficial gut ecosystem, while the 
temperate phage may promote conditions enabling diseases to occur. 
Several studies have shown the efficacy of phage therapy in reducing intestinal 
pathogens. However, phage-based probiotic treatment is poorly studied in view of 
effects on the gut microbiota and intestinal inflammation. In this study, lytic 
(approximate 4×108 PFU per day) or temperate phages (approximate 4×108 PFU per 
day) or a streptomycin solution (approximate 40mg per day) were preadministered to 
mice via drinking water for 31 days. Subsequently, mice were challenged with 
Salmonella Typhimurium, which was not the host of both phages, and the 
composition of the gut microbiota and the counts of Enterobacteriaceae and 
Lactobacillus spp. in cecum were determined and compared with those of non-treated 
mice or mice challenged with Salmonella Typhimurium. For intestinal inflammation 
evaluation, mice were given one dose of streptomycin for 24h before the Salmonella 
Typhimurium challenge. High-throughput sequencing analysis revealed that the 
phylum Firmicutes became the most abundant, while the phylum Actinobacteria 
increased and the phylum Tenericutes declined in pretreatment with both phages. The 
alpha diversity of bacterial communities was higher in these two groups compared to 
other groups. Moreover, pretreatment with the lytic and the temperate phage before 
bacteria challenge increased two beneficial genera, Lactobacillus and Bifidobacterium. 
However, in mice pretreated with the temperate phage, an increased abundance of the 
genus Escherichia/Shigella was noted. Counts of Enterobacteriaceae and 
Lactobacillus spp. in the mice pretreated with phages were not different from the 
control mice. According to the pathological analysis of ileum and cecum, the 
pretreatment using temperate or lytic gut phage markedly reduced intestinal 
inflammation, which was also confirmed by the lower concentration of LPS and DAO 
in the serum and lower expression of most of inflammatory cytokines in the jejunum 
compared to the mice challenged with Salmonella Typhimurium and streptomycin 
treated mice.  
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INTRODUCTION 
The rapid emergence of multi-drug-resistant Salmonella spp. and the serious damage 
inflicted upon the bacterial flora in the gut due to antibiotic overuse are an emerging 
global crisis (Gould and Bal, 2013; Martin et al., 2015; Ventola, 2015), reflecting the 
worldwide misuse of antimicrobial agents in animal breeding (Bartlett et al., 2013; 
Park et al., 2017). Most of the antimicrobial agents are used globally as growth 
supplements in livestock production (Van Boeckel et al., 2015). A study showed that 
92,700 tons of antibiotics inclusive of 36 kinds of antibiotics were consumed in China 
in 2013, of which 52% were consumed by animals (Zhang et al., 2015). The incidence 
of intestinal Salmonella spp. infections has increased dramatically in recent years in 
poultry and pig farming (Christenson, 2013). There are more than 93 million cases of 
foodborne salmonellosis annually (Majowicz et al., 2010), at an average cost of more 
than $1000 per case in each country (FCC, 2011; Scharff, 2012). The European Union 
began to restrict antibiotics use as growth promoters for farm animals (EC, 2005). 
Therefore, research has been carried out to identify alternatives to antibiotics such as 
bacteriophages, probiotics, enzymes, and organic acids (Bourassa et al., 2018; Cresci 
et al., 2013; Golkar et al., 2014; Koyuncu et al., 2013).  
Among the alternatives to antibiotics, bacteriophages (phages), which are the most 
abundant entities on earth, can attack and kill a target bacterium, including even 
multi-drug resistant bacteria (Ahmadi et al., 2016; Hong et al., 2016; Latz et al., 2016). 
For many years, phages have been used to biocontrol infections caused by pathogenic 
bacteria in animals (Housby and Mann, 2009; Sharma et al., 2017). Phages inevitably 
encounter diverse enteric pathogens and other microorganisms in the complex gut 
ecosystem of animals (Olivo et al., 2016). However, little is known about the role of 
phages in the gut.  
Perhaps as many as 1015 phage particles exist in the mammalian gut, collectively 
referred to as the ‘phageome’ (Dalmasso et al., 2014). They are perhaps the most 
abundant living beings in the gut (Gaidelyte et al., 2005; Ventura et al., 2011). Most 
phages in the animal gut are likely temperate phages, which often exist in the form of 
prophages (Held and Sidhu, 2004; Kanji et al., 2017).  
Metagenomics have been increasingly employed as an efficient method for exploring 
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and charting the virome (Dutilh et al., 2014). Metagenomic studies have indicated the 
existence of a large diversity of phages in the gut. Indeed, the mammalian gut may be 
the ideal place for phage propagation (Comeau and Krisch, 2005). The vast majority 
of phages are unknown in the animal gut, mainly because most of their genome 
sequences are still unknown (Kleber-Janke et al., 2001; Ventura et al., 2011). Dutilh 
and colleagues (2014) recently discovered a previously unidentified phage referred to 
as crAssphage, which is present in the majority of mammalian fecal metagenomes. 
Several kinds of phages, such as Escherichia coli phages, Salmonella phages and 
Bacteroides fragilis phages, have been isolated from feces, at up to 105 PFU/g of 
phages using cultural methods (Breitbart et al., 2003). Gut-associated phages 
therefore likely affect the diversity and structure of the bacterial microflora in the 
intestinal tract (Lepage et al., 2008); however, they have not been extensively studied.  
The gastrointestinal tract (GIT) of animals is an incredibly complex ecosystem (John 
and Mullin, 2016; Korecka and Arulampalam, 2012). It is the most densely populated 
area of the body, is inhabited by lots of microbes including large amounts of bacteria, 
viruses, fungi, and contains a plethora of collective interacting genomes (Minot et al., 
2011; Ogilvie and Jones, 2015). The intestinal microbiota is thought to outnumber the 
cells of the animal body by approximately 10 to 1, and is believed to play a crucial 
role in animal health (Bianconi et al., 2013; Hao and Lee, 2004). In recent years, 
diverse microorganisms in the animal gut (gut microbiota) have been shown to affect 
mammalian health and overall well-being, as well as diseases of the gut (Betrapally et 
al., 2017). The gut microbiota provides some important functions maintaining animal 
health, such as supporting food digestion, developing immune system, and preventing 
pathogenic infection (Kinross et al., 2008; Koch, 2015). The relationships between 
gut microbiota and health have therefore been recognized as a major challenge in the 
21st century.  
The viral gut community, also known as the gut virome, is a highly complex 
community (Cadwell, 2015). It contains the eukaryotic virome, phages, the archaeal 
virome, and viral genes (Virgin et al., 2009). Moreover, phages are the dominant 
fraction in the gut virome (Dunn et al., 2016). However, it is rarely known that the 
effect of abundant phages in the GIT on the gut ecosystem, although Mills et al. (2013) 
demonstrated that the influence of phages on the gut ecosystems is manifold, 
including the shaping of the mammalian gut microbiota. It is established that 
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temperate phages confer horizontal gene transfer between the bacterial communities 
of gut microbiota (Koskella and Brockhurst, 2014; Ley et al., 2006) and are important 
factors for dissemination of the resistance genes (Brussow et al., 2004; Harrison and 
Brockhurst, 2017; Reyes et al., 2010). Our current knowledge is still limited and too 
fragmented to understand the roles of phages in animal health comprehensively, 
especially in view of shaping the gut microbiota of healthy and sick animals.  
The aims of this thesis were to: 
1. Isolate and comprehensively characterize a lytic and a temperate Salmonella gut 
phage.  
2. Understand the distribution of both phages in the animal GIT using a mouse 
model. 
3. Analyze their impact on the diversity and composition of gut microbiota by 
metagenomic analysis. 
4. Elucidate the roles of these phages in modulating intestinal microbial 
communities composition for a long-term and resistance to intestinal 
inflammation caused by Salmonella enterica subsp. enterica serovar 
Typhimurium. 
This thesis consists of six chapters. The first chapter is the literature review that 
describes general characteristics, phage application, the animal intestinal ecosystem, 
the relationship between phages and intestinal ecosystems, and the possible role of 
phages in gut microflora disorders. The second, third, fourth, and fifth chapter report 
on the experiments undertaken in this study. Each chapter is an independent research 
article. The second chapter reports the morphological, physiological, and molecular 
characterization of lytic gut phage vB_SenM-PA13076 and temperate gut phage 
vB_SpuP-BP96115 isolated from chicken feces. The third chapter is on the 
distribution of orally administrated lytic and temperate Salmonella gut phages in mice. 
The fourth chapter reports alterations in the diversity and composition of mice gut 
microbiota by lytic or temperate Salmonella gut phage treatment. The fifth chapter is 
the impact of preadministration of lytic and temperate Salmonella gut phage on gut 
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microbiota composition and intestinal inflammation in a mouse model. The last 
chapter, chapter six, summarizes and analyses the main findings and points out the 
direction of further research. 
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 Bacteriophages 
Bacteriophages (simply known as phages) are parasitic bacterial viruses, which 
amplify using their bacterial host (Twort, 1936). The term “bacteriophage” came from 
Greek “φαγειν”, “to devour”, which literally means “bacteria eater” (Schultz, 1927). 
As early as 1896, researchers reported that there was something in the water of 
Ganges River acted against cholera and can across a very small pore size filter. In fact, 
phages were formally discovered in the mid to late 20th century with the first 
publication by Edward Twort in 1915 and the second in 1917 by Felix d’Herelle (Ho, 
2001), who devoted his life to phages and their therapeutic uses in humans and 
animals. Phages are the most common, abundant, and diverse organisms in 
the biosphere (Hatfull, 2015). They are ubiquitous viruses, which exist anywhere in 
the presence of bacteria. The number of phages is estimated to reach upwards of 
1031 PFU on the earth, more than all other organism combined, including bacteria 
(Suttle, 2005; Weinbauer, 2004). Each phage particle is composed of 
proteins that encapsulate its nucleic acid genome and may have relatively simple or 
refined structures. The genetic material of phages can be either DNA or RNA (Weitz 
et al., 2005). They often contain unusual or modified bases in the nucleic acids of 
phages. These bases prevent phage nucleic acids from nucleases splicing during 
infection (Court et al., 2007). They attach themselves to susceptible bacteria and 
infect host cells by replicating in the bacterium after injection of their genome into the 
intracellular. Following infection, the phage prevents the bacterium from replicating 
of bacteria and instead uses the bacterial cell machinery to produce their own 
components. Eventually, new offspring phages break through the bacterial cell 
membrane in a process called lysis (Mavrich and Hatfull, 2017). 
1.2 General characteristics of phages 
1.2.1 Life cycles 
Phages have different life cycles relating with the interacted physical environment 
(Hargreaves et al., 2014). However, phages primarily exhibit two classic lifestyles: 
virulent or temperate (Aitken, 2009) (Fig.1.1). 
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Fig. 1.1 Phage life cycles (Ofir and Sorek, 2018). 
Lytic bacteriophages reproduce themselves based on host bacterial cell and produce 
their progeny at the end of their life cycles. Lytic phage can govern the number of 
bacterial population in various environments by destroying bacteria and occasionally 
assist bacterial long-term evolution via generalized transduction (Weinbauer and 
Rassoulzadegan, 2004). Phages encounter their bacterial hosts randomly and attach to 
the host cell via specific receptors, including proteins, oligosaccharides, teichoic acids, 
peptidoglycans and lipopolysaccharides (Park et al., 2012). The second step is that of 
phage synthesis and assembly, which is also called the eclipse phase. Phage DNA is 
transcribed into mRNA, although this step is not required for RNA viruses. The third 
step, depending on the energy and reproduction elements of its bacterial cell, the 
phage produces a lot of its own nucleic acids and proteins in the bacterial cell using its 
genome as a template, and then assembles into thousands of phage particles. After a 
given period of time, the bacteria begin to be lysed due to accumulation of endolysin 
and offspring phages are released from the bacteria into the surrounding environment. 
Although the burst size is typically in a range from 50 to 100 phage particles, there 
are some special phages, the burst size of which is as high as 1000 progeny phages 
particles (Santos et al., 2015). 
Lysogenic or temperate phages enter a state of equilibrium in which the phage 
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becomes part of the bacterial cell (Santillan and Mackey, 2004). In this quiescent state, 
the phage genome becomes circular and latent, persisting in an integrated form within 
the bacterial genome or independently, in the cytoplasm as a circular ‘plasmid’ 
(Abedon, 2017). The genome of phages, which is integrated into its host genome, is 
called a prophage. The prophage is not a real phage, but can be converted to a phage 
by induction of its external environment (Zhao et al., 2010). The presence of the 
prophage will not adversely affect its host and this state will not change until the link 
between phage and host breaks down, either spontaneously or under the action of 
physical or chemical agents. The host bacterial cell containing one or more prophages 
is termed a lysogenic bacteria and the process that produces novel phages in the 
presence of specific agents is called “induction” (Broudy et al., 2001). 
1.2.2 Classification 
As early as 1962, the LHT system was proposed to be a classification method, which 
is based on the type of nucleic acid, the shape of the capsid, and numbers of envelope 
and capsomers (Lwoff, 1962). Until 1965, the Provisional Committee on 
Nomenclature of Viruses (PCNV) adopted the LHT scheme for viruses’ classification. 
In 1966, this organization was renamed the International Committee for classification 
of viruses (ICNV), and in 1973, International Committee on Taxonomy of Viruses 
(ICTV) became the professional organization for viruses classification (Matthews, 
1983). The first report of the ICTV on the classification of viruses included six phage 
genera and their descriptions: T4 and relatives, λ, lipid-containing phage PM2, 
ψ174-like phages, filamentous phages, and the ‘ribophage’ group (Fenner, 1971). This 
was followed by several ICTV reports published at irregular intervals. Phages are 
extremely multifarious in their genomic and proteins’ characteristics. The genetic 
materials are double-stranded (ds) or single-stranded (ss) DNA or RNA. Phage 
particles are isometric, polyhedral, pleomorphic, filamentous, tailed or no tail 
(Fig.1.2).  
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Fig. 1.2 Basic phage morphologies (Borysowski, 2014) 
The majority of phages are dsDNA, while ssDNA, ssRNA, and dsRNA are only small 
part. In 2010, phages comprised of three orders, the Caudovirales, Ligamenvirales, 
and the unassigned, and 19 families and 348 genera were recognized that infect 
bacteria and archaea (Onodera, 2010).  Among them only two viral families contain 
RNA. Of the families with DNA genomes, only two are ssDNA, eight are circular 
while nine are linear. Studying on more than 5568 strains of phage by the electron 
microscopy, the results indicated that most of phages belong to Caudovirales 
(Ackermann, 2007). Although up to 40 classification criteria are used, there are still 
no effective standard for phage classification (Kutter and Sulakvelidze, 2005). As of 
2017, 9 orders, 131 families, 46 subfamilies, 803 genera, and 4,853 species of viruses 
have been defined by the ICTV. However, the number of phage genera and species is 
in constant expansion and can only be estimated. 
1.2.3 Host range 
Host range is an important biological characteristic of the phage (Kutter, 2009). Host 
ranges are different from non-productive infections (i.e., restrictive, abortive, or even 
lysogenic) to productive infections (Hyman and Abedon, 2010). Thus, the selected 
method of measuring the host range of a specific phage is very important. Many other 
factors affect host ranges such as receptor alteration, epitopes inhibition of DNA 
13 
 
injection, superinfection immunity by resident prophages, restriction endonucleases 
destroying, or the clustered regularly interspaced palindromic repeat (CRISPR) 
system (Barrangou et al., 2007). The most common method for detecting host range 
of phage is the spotting test. In this method, a drop of phage suspension is dripped on 
to a lawn of tested bacteria. However, spotting test tends to overestimate the real host 
range (Khan Mirzaei and Nilsson, 2015). Thus, the efficiency of plating (EOP) using 
the double agar layer method is more efficient for identification and selection of good 
phages, which are broad range. 
Host recognition is an important factor that determines the host range of a phage. This 
is determined by interaction between specific receptors of bacterial host’s surface and 
the receptor binding proteins (RBPs) of phage (Mahony and van Sinderen, 2012; 
Simpson et al., 2016). The first step of phage infection is reversibly. However, during 
the infection step, phages attach to the same receptor as in the adsorption step or to 
another receptor nonreversible (Dowah and Clokie, 2018). The receptors can be 
lipopolysaccharides (LPS), membrane proteins or teichoic acid (Bertozzi Silva et al., 
2016). For the phage of Gram-negative bacteria, LPS is the most common receptor for 
phage targeting (Hyman and van Raaij, 2018). For example, there are two distinct 
ways that the phage T4 recognizes E. coli strains, OmpC-dependent and 
OmpC-independent (Washizaki et al., 2016). Similarly, membrane protein OmpC is 
the receptor of Salmonella phage Gifsy phage (Ho and Slauch, 2001), while T5-like 
phages uses vitamin B12 protein BtuB as its receptor (Kim and Ryu, 2011). The RBPs 
of Salmonella phage SP6 determines the host range and this phage exhibits double 
host adsorption systems (Gebhart et al., 2017). Understanding the phage recognition 
process and specificity is therefore very important and may facilitate the 
implementation of successful phage therapy. 
1.2.4 Genome 
Phage genomic sequences are as rich as the number of phages on earth (Rohwer, 
2003). So far, genomes of a number of selected phage strains have been sequenced 
including coliphages, mycobacteriophages, bacteroid phages, and dairy phages 
(Chibani- Chennoufi et al., 2004). Since the first complete genome of phage ΦX174 
was published in 1977 (Sanger et al., 1977), the number of sequenced phage genomes 
have been steadily increased. Nevertheless, the known genomes of phage are still 
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small compared to the bacterial sequenced genomes (Hatfull, 2008; Weinbauer, 2004). 
Recent metagenomic phage studies have highlighted the extraordinarily high phage 
genome diversity. The size of sequenced phage genomes varies dramatically, from 
2,435 base pairs [bp] (Leuconostoc phage L5) to 497,513bp (Bacillus phage G) 
(Deschavanne et al., 2010). The majority of phages belong to Siphoviridae, according 
to their genomic information, which account for approximately 55%, while small 
genomes ranging from 5 kb to 20 kb are the second most abundant group and account 
for approximately 27% (Deschavanne et al., 2010). Double stranded DNA phages are 
predominant and are an enormous source of unknown phage genes. Phage genomes 
are critical for the expression of proteins ensuring replication, the assembly of newly 
formed progeny virions, and lysis of host cells (Klumpp et al., 2013). Generally, 
genes coding for regulatory proteins or transfer RNAs (tRNAs), which can replace 
host functions under specific conditions of bacterial cell growth, are absent in small 
phage genomes (Henry et al., 2010). However, Pseudomonas phage 201φ2-1 has a 
large phage genome of 316,674bp, which includes one tRNA-encoding gene. 
Conversely, there are 41 tRNAs encoded in the genome of the phage Myrna, which 
has a size of 164,602 bp. 
1.3 Application of phages in reducing pathogens 
Phages have been employed for more than 100 years. Phage therapy mainly uses for 
treating pathogenic infections in humans and animals (Zelasko et al., 2017). The 
emergences of multi-resistant bacteria continue to threaten standard therapies against 
bacterial infections. However, the developments of new antimicrobial compounds are 
not sufficient to replace old and obsolete drugs (Hughes and Karlen, 2014). This is the 
main driver for searching alternatives to treat antibiotic-resistant bacterial infections 
(Mattila et al., 2015; Periasamy and Sundaram, 2013). Phages have therefore received 
renewed attention and are promising products to replace antibiotics in the control of 
bacterial infections (Pirisi, 2000; Speck and Smithyman, 2016).  
1.3.1 Purification 
Because bacterial lysis is involved in phage stock preparation and has the potential to 
release bacterial toxins, including endotoxins from Gram-negative bacteria (Gill and 
Hyman, 2010), an ongoing concern with respect to phage therapy is the potential for 
injection of bacterial toxins into patients over the course of phage application. A 
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standard method for phages preparation and application is still lacking, but is 
necessary to ensure that toxins are not introduced into patients. Thus, phage 
preparations must be purified. To date, various techniques including phase separation 
(Aida and Pabst, 1990), anion exchange and affinity chromatography (Liu et al., 1997; 
Petsch et al., 1997) have been investigated to remove toxins from recombinant protein 
solutions. In a recent study, Khan Mirzaei et al. (2016) used polyethylene glycol (PEG 
8000) for precipitation and followed by using cesium chloride (CsCl) gradient 
ultracentrifugation, achieving LPS levels in the phage preparation below 1.0 
endotoxin units/mL. Dufour et al. (2016) subsequently contradicted that this protocol 
is not efficient to remove endotoxin from the phage solution. His team used a 
different protocol, which was composed of concentration, ultrafiltration and two 
ultracentrifugation steps (one CsCl gradient and one isopycnic gradient). Following 
dialysis, commercial affinity chromatography columns were used to remove 
endotoxins, with the last step repeated for three to five times. For most phage 
solutions, this protocol can guarantee below 0.5 endotoxin units/mL (Henry et al., 
2013). Another efficient method for endotoxin removal is a combination of 
deoxycholate treatment and ultrafiltration from T7 phage preparations (Hashemi et al., 
2013). The advantage is that deoxycholate’s small molecular weight enables it easy 
removal by ultrafiltration. The results indicated that a single round of deoxycholate 
treatment and ultrafiltration was able to reduce LPS concentration by 42% without 
any significant loss of the phage recovery. After three cycles of deoxycholate 
treatment and ultrafiltration, the concentration of LPS was reduced to 0.83 EU/ml. 
Using this method for the removal of LPS from other phage particles such as λ and T4 
or virus-like particles (VLPs) may be beneficial and convenient for the development 
of quality phage for animal health and food safety (Hashemi et al., 2013). Hence, the 
combination of deoxycholate treatment and ultrafiltration appears to be a worthy 
method for removing LPS from phage solutions.  
1.3.2 Clinical experience 
Phage therapy against bacterial infections in humans has a long tradition. Clinical 
phage therapy was frequently employed in the former Soviet Union, the Republic of 
Georgia, as well as in Russia, and Poland (Waldor et al., 2005). Most of the phage 
products were used for the military during the Second World War and much of the 
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literatures mainly descripted phage therapy of the major problems such as gangrene 
and dysentery in wartime (Hanlon, 2007). Currently, studies of phage therapy focus 
on three main fields: to combat antibiotic-resistant bacteria infections; to combat the 
untreatable infections in patients (e.g., due to poor circulation, biofilm formation, 
diabetic ulcers or osteomyelitis); and to combat targeting bacteria, for example, due to 
patient allergy to beta-lactams, intractable bowel problems or Clostridium difficile. In 
addition, concerns with excess exposure of human and environment to antibiotics in 
food and agricultural applications (Abedon et al., 2011; Periasamy and Sundaram, 
2013). A recent study showed that phage therapy could cure patients with recalcitrant 
chronic respiratory tract infections caused by multidrug-resistant Pseudomonas 
aeruginosa strains, which indicates a new treatment method for those multi-resistant 
bacterial infections (Waters et al., 2017). Phage BioDerm, a kind of phage product, 
has been licensed and approved in Georgia. It is a mixture of non-toxic polymer with 
phages as well as the antibiotics ciprofloxacin and benzocaine (Markoishvili et al., 
2002). In Poland, phage therapy was also performed successfully for treating patients 
with antimicrobial-resistant bacterial infections (Miedzybrodzki et al., 2012). So far, a 
trial of phage therapy in children using a commercial coliphage product demonstrated 
a safe gut transit and improved diarrhea outcome, but failed phage amplification in the 
gut (Sarker et al., 2016). The emergence of this phenomenon may be caused by low 
concentrations of pathogenic E. coli or the insufficient phage coverage. Therefore, 
more research should be studying the phage-bacterium interaction in vivo. Despite 
some of the potential obstacles of phage treatment, the current knowledge regarding 
phages indicates that phage application has scientific merit and deserves attention. 
1.3.3 Use of phage against intestinal pathogens  
Smith’s group published a series of successful phage studies demonstrating the 
efficient use of phages in treating E. coli infections in many animals (Smith and 
Huggins, 1982, 1983; Smith et al., 1987). Phages have also been proved to protect 
mice from systemic infections (Pouillot et al., 2012; Soothill, 1992). A number of 
studies demonstrated that phages are good alternatives to control animal diseases 
(Callaway et al., 2011; Cisek et al., 2017; Gorski et al., 2016; Kaur et al., 2016). 
Because of the lesser efficacy of antibiotics for cleaning out pathogens of intestinal 
carriage, phage therapy is now a method to be considered for the treatment of the 
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intestinal pathogens. However, the treatment of enteric and zoonotic pathogens using 
phages might fail because of the possible development of resistance (Barrow, 2001; 
Sabouri et al., 2017). Furthermore, the study of Maura et al. (2012) indicated that the 
entero-aggregative E. coli O104:H4 phages were not uniformly distributed throughout 
the gut in mice, which might be another reason for less efficiently reducing pathogens 
in the animal gut. Three strains of virulent gut phages had been proved to be useful 
for reducing E. coli O157:H7 via oral administration (Tanji et al., 2005), but they did 
not completely eliminate the pathogens from the animal gut. In fact, the number of 
pathogens was simply reduced to too low level to cause clinical diseases. Thus, 
bacterial phage resistance is a concern when controlling bacterial infections (Sanchez, 
2011). Even an obligate lytic phage may be unsuitable for therapeutic application 
when bacteria can acquire resistance to this phage (Orquera et al., 2015). However, 
different from the bacterial resistance to static antibiotics, phages and bacteria 
coevolve (Betts et al., 2016). To overcome bacterial phage resistance, a therapeutic 
phage cocktail, which is composed of more than one phage, can be used (Gill and 
Hyman, 2010) and this cocktail was successful in treating Salmonella enterica subsp. 
enterica serovar Typhimurium U288 contamination (Hooton et al., 2011). Several 
factors such as environmental conditions and animal organs will affect the 
effectiveness of phage therapy. The biggest problem with oral administration of 
phages is the destruction caused by the stomach’s acids and the damage caused by 
proteolytic activity (Ryan et al., 2011). A possible solution is the use of 
microencapsulation of phage particles. The microencapsulated Salmonella phage 
FelixO1 using the method of Chitosan-Alginate survived well in the pig GIT (Radford 
et al., 2017; Whichard et al., 2003).  
Unfavorable environmental factors, such as salinity, gastrointestinal conditions, pH, 
and temperature, affect the vitality and survival of phages (Lobocka et al., 2018). In a 
previous study, when microencapsulated phages were stored at -80℃ for one month, 
there was only a minor reduction of phage titers (Ramirez et al., 2018). In addition, 
the stability of microencapsulated phages decreased slightly after three and six 
months (Colom et al., 2017). Therefore, studying the influence of environmental 
factors on the stability and sensitivity of phage is important and challenges the 
development and application of phage products. 
18 
 
1.3.4 Biocontrol using phages 
Phages are a sustainable and well established alternative to antimicrobial agents that 
improve food safety (McCallin et al., 2013) and can be used therapeutically or for 
disinfection in foods (Hudson et al., 2005; Mahony et al., 2011). Phage biocontrol in 
food mainly includes two types of application: (i) decontaminating pathogen cross- 
contaminated surfaces of equipment and tables in food-processing and other food 
establishments; and (ii) biocontrol of the harvested food using direct applications of 
phages (Endersen et al., 2014; Sulakvelidze, 2013). In 2006, a phage product, which 
was composed of six kinds of purified phages, was approved to be used against 
Listeria monocytogenes on the surface of ready-to-eat food by the US Food and Drug 
Administration (FDA) (Lang, 2006). In addition, E. coli phage product (EcoShield 
ECP-100, Intralytix), a cocktail of three E. coli O157:H7 phages was approved by 
FDA and USDA food safety and Inspection Service for food application in 2011 (Bai 
et al., 2016). Recently, Salmonella phage product (SalmoFresh, Intralytix), which is a 
cocktail of six Salmonella phages, was designated “generally recognized as safe” by 
the FDA in 2013 (Sharma, 2013). Currently, research is focused on the phage therapy 
in foods to control a broad range of pathogens such as Listeria spp. (Bigot et al., 2011; 
Guenther et al., 2009; Oliveira et al., 2014), Salmonella spp. (Augustine and Bhat, 
2015; Guenther et al., 2012; Woolston et al., 2013), pathogenic E. coli (E. coli 
O157:H7, in particular) (Abdulamir et al., 2014; Abuladze et al., 2008; Kudva et al., 
1999), Campylobacter jejuni (Goode et al., 2003; Loc Carrillo et al., 2005), and 
Staphylococcus aureus (Garcia et al., 2007; Garcia et al., 2009; O'Flaherty et al., 
2005). These studies have indicated that phages might be efficient alternative products 
to control specific food-borne pathogens and are considered safe for human 
consumption. 
1.4 Gut microbiota 
The animal GIT is composed of trillions of intestinal microorganisms. These 
microorganisms are referred to as gut microbiota (Walter, 2008), the amount of which 
is approximately 10 times bigger than the amount of human body cells (Eckburg et al., 
2005). The stomach typically contains 103-104 cfu of bacteria, the jejunum 105-106 cfu, 
the terminal ileum 108-109 cfu, while the largest number of bacterial cells is found in 
the cecum and colon, with 1011-1012 cfu/g of bacteria (Tlaskalova-Hogenova et al., 
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2011). The complex microbial community of the gut contains bacteria, eukaryotes, 
viruses, and archaea (Ferrario et al., 2017). The gut microbiota is extremely diverse 
and contains approximately 1000 different kinds of bacterial species (Brestoff and 
Artis, 2013). Although there are more than 50 known bacterial phyla, gut-associated 
microbiota in animals are dominated by four bacterial phyla, Bacteroidetes, 
Firmicutes, Fusobacteria and Proteobacteria (Zhang et al., 2016), even though only a 
minority of these microbial taxa can be cultivated by current microbiological methods 
(Shendure and Ji, 2008). Nevertheless, recent work has increased the number of 
species that can be recovered from the gut by improving cultural isolating techniques 
(Lagier et al., 2016). The virome, which is an important part of the microbiome, 
comprises bacteriophages, eukaryotic and prokaryotic viruses, and endogenous 
retroviruses (Pfeiffer and Virgin, 2016). More recently, the remarkable diversity of 
the gut virome, which is composed of viruses that infect prokaryotic and eukaryotic 
cells, has increasingly attracted interest (Virgin, 2014), with highly diverse and 
abundant phages present in the mammalian gut (Mills et al., 2013). The commensal 
bacteria play a very important regulatory role for health and disease; thus, gut 
microbiota can be considered as a metabolic organ (O'Hara and Shanahan, 2006), 
which is critical for overall health of animals. Of particular interest is its ability to 
resist the colonization of pathogens, so called colonization resistance, which is 
particularly important in young animals.  
1.5 Roles of phages in the gut ecosystem 
Phages are ubiquitous in the world, and their potential impact on the ecology of the 
environment has been recognized (Parmar et al., 2017). Phages are also the most 
abundant biological entities in the animal gut (Virgin, 2014). 
1.5.1 Abundance and diversity of phages in the gut 
Some studies have described the presence of phages in human and animal feces (Calci 
et al., 1998; Dhillon et al., 1976; Dutilh et al., 2014; Hartard et al., 2015; Sazinas et al., 
2016). There are at least 109 virus like particles (VLPs) per gram in the feces (Kim et 
al., 2011; Rohwer, 2003). VLPs in the feces appear to be dominated by temperate 
phages, but the situation are exactly opposite in aquatic environments where mainly 
occupying by lytic phage (Reyes et al., 2010). A previous study estimated that there 
are up to 1015 individual phage particles in the mammalian gut (Lepage et al., 2008). 
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However, the viral particles, which referred to gut virome, are extremely different 
between individualities, even when comparing a mother and her daughter (Minot et al., 
2011; Reyes et al., 2010). A high frequency of specific E. coli phages in feces (about 
90% of fecal samples) was reported, while the percentages of other phages were 
relatively low (Cornax et al., 1994). Gantzer et al. (2002) also showed that up to 70% 
of human fecal samples contained up to 4×103 plaque forming units (PFU/g) of 
coliphages. The first metagenomic analyses of the gut virome of human feces showed 
that the recognizable viruses were primarily Siphophages (Breitbart et al., 2003). 
Therefore, it appears that the species and concentration of phages differs among 
individuals and shows no relationship with sex or age (Rohwer, 2003). 
1.5.2 Impact of phages in the healthy animal gut 
It has been well established that phages are important vectors for horizontal gene 
transfer in complex environmental conditions, and in particular, in the gut ecosystem 
(Modi et al., 2013; Ogilvie et al., 2013; Reyes et al., 2010). This process is called 
transduction, which means that DNA is moved from one bacterium to another via 
phages (Goh, 2016). Phages may impact the gut bacterial community function 
through gene transfer, or may themselves encode some functions benefit to the host 
(Reyes et al., 2013). For example, E. coli prophages are essential to their bacterial 
hosts, enhancing their host’s tolerance to adverse circumstances such as oxidative, 
osmotic, and acid; as well as bacterial biofilm, thereby increasing host survival (Wang 
et al., 2010). Intestinal phages are important for controlling local bacterial populations, 
according to the principal model of phage therapy (Atterbury et al., 2005). Barr et al., 
(2013) demonstrated phages enriched within mucosal samples suggesting that phage 
depended on their immunoglobulin-like protein domains adherence to mucus through 
a non-host-derived immunity. Thus, phages can limit and control mucosal bacteria 
and interact more frequently with bacteria and animal hosts (Barr et al., 2013). These 
results indicate that phages do a certain affect human health. However, the ecological 
impacts of phages on the microbial community structure in the animal gut and how do 
they affect animal health are unknown,  
1.5.3 Phage and host immunity 
Oral or intravenous administration of phages may result in rapid elimination from the 
circulatory system (Bruttin and Brussow, 2005; Speck and Smithyman, 2016), with 
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the capsid protein of phages responsible (Leiman et al., 2003). Indeed, foreign phages 
can directly act on the immune system and give rise to humoral immunity. For 
example, high titers of staphylococcal phage antibody could be detected in 10% of 
healthy persons and 44% of staphylococcus infections (Hedstrom and Kamme, 1973; 
Kamme, 1973), while two studies showed that orally administered phages triggered 
both innate and adaptive immune responses (Duerr et al., 2004; Hamzeh-Mivehroud 
et al., 2008). Moreover, the humoral immune response was induced by foreign phages 
(Gorski et al., 2012; Majewska et al., 2015). Phages can additionally inhibit immune 
cells to produce reactive oxygen species when challenged by endotoxins 
(Miedzybrodzki et al., 2008; Przerwa et al., 2006). This indicates phages play a 
potential protective role in oxidative stress (Miedzybrodzki et al., 2008; Przerwa et al., 
2006). However, the induced humoral immune response does not follow by a simple 
scheme, instead appearing to depend on characteristics of the phage and the route of 
phage therapy (Gorski et al., 2006). The influence of phages on the immune system 
also depends on the dosage and application schedule, and may depend on other 
undetermined characteristics (Dabrowska et al., 2014; Gorski et al., 2012). However, 
little is known on the mechanism of phages eliciting innate immune responses. In the 
mammalian body, immunological reaction caused by foreign phages is strictly 
regulated by the cytokines secreted by immune cells. Endotoxin-free phage particles 
stimulate macrophages to produce tumor necrosis factor alpha (TNF-α) and 
interleukin-1beta (IL-1β) (Eriksson et al., 2009). The immune cells recognize foreign 
antigens or the molecular patterns (Virgin, 2014). Toll-like receptors (TLRs), such as 
TLR2, TLR3, TLR7, TLR8 and TLR9 are innate immune sensors. It was reported that 
they are involved in the identification of viral structure (Foca et al., 2015). Further, 
the activation of Toll-like receptors triggers activation of the nuclear transcription 
factors such as nuclear factor-κB (NF-κB), interferon regulatory factor (IRF) 3, and 
IRF7. Finally, these effectors promote the expression of the next level of antiviral 
effectors such as type I interferon, pro-inflammatory cytokines such as Interleukin 
(IL)-1𝛽𝛽 and IL-6, and chemokines such as IL-8 and C-X-C motif chemokine 10 (Yan 
and Chen, 2012). The interactions of phages and the immune system are a fascinating 
and novel field that is worth to study in-depth because these interactions can 
synergistically affect bacterial pathogen elimination. Further deep-going studies are 
needed to elucidate the interactions of phage with the immune system, and the 
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contribution of phage to homeostasis based on this relationship. 
1.5.4 Phages and gut microflora disorders 
Due to its relevance for health, in recent years, researches have focused on the 
bacterial dysbiosis of diseases characterized by alterations in the composition of 
intestinal microbiota (Clemente et al., 2012; Sobhani et al., 2011). For example, 
differences in the number of VLPs are apparent between healthy people and Crohn’s 
disease (CD) patients; the titers of VLPs in the intestinal mucosa in CD patients 
(2.9×109 VLPs/biopsy) was 24 times as large as that of healthy individuals (1.2×108 
VLPs/biopsy) (Lepage et al., 2008), and the increase of gut virome abundance and 
reduction of bacterial flora diversity was significant in CD patients and ulcerative 
colitis patients (Perez-Brocal et al., 2013). Gut phages may cause ecological disorders, 
leading to the transition from health to disease, which is defined as the imbalance 
between symbiotic bacteria (De Paepe et al., 2014). Phages may give rise to the 
realization of non-host derived immunity. It is possible to prevent and/or treat 
intestinal diseases by regulating mucosal phage complements (Barr et al., 2013). Such 
a micro tuned modulation of phage on the immune responses of intestinal may allow 
foreign pathogens to invade intestines through the epithelial cell layer (Fig. 1.3). The 
filamentous phage M13 has been applied as vector for treating Alzheimer’s disease 
and Parkinson’s diseases, because it can combine the typical β-amyloid and 
α-synuclein plaques causing plaque depolymerization in the brain (Ksendzovsky et al., 
2012). Phages have been verified to successfully inhibit tumor formation and promote 
tumor regression (Dabrowska et al., 2004; Pajtasz-Piasecka et al., 2008). The 
inflammatory cells were recruited and cytokines were induced after phage therapy for 
cancer, so that the life span of mice is prolonged. Genetically engineered phages can 
also be used as delivery vectors of anticancer drugs (Kia et al., 2013), as well as 
anticancer proteins, which induce the apoptotic death of cancer cells resulting in 
breast tumor regression (Shoae-Hassani et al., 2013). 
Phages can affect the ecosystem of the intestinal community through several 
mechanisms (De Paepe et al., 2014). First, the gut ecosystems is affected by the 
predation and propagation on sensitive bacteria using the “kill the winner” model 
(Allen et al., 2011; Golomidova et al., 2007; Weinbauer, 2004). Phages also can 
interact with the bacterial ecosystems in the gut via the clustered regularly interspaced 
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short palindromic repeat (CRISPR) systems of the bacteria. CRISPR systems of 
bacteria can identify and silence foreign genes such as phages, thus providing an 
acquired immunity (Duerkop and Hooper, 2013). The third mechanism, defined as the 
“biological weapon” model, describes that the symbiotic bacteria can use phages to 
kill their competitor present in the gut ecosystem (Bossi et al., 2003; Brown et al., 
2006). Another model, which was called the “community shuffling” model, is used by 
temperate phages. These phages can lyse their former lysogenic host upon induction 
(Zhang et al., 2000). Moreover, temperate phages also use the “emergence of new 
bacterial strains” model to impact the ecosystem. They carry genes which modify 
bacterial phenotypes but without killing bacteria (Martinsohn et al., 2008). 
 
Fig. 1.3 Phage effects on homoeostasis and dysbiosis (Ogilvie and Jones, 2015). 
The phage adherence to intestinal mucosa is modified by genetic factors and 
environmental stressors. Compared to healthy individuals, the properties of the 
mucosal phages are altered in the diseased status, which leads to intestinal flora 
dysbiosis.  
1.6 Detection methods for gut microbiota 
The study on gut microbiota is mainly limited by the available qualitative and 
quantitative detection methods for microorganisms, including viruses (Foca et al., 
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2015). In fact, in order to characterize the composition of the bacterial community in 
the intestine, research approaches have shifted from traditional culture and 
microscopy-based observation to sequencing technologies for studying the potential 
diversity at genomic level (Ogilvie and Jones, 2015). The traditional culture method is 
used to isolate phages from environmental and intestinal samples using a bacterial 
strain as the decoy. It has been used to characterize and understand phages since the 
first discovery of phages, and will continue to be an important tool for the analysis 
and study of the gut virome. These techniques are essential, inexpensive tools and 
ongoing efforts have increased the numbers of culturable microorganism 
(Rajilic-Stojanovic and de Vos, 2014). However, because of the inherent limitation of 
the current culture technologies, it is impossible to cultivate the majority of the 
microbial species. Another similarly important technique for phage analysis is 
transmission electron microscopy (TEM), which is effective in studying phage 
morphologies and classification. In fact, TEM studies have revealed that tailed phages 
(Order Caudovirales) are most prevalent in the animal gut (Flewett et al., 1974; 
Letarov and Kulikov, 2009). The combination of sequencing technologies and related 
bioinformatics tools enable us to better comprehend the composition, structure, and 
function of gut microbiota. Although some of the entities present in the animal gut 
have been characterized benefiting from the development of metagenomic sequencing 
techniques, in-depth genomic studies of gut microbiota using NGS sequencing 
technology mainly depend on how to efficiently assemble sequence fragments of 
genes into a large genome.  
The virus-like-particles (VLPs) in fecal samples are generally isolated using filtration 
with 0.22 μm pore size and ultra-centrifugation employing a CsCl-density gradient 
(Thurber et al., 2009). The matching metagenomic sequences of viral genomes can be 
gained via the following extraction of nucleic acids (Thurber et al., 2009). The 
detection of VLPs provides for a better understanding of the gut virome, and enables a 
deeper analysis of the inventory, composition and function of gut viral particles 
(Breitbart et al., 2003; Kim et al., 2011; Minot et al., 2011). However, RNA viruses 
are often ignored using metagenomic sequencing analyses and the current VLP 
isolation method may not efficiently detect all viruses in fecal samples (Virgin, 2014). 
It has been estimated that only 0.0002% of viral genes have been sequenced (Rohwer, 
2003). Moreover, VLPs from environmental and intestinal samples using 
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metagenomic sequencing yield large quantities of unidentified sequences (Breitbart et 
al., 2003; Minot et al., 2011; Reyes et al., 2010). Therefore, studying intestinal VLPs 
using metagenomic technologies can be an efficient way to discover new phage 
genomes. However, to further study the function of phages still requires cultivating 
the phage and its host based on the traditional culture method. Moreover, research 
approaches need to optimize the combination of high-throughput “omics” analyses 
and biological data and should further develop comparative volunteer studies to 
enable a better understanding of the roles of phages in intestinal disorders.  
1.7 Conclusions 
Phages are the most abundant biological entities on the earth, thriving and coexisting 
with their bacterial hosts. Lytic phages are potential means to reduce contaminations 
due to pathogenic bacteria in foods, or to tackle bacterial infections in animal 
breeding. Presumably, most of the phages in the intestinal tract are lysogenic, which is 
a particularly advantageous status in the gut. In addition, studies on the mammalian 
gut virome have provided an understanding of the extreme diversity of the phage 
community. It can be expected that phages often play an essential role in regulating 
the composition of the mammalian gut microbiota. However, as research on the 
effects of phages in the gut ecosystem is still in its infancy, particularly regarding the 
manipulation of the gut microbiota in intestinal diseases, addressing these research 
questions will ultimately lead to innovative applications of phages in animal health. 
These could enable the reliable identification and eradication of harmful imbalances 
in the gut microbiome, and by employing appropriate experimental strategies pinpoint 
the best possible treatment for intestinal diseases. 
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CHAPTER TWO 
MORPHOLOGICAL, PHYSIOLOGICAL AND MOLECULAR 
CHARACTERIZATION OF LYTIC GUT PHAGE vB_SenM-PA13076 AND 
TEMPERATE GUT PHAGE vB_SpuP-BP96115 ISOLATED FROM CHICKEN 
FECES 
2.1 Introduction 
Salmonella enterica subsp. enterica serovar Entertidis and Pullorum are important 
reported bacterial pathogens, not only related to the prevalence of salmonellosis in 
farm animals but also related to foodborne disease outbreaks and public health 
(Christenson, 2013; Ebel et al., 2016). Salmonella infections remain a cause for global 
concern and cause significant economic losses due to morbidity (Taylor et al., 2015). 
Moreover, Salmonella can colonize the intestinal tract and cause systemic infections, 
gastroenteritis and septicaemia, depending on the animal species and the infecting 
bacterial strain (Schultz et al., 2017; Szmolka et al., 2015). Salmonella infects animals 
mainly through the oral route and the pathogenesis of Salmonella is extremely 
complex (Bello et al., 2016; Christenson, 2013).  
Prophylactic use of nonantibiotic products to promote gut health of animals is 
important for sustaining animal production. Although these alternative products are 
contradictory to antibiotics, they have generated financial benefits to producers. They 
improved feed conversion, developed innate immunity, stimulated immune response, 
increased vitality, and decreased mortality (Francois et al., 2016). 
Phages are ubiquitous in nature and the most abundant living entities on earth 
(Abedon et al., 2017; Rohwer, 2003), and show host specificity. Phages can exhibit 
one of two life cycle types, lytic or temperate (Hobbs and Abedon, 2016). The ability 
of lytic phages to lyse host bacterial cells rapidly forms the basis for the development 
of phage therapy for controlling bacterial pathogen contamination or infection, 
whereas the DNA of temperate phages is often integrated into the host’s DNA 
(Sharma et al., 2017). Furthermore, temperate phages go into the prophage state and 
multiply by the reproduction of the host, and producing independent phages under 
adverse circumstances (Hendrix et al., 1999). Prophage DNA is replicated with the 
replication of the cell genome and the DNA is inherited to offspring (Obregon et al., 
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2003). Phages are present in all environments, including oceans, soil, and 
gastrointestinal tracts (Gross, 2014). In the gastrointestinal tract, total phage densities 
have been estimated as 1015 phage particles, dominated by temperate phages 
(Dabrowska et al., 2005; Dalmasso et al., 2014). Temperate phages have potential 
functions in regulating the microbial balance in the gut ecosystem by horizontal gene 
transfer to exchange genetic material between bacteria (Bakhshinejad and Ghiasvand, 
2017; Holmes, 2011). Since Salmonella spp. infections of the intestinal system are an 
emerging problem in animal farming (Schulte and Hensel, 2016), phages isolated 
from animal feces, known as gut phages, were suggested as an alternative to treat 
gastrointestinal disease (McCarville et al., 2016). While a temperate phage, which 
integrates its DNA into its host genome without lysis action is not suitable for phage 
therapy, lytic phages bring about rapid lysis of bacteria, and are therefore good agents 
for phage therapy (Jin et al., 2014). In fact, orally administrated encapsulated lytic 
phages are efficacious in protecting broiler intestines against Salmonella colonization 
(Colom et al., 2015). Similarly, oral administration of lytic phage mixtures 
significantly reduced gastrointestinal Escherichia coli O157:H7 (Tanji et al., 2005), 
Shigella spp. (Volker, 2015) and Listeria monocytogenes (Mai et al., 2010) in 
experimentally infected mice. 
So far, there are more than 6600 complete genomes of phages in GenBank of the 
National Center for Biotechnology Information (NCBI) (June 2018). Typical 
Salmonella lytic and temperate phages, including FelixO1 (Whichard et al., 2010), 
SP6 (Dobbins et al., 2004), Gifsy-2 (GenBank accession No: NC_010393.1), and P22 
(Vander Byl and Kropinski, 2000) have been reported and their genomes sequenced. 
Comparative genome analysis is an important method for understanding the 
evolutionary genetics of phage genomes and the functions of all kinds of coding genes 
(Al-Jarbou, 2012). In despite of lots of sequenced phage in the GenBank, the 
information on the genomics of gut-associated phages is still limited. Moreover, 
characterization of phages’ genome is a requirement before practical application. The 
objectives of this study were to characterize the properties of a lytic and temperate 
Salmonella phage isolate from chicken feces, as well as to sequence and analyze the 
phage genomes.  
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2.2 Materials and Methods 
2.2.1 Bacterial strains and media 
In total, 311 strains of Salmonella spp. were used in this study (Table S2.1, 
supplementary material). All of the strains were isolated and characterized from 
diseased chicken and foods in accordance with the National Standard of China (GB/T 
4789.4-2010). Among the 311 tested strains, Salmonella enterica subsp. enterica 
serovar Enteritidis (Salmonella Enteritidis) ATCC13076 was used as a reference strain 
and Salmonella enterica subsp. enterica serovar Pullorum (Salmonella Pullorum) 
SPu-115 was an isolated strain from diseased chicken gut. All strains were cultivated 
at 37℃ in liquid TSB or solid TSB. 
2.2.2 Isolation of lytic gut phage vB_SenM-PA13076 
Several fecal samples of chicken obtained from different parts of Jiangsu Province 
were used for isolating lytic gut phages. Five gram of chicken feces were suspended 
in 50 mL of SM buffer (50 mM Tris-HCl [pH 7.5], 0.10 M NaCl, 8 mM MgSO4·7H2O 
and 0.01% gelatin) and left overnight on a shaker (HY-8A, Jingda instruments 
manufacturing Co., Ltd, Jintan, China) at room temperature (25℃) and at 100 
rpm/min. Twenty-five milliliters of the sample solution was centrifuged (15,000×g, 15 
min, 4℃) and the supernatants were filtered through a 0.22 μm pore-size filter (Merck 
Millipore, MA, USA). Filtered solution (10 mL) was mixed with 500 μL of 12 h-old 
Salmonella Enteritidis ATCC13076 cultures grown in 20 mL TSB broth at 37℃. After 
incubation for 18 h, the mixture was centrifuged using the same method as above, 
filtered again and the filtrate was tested for the presence of lytic phages by inoculating 
10 μL of the filtrate on lawns of Salmonella Enteritidis ATCC13076 prepared on TSB 
agar. The plates were cultured for 18 h and inspected for clear zones. The filtrate 
causing lysis was inoculated at 500 μL per 10 mL fresh TSB with Salmonella 
Enteritidis ATCC13076 for phage amplification. Lytic phages were purified according 
to the method of Adams (Adams, 1959). 200 μL of phage filtrate was mix with 200 μL 
of Salmonella Enteritidis ATCC13076 culture (1×109 cfu/mL) and the mixture was 
immobile at room temperature for 20 min. 4 mL of liqiud LB agar (0.7%) was added 
and paved on the prepared LB agar. After solidification, the plates were incubated 
42 
 
overnight at 37℃. Clear plaques were selected for the following experiments. For 
amplification, the mixture of the phage and the host strain at a multiplicity of 
infection (MOI) 0.1 was added to 10 mL of TSB medium at 37°C for 6 h. The phage 
lysate was prepared by centrifugation at 12000×g for 10 min at 4℃ and the 
supernatant was filtered through a 0.22 μm pore size membrane (Merck Millipore Ltd., 
Ireland). The phage titers were determined using the double-layer agar method.  
2.2.3 Induction of temperate gut phage vB_SpuP-BP96115 
First, exponential cultures of selected Salmonella strains (10 putative lysogenic strains 
containing the prophage) which were isolated from the guts of diseased chickens, 
were prepared by growing cultures until an OD600nm of 0.3 was reached. Mitomycin C 
(Sigma, USA) was then added at a final concentration of 0.5 μg/mL and the 
suspension was incubated at 37℃ for 4-5 h under vigorous shaking (Garcia et al., 
2007). The treated bacterial cultures were centrifuged (11,000×g, 10min, 4℃) and 
filtered by 0.22 μm. The presence of temperate phages was determined by adding a 10 
μL volume of filtrate onto lawns of 10 Salmonella strains. Finally, the temperate gut 
phage was successfully induced from the gut-associated strain Salmonella Pullorum 
SPu-115, and its host was Salmonella Pullorum SPu-109. The obscure plaques formed 
were picked up for further propagation and purification. 
2.2.4 Purification, propagation of phage and precipitation of phage particles 
Single plaques was picked and dissolved in 1 mL SM buffer at 4℃ overnight. As 
105-106 PFU/mL of phage per plaque, 103 and 104 dilutions of this suspension were 
used for the next cycle of purification, with at least 5 cycles carried out. Before 
amplifying the phage, the optimal multiplicity of infection (MOI) were determined 
using the different ratio of phage to its host among 0.001~1000. For inoculation, 
exponentially growing host strains were infected with the phage at 1 of optimal MOI 
in 100 mL TSB at 37℃ for 6 h. Then, crude phage lysate was obtained after 
centrifugation and filtration. After appropriate dilution with SM buffer, phage titers 
were detected.  
Phage particles were precipitated with 1M NaCl and 10% (w/v) PEG 8000 (Amersco, 
Ohio, USA). After decanting the supernatant, sediments were dissolved with 2 mL 
SM buffer. The resulting mixture was extracted with chloroform, followed by 
43 
 
centrifugation (3000×g, 15 min, 4℃). Phage particles were drawn using pipette and 
stored at 4℃. And then, they were further ultracentrifuged by the method of cesium 
chloride gradient at 100,000×g (Beckman L-80XP, CA, USA) for 24 h at 4℃ (Ozkan 
et al., 2016). 
2.2.5 Electron microscopy 
The precipitated phage particles were diluted with SM buffer without gelatin. Phages 
particles (~108 PFU/mL) were negatively stained with phosphotungstic acid (1% w/v, 
pH 7.2). The morphologies of phages were examined with a transmission electron 
microscope (TEM) (H-7650, Hitachi High-Technologies Corporation, Japan) at 
different magnifications. The phage sizes were calculated.  
2.2.6 Optimization of multiplicity of infection (MOI)  
The optimization of phage replication was determined in mixtures of phage and host 
at different MOI ratios (0.001-1000) according to the titers (Wong et al., 2014). The 
host strain culture containing 1×108 CFU of cells was added into phage solutions and 
multiplicities of infection are 0.01, 0.1, 1, 10, 100 and 1000. After incubation for 8 h, 
the phage titers were established using double-layer agar plates after preparing 
dilutions of the filtrate in SM buffer.  
2.2.7 Host range determination 
The host ranges of the phages were detected using the spotting test as described by 
Atterbury et al. (2007). 311 strains of epidemic Salmonella spp. were used for host 
range detection of lytic phage PA13076 in this study. Because temperate phage 
BP96115 was not suitable for phage therapy, only twenty-six strains of Salmonella, the 
majority of which were serovar Pullorum, were used for detecting the host range of 
BP96115. Ten microliters of phage solution (~108 PFU/mL) was spotted on the lawn 
of the bacterial test strains. Plaque was observed next day. 
2.2.8 Thermal and pH susceptibility tests 
Phage solutions were cultured ranging from 30 to 90℃ for 30 min or 60 min to 
determine thermal resistance. Phage solutions were mixed with buffered peptone 
water (BPW) at different pHs (adjusted using 1 mol/L of NaOH or HCl) to detect the 
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pH resistance. The mixed solutions were incubated at 37℃ for 2 h. Phage titers at the 
different temperature and pH value were determined. 
2.2.9 One-step growth curve 
One-step growth curves of phages were established using a 10-min interval method as 
previously described (Bao et al., 2011). Host cells (108 cfu/mL) and the specific phage 
were mixed at a MOI of 10~100 without shaking at 37℃ for 20 min. After 
centrifugation at 12,000×g for 60 s, the sediments of infected host cells were 
re-suspended in 10 mL of pre-warmed TSB and were incubated at 37℃. After 
samples was centrifuged, the phage titer of supernatant was determined every 10 min. 
Assays were repeated for three times. Latent period and burst time were determined 
according to the one-step growth curve. Burst sizes were defined as the final titers of 
phage divided by the concentration of initial host cells.  
2.2.10 Phage adsorption 
Adsorption kinetics of phages was determined as described by Tanji et al. (2004). 
Exponentially growing (OD600nm=0.5) cells of host strains in LB or TSB broth were 
centrifuged and diluted to 1×108 CFU/mL with 10 mL of fresh sterile LB/TSB broth. 
Phage inoculum was added (MOI=0.1) to be 1×107 PFU/mL for the final 
concentration and the mixtures were incubated at 37℃. 200 μL samples were taken 
and centrifuged. Then, the titers of free phages in the supernatant were determined. 
The adsorbed rate was 0 at the beginning. 
2.2.11 Phage DNA extraction, sequencing and genomic analysis 
A high titer suspension of phage particles (>109 PFU/mL) in SM buffer was prepared. 
The phage genome was extracted according to Kang et al. (2013). Briefly, 1 μL 
DNase I (10 mg/mL; Sigma-Aldrich, UK) and 1 μL RNase A (10 mg/mL; 
Sigma-Aldrich, UK) were added in 750 μL of phage suspension and they were 
cultured at 37℃ for 30 min. Then, 75 μL 5% sodium dodecyl sulfate (SDS) and 75 μL 
500 μg/mL proteinase K were added and the mixture was incubated at 56℃ for 1 h. 
Then, using equal volumes of phenol-chloroform-isoamyl alcohol (25:24:1, vol/vol/ 
vol, Sigma-Aldrich) to extract the phage genome. The phage genomes were 
precipitated with 0.1 volume of 3 M sodium acetate (pH 5.2) and 2 volumes of cold 
ethanol and centrifuged (15,000×g, 30 min, 4℃). The pellets were rinsed twice with 
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70% ethanol, dried in air, and then dissolved in 100 μL sterilized deionized distilled 
water containing 50 μg/mL RNase A.  
The phage whole genome sequencing was done by Guangzhou Gene de-novo 
Biotechnology Co. Ltd (Guangzhou, China). The genomic library was prepared using 
an Illumina® TruSeq® Nano DNA Library Prep kit (Illumina, CA). Phage DNA was 
sequenced on an Illumina HiSeq X-Ten platform to 100-fold coverage. The poor 
quality data in the original sequences were removed, and assembled to a genome by 
SeqMan II sequence analysis software (DNASTAR Inc.). 
The open reading frames (ORF) were analyzed using ORF Finder and verified by 
Glimmer 3.02 (Bardina et al., 2016). Homologs of nucleotide sequences and predicted 
protein sequences were scanned using search tools (BLASTP and BLASTN) available 
at the NCBI database. The annotations were compared to published genomes of other 
phages. 
2.2.12 SDS-PAGE analysis 
A high titer (1×1011 PFU/mL) of phage was used for SDS -PAGE analysis. 80 μL of 
phage particle solution was mixed with 20 μL 5×SDS loading buffer (Solarbio, China) 
and heat denatured at 95℃ for 5 min according to Niu et al. (2012). Then, the phage 
samples were loaded onto a standard ready to use 12% SDS-PAGE gel (Yeasen, 
China). The gels were run at a constant voltage of 120V. After staining with 
coomassie brilliant blue G-250 colloidal protein stain (EZBlue G1041, Sigma-Aldrich, 
UK), protein bands were visualized using a transilluminator (Bio-Rad, Hercules, CA). 
2.2.13 Accession number of genomes 
The complete genomes of PA13076 and BP96115 have been deposited in GenBank 
under the accession numbers MF740800 and MG407615. 
2.3 Results 
2.3.1 Lytic and temperate gut phage isolation 
One lytic gut phage, named vB_SenM-PA13076 (subsequently referred to as 
PA13076), was successfully isolated from the fecal samples collected from a 
commercial chicken farm in Haimen city, Jiangsu Province, China. After successive 
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purification steps by picking plaques, this lytic gut phage formed the same size of 
plaques on lawns of its host strain Salmonella Enteritidis ATCC13076. The gut phage 
PA13076 formed clear plaques using the host strain Salmonella Enteritidis 
ATCC13076 with a diameter of 0.8±0.05 mm (Fig.2.1A). Furthermore, a lysogenic 
prophage (temperate), named vB_SpuP-BP96115 (subsequently referred to as 
BP96115), was released from the gut pathogen Salmonella Pullorum SPu-115, 
induced by mitomycin C (0.5 μg/mL). Gut phage BP96115 was temperate, and 
formed turbid plaques on Salmonella Pullorum SPu-109 (its host strain) (Fig. 2.1B). 
The diameter of plaques formed by temperate gut phage BP96115 was 4.0±0.5 mm.  
 
Fig. 2.1 The plaques of the isolated phages PA13076 (A) and BP96115 (B). 
2.3.2 Morphological characterization of isolated phages 
According to the TEM analysis, phage PA13076 was characterized by an oval head 
with a length of 66±4 nm and a contractile tail of 90±5 nm in length (Fig. 2.2A), 
characteristic of the family Myoviridae (Maniloff and Ackermann, 1998). However, 
BP96115 matched the Podoviridae family C1 morphotype, with a small head 
(diameter, 54±4nm) and a short tail with tail fibers (10±2 nm in length) (Fig. 2.2B).  
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Fig. 2.2 TEM images of lytic phage PA13076 (A) and temperate phage BP96115 
(B). Phages were negatively stained with 1% phosphotungstic acid. Bar=50 nm. 
2.3.3 The optimal MOI of lytic phage PA13076 and temperate phage BP96115 
The highest propagation titers for phage PA13076 and BP96115 were observed at the 
lowest (MOI=0.01) and the highest MOI ratio (MOI=1000), respectively (Table 2.1). 
Thus, the optimal MOI is 0.01 for phage PA13076 and 1000 for BP96115. 
Table 2.1 The MOI of lytic phage PA13076 and temperate phage BP96115. 
MOIa Number of 
host bacteria 
(CFU) 
Number of 
phages (PFU) 
Propagating titers of 
PA13076 (PFU/mL) 
Propagating titers of 
BP96115 (PFU/mL) 
0.01 1×108 1×106 1.1×1010 7.3×109 
0.1 1×108 1×107 3.4×109 4.2×109 
1 1×108 1×108 8.6×109 3.6×109 
10 1×108 1×109 7.5×108 9.0×108 
100 1×108 1×1010 1.4×108 1.1×1010 
1000 1×108 1×1011 2.7×109 5.9×1010 
 aphage titer/ bacterial cfu 
48 
 
2.3.4 One-step growth curve of lytic phage PA13076 and temperate phage 
BP96115 
The latent period for both phages was about 10 min (Fig. 2.3), while the average burst 
size of phage PA13076 and BP96115 was calculated to be 21 and 24 phage particles 
per infected cell, respectively. 
 
Fig. 2.3 One-step growth curves of lytic phage PA13076 (A) in Salmonella 
Enteritidis ATCC13076 and temperate phage BP96115 (B) in Salmonella 
Pullorum SPu-109 in TSB broth at 37℃. Values correspond to the numbers of PFU 
per infected cell. 
2.3.5 Phage adsorption 
The adsorption of PA13076 to its host Salmonella Enteritidis ATCC13076 is shown in 
Fig. 2.4A. Phage particles adsorbed to host cells indicated that approximately 40% 
within 2 min, 75% in 4 min, and nearly 98% in 10 min. For the adsorption of 
temperate phage BP96115 onto its host strain Salmonella Pullorum SPu-109, 
approximately 80% at 2 min, more than 83% within the first 5 min, and 99% were 
adsorbed at 10 min post-infection.  
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Fig. 2.4 Adsorption of lytic phage PA13076 (A) and temperate phage BP96115 (B) 
to their host cells. Each data point is the mean ± standard deviation from three 
independent experiments. 
2.3.6 Host range of phage PA13076 and BP96115 
The lytic phage PA13076 possessed a wide host range. The spotting test results 
indicated that phage PA13076 lysed 71.4% (222/311) of epidemic Salmonella isolates 
tested (Table S2.1, supplementary materials). However, the temperate phage BP96115 
had a narrow host range with lytic effect on only 34.61% (9/26) of tested strains. 
Phage BP96115 can only infect specific strains of the serotypes Pullorum, Enteritidis, 
and Typhimurium of Salmonella enterica subsp. enterica (Table S2.2, supplementary 
materials).  
2.3.7 Thermal and pH susceptibilities of PA13076 and BP96115 
PA13076 was most stable at pH 5-9 (Fig. 2.5A), while BP96115 was most stable at 
pH 5-7 (Fig. 2.5B), with decreased stability observed at pH values <5 and >7. Both 
phages were stable between 30℃ to 60℃ for 30 min and 60 min, with a sharp decline 
in the phage titer above 60℃, decreasing to 0 PFU/mL at 70℃ for PA13076 for 30 
min and 60 min (Fig. 2.5C). However, 2.59% viability of BP96115 was retained at 
70℃, relative to the observed phage titer at 60℃, with a total viability loss at 80℃ 
(Fig. 2.5D).  
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Fig. 2.5 pH stability of lytic phage PA13076 (A) and temperate phage BP96115 (B) 
and thermo-stability of lytic phage PA13076 (C) and temperate phage BP96115 
(D). 
2.3.8 The lytic gut phage PA13076 genome sequence 
The lytic gut phage PA13076 contained double-stranded DNA with 52,474 bp and a 
G+C content of 46.12 mol%. Genome analysis of the phage revealed 69 ORFs, but no 
tRNA genes. However, most of the genes (44 of 69 ORFs) were hypothetical proteins 
(Table S2.3, supplementary material).  
The genome of PA13076 is comprised of four main functional protein clusters: (1) 
DNA packaging (ORF18: terminase large subunits), (2) structural assembly proteins 
(ORF8, ORF9, ORF64: tail protein, ORF62, ORF63: tail fiber assembly protein, 
ORF15: major capsid protein, ORF16: scaffold protein, ORF17: portal protein), (3) 
host lysis proteins (ORF60: lysozyme), and (4) DNA replication, modification, 
regulation proteins (ORF22: thymidylate kinase, ORF32: TPR repeat: kinesin light 
chain, ORF36: primase, ORF39: putative DNA binding protein, ORF43: PAS domain 
S-box, ORF46: nucleotide-binding protein, ORF48 deoxycytidylate deaminase, ORF 
51 
 
50: DEAD box helicase, ORF54 thymidylate synthase, ORF55, DNA polymerase beta 
subunit, ORF56: DNA polymerase (Fig. 2.6).  
A progressive MAUVE multiple alignment revealed considerable sequence similarity 
between the genomes of phage PA13076 and Salmonella phage BP63 (GenBank 
accession no. KM366099.1) and Salmonella phage UPF_BP2 (GenBank accession no. 
KX826077.1) (Fig. 2.7). Phage PA13076 showed 97% DNA sequence similarity to 
phage BP63 and 97% DNA sequence similarity to phage UPF_BP2 (Fig. 2.7).
 
Fig. 2.6 Genome map of PA13076. Genes are numbered according to annotation. 
The lysozyme gene is shown in blue, DNA packaging, replication and modification 
genes are shown in green, structural genes are depicted in yellow, while the tail 
proteins are shown in red. 
  
 
 
Fig. 2.7 Genome comparison of PA13076 (A) with Salmonella phage BP63 (B) 
and UPF_BP2 (C) at DNA level.  
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2.3.9 The genome analysis of temperate phage BP96115 
The genome of temperate phage BP96115 consists of a double-stranded linear DNA 
molecule of 41,264 bp, containing 62 ORFs ranging from 81 to 2178 bp in length, 
possessing an overall GC content of 48.71%. Of the 62 ORFs, 47 predicted proteins 
with good coding potential. A complete list of ORFs is shown in table S2.4 of 
supplementary material. The nucleotide sequence of temperate phage BP96115 shared 
high similarity with that of other temperate phages, enterobacteria phage ST104 
(GenBank accession no. AB102868.1) (coverage 100%, identity 99%), Salmonella 
phage SE1 (GenBank accession no. DQ003260.1) (coverage 74%, identity 98%), 
Salmonella phage vB_SalP_PM43 (GenBank accession no. MF188997.1) (coverage 
63%, identity 97%), Salmonella phage ST64T (GenBank accession no. AY052766.1) 
(coverage 63%, identity 97%), phage P22 (GenBank accession no. AF217253.1) 
(coverage 62%, identity 98%) and Salmonella phage epsilon34 (GenBank accession 
no. EU570103.1) (coverage 43%, identity 97%).  
 
Fig. 2.8 Schematic representation of the linear dsDNA genome of temperate 
phage BP96115. Positions and predicted functions of ORFs are represented by an 
arrow. The lysis genes are shown in blue. DNA packaging genes are shown in yellow. 
Structural genes are marked in red. Genes involved in DNA replication/modification/ 
regulations are shown in green, while the lysogeny genes are marked in purple.  
Genomic analysis indicated that temperate phage BP96115 carries DNA replication, 
conversion cassette, integrase, superinfection exclusion, antitermination, 
endopeptidase, probable regulatory protein N, packaging head, lysis, and tail proteins, 
while it also contained hypothetical genes (Fig. 2.8). ORF5 (1902-2123, unknown) 
was present in BP96115 but absent in other similar temperate phages. Comparative 
genomic analysis indicated that BP96115 has a different genomic organization 
compared to enterobacteria phage ST104, and Salmonella phages P22, epsilon34, SE1, 
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vB_SalP_PM43 and ST64T (Fig. 2.9). Most of the protein sequences of temperate 
phage BP96115 were closely related to those of other temperate phages. 
 
Fig. 2.9 Alignment of the genome of temperate phage BP96115 with other phages 
using software MAUVE V2.3.1. Names of the phages are mentioned under their 
maps line, from top to bottom; (A) BP96115, (B) ST104, (C) P22, (D) epsilon34, (E) 
SE1, (F) vB_SalP_PM43 and (G) ST64T. Colored blocks indicate regions of 
nucleotide similarity while colorless blocks correspond to dissimilar regions. 
2.3.10 SDS-PAGE analysis 
SDS-PAGE analysis was conducted on both PA13076 and BP96115. For phage 
PA13076, six protein bands were observed, with the most abundant polypeptide 
having a molecular mass of about 35 kDa. Two main bands with molecular masses of 
about 58 and 70 kDa were observed in BP96115 samples (Fig. 2.10). These bands, 
which were easily detected, were most likely the major head and tail proteins. 
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Fig. 2.10 SDS-PAGE analysis of proteins of lytic phage PA13076 (1) and 
temperate phage BP96115 (2). Lane M are the protein molecular size markers (kDa).  
2.4 Discussion 
Salmonella spp. are Gram-negative rods with more than 2,600 serovars (Wu et al., 
2016). They can infect animals and humans, cause inflammation of the intestine and 
generally produce a chronic asymptomatic carrier state (Kurtz et al., 2017). The 
control strategies adopted for treating Salmonella infections, including preventive 
measures and antibiotic treatments, have not been sufficient to eradicate salmonellosis. 
Moreover, several studies reported the emergence of multidrug-resistant Salmonella 
strains (Pan et al., 2009; Venza Colon et al., 2004). Phages are the most numerous and 
ancient biological entities in microbial ecosystems of water, soil, and the animal gut 
(Skurnik and Strauch, 2006). Phage abundance exceeds host populations by 
10-100-fold (Manrique et al., 2017). However, the majority of phages in the animal 
gut is lysogenic, and therefore spend most of the time as integrated prophages 
(Cadwell, 2015).  
In this study, one lytic gut phage and one temperate prophage were isolated and 
named as vB_SenM-PA13076 (PA13076) and vB_SpuP-BP96115 (BP96115), based 
on the naming rules for phages (Kropinski et al., 2009). The tailed phages comprise of 
three families (Myoviridae, Siphoviridae and Podoviridae) (Ackermann, 1998), and 
about 96% of investigated phages belonged to the tailed phages (Ackermann, 2007). 
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The lytic gut phage PA13076 matched the Myoviridae based on the contractile tail. 
Although this phage is unique, its head is oval in shape, which is very different from 
other reported Salmonella phages belonging to the Myoviridae (Santos et al., 2011; 
Whichard et al., 2010), it is a classical virulent Myoviridae phage. The temperate 
phage BP96115 with short, noncontractile tails was morphologically similar to 
members of family Podoviridae (Ackermann, 1998). The size of this phage was close 
to that reported for the phage P22 with a capsid length of 64 nm and the tailspike 
length of 6.4 nm (Venza Colon et al., 2004).  
Determination of the host range of phages is important in order to properly 
characterize them. The lytic phage PA13076 demonstrated a wide host range, similar 
to Salmonella phage PVP-SE1 (Santos et al., 2011) and T-even phage S16 (Marti et 
al., 2013). The previous studies on these wide host range phages indicated that they 
were suitable and good candidates of phage therapy. However, the host range of the 
temperate phage BP96115 was relatively narrow. The host range of BP96115 was 
almost the same as that of temperate phage P22, which was reported to inhibit about 
12 isolates of Salmonella Typhimurium as well as Salmonella Derby and Salmonella 
Enteritidis but not strains of serotypes Newport, Muenchen and Muenster (Zinno et al., 
2014). Therefore, phage BP96115 may also be used as a tool of molecular biology 
like phage P22. The tail fibers and the base plate determined the host cell recognition 
(Garcia-Doval and van Raaij, 2012; Rego et al., 2012). Phage P22 tail fiber proteins 
bind to the O-antigen moiety of the LPS of its Salmonella host (Andres et al., 2010). 
Therefore, due to the high similarity of the tail fiber proteins between phage P22 and 
the isolated phage BP96115, the receptor molecules of BP96115 may also be 
O-antigens of the lipopolysaccharide (LPS). The burst sizes of both phages were 
somewhat smaller than that of previously reported Myoviridae phages (50-100 
PFU/cell) (Chang et al., 2005; Park et al., 2012; Raya et al., 2006) and smaller than 
that of the previously characterized Salmonella Pullorum phage PSPu-95 (78 particles 
per cell) and PSPu-4-116 (86 particles per cell) (Bao et al., 2011). Similar small burst 
sizes have been found in other phages such as Staphylococcus phages phiIPLA-RODI 
and phiIPLA-C1C (25 and 15 particles per cell) (Gutierrez et al., 2015), Salmonella 
Typhimurium lytic phage Φst1 (22 particles per cell) (Wong et al., 2014), and 
Leuconostoc mesenteroides phage 1-A4 (24 particles per cell) (Mudgal et al., 2006). 
The latent period was shorter compared with phage Φst1, whose latent period was 40 
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min (Wong et al., 2014), but similar to the Salmonella lytic phages ST4 and SG3 
(10min) (Hong et al., 2013). In this study, 98% of lytic phage PA13076 and 99% of 
temperate phage BP96115 particles adsorbed to their host cell within the first 10min. 
Similarly, all of the E. coli phage JS09 particles adsorbed to their host cells within 9 
min (Zhou et al., 2015). However, the adsorption was approximately 30% of phages 
ΦPSA1 and ΦPSA2 in 5 min, increasing very slowly to 40-50% after 30 min (Di 
Lallo et al., 2014). The adsorption rate is a specific property of each phage-host pair 
and may vary depending on phage/host ratio, pH, temperature, or the media 
composition (Lau et al., 2012; Rakhuba et al., 2010). Multiplicity of infection (MOI)–
often defined as the “ratio of phage particles and host cell”– is the key factor 
governing the phage titers. Depending on the phage–host interactions, MOI should be 
adjusted to an appropriate value to beneficial phage amplification, so that high phage 
titers are obtained in the liquid amplification culture (Hyman, 2009). This 
characteristic also seems to be an important factor to the successful in phage therapy 
(Sharma et al., 2017). As demonstrated in previous studies, the MOI ranging from 10 
to 10000 in Salmonella phage PC1 administration reduced Salmonella Typhimurium 
U288 cells significantly (Hooton et al., 2011). Both phages analyzed in the present 
study showed resistance to heat (up to 60℃) and pH (ranging from 5-9 for PA13076 
and 5-7 for BP96115), similar to the Salmonella phages ΦSG-JL2 (Kwon et al., 2008). 
The resistance to heat and pH can influence the efficacy of phage therapy for 
preventing Salmonella infections.  
Genomic studies of gut phages remain rather limited. Temperate phages are related to 
the virulence, species diversity and evolution of species (Dalmasso et al., 2016; 
Moreno Switt et al., 2013), with most of the temperate phages able to transfer 
horizontal gene by transduction (Schicklmaier and Schmieger, 1995). Up to 80% of 
phage-encoded proteins from virus-like-particle derived metagenomics in the gut have 
been reported not to match known proteins (Mills et al., 2013; Reyes et al., 2013). The 
genomic information indicated that PA13076 are an unique lytic phage. Furthermore, 
only very small fractions of abundant lytic Salmonella phages have been 
characterized, including: FelixO1 (Whichard et al., 2010), vB_SenM-S16 (Marti et al., 
2013), SPN1S (Lim et al., 2012), SP6 (Dobbins et al., 2004), and ΦSG-JL2 (Kwon et 
al., 2008). Thus, it was not surprising that many proteins of the newly sequenced 
phage PA13076 carried numerous genes of unknown function. However, there are no 
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integrase, repressor or transposase genes in its genome, which shares the same 
characteristics with lytic phages (Whichard et al., 2010; Marti et al., 2013; Lim et al., 
2012). However, temperate phage BP96115 was highly similar with other temperate 
phages such as the well-characterized phage P22 (Vander Byl and Kropinski, 2000), 
and enterobacteria phage ST104 (Tanaka et al., 2004). Because of the 
well-characterized genes and proteins of phage P22, most of the ORFs of temperate 
phage BP96115 matched known proteins. The high similarities of phage BP96115 
proteins with other temperate phages’ indicated that it is a real temperate phage 
(Zinno et al., 2014). 
The instinct of a phage is the lytic ability for bacteria. Therefore, research on the 
endolysin gene is very import for understanding phage evolution and the impact of 
phages on the bacterial flora in animal intestine. In fact, the majority of tailed phages 
use a lysis cassette containing endolysin and holin components to puncture the 
cytoplasmic membrane and lyse the peptidoglycan layer of the bacterial cell wall 
(Young, 2014). The holin genes are usually in the upstream of the endolysin, 
occasionally overlapping it (Santos et al., 2011). However, the position of the holin 
gene is far from the putative endolysin (ORF60) in phage PA13076. In the temperate 
phage BP96115, ORF22 encodes the holin protein, which belongs to the Class II holin 
family. In addition, the lysozyme of phage BP96115 is equal to the Rz/Rz1 accessory 
lysis element, which is ubiquitous in Gram-negative bacteria phages (Summer et al., 
2007).  
In this study, the phage structural proteins were not identified using mass 
spectrometry. However, the most abundant protein may likely be the major head 
protein, according to the study of the structural proteins of Salmonella phage 
PVP-SE1 by ESI-MS/MS (Santos et al., 2011). The precursor of major head was 32.6 
kDa, and it was smaller than its predicted size (50.6 kDa) (Niu et al., 2012). 
According to Niu et al. (2012), the predicted protein molecular weights did not agree 
with the observed protein molecular weights, likely because of proteolytic cleavage. 
Phage PA13076 is a classical lytic phage and Phage Bp96115 is a temperate 
phage. The above data of characteristics are the basis for studying of gut phages in 
regulating gut microbiota (Lusiak-Szelachowska et al., 2017).  
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2.5 Supplementary material 
Supplementary material: table S2.1, S2.2, S2.3 and S2.4. 
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CHAPTER THREE 
DISTRIBUTION OF ORALLY ADMINISTRATED LYTIC AND 
TEMPERATE SALMONELLA GUT PHAGES IN MICE 
3.1 Introduction 
Phages infect bacterial cells and disrupt bacterial metabolism. In case of lytic cycle, 
phages cause the bacterium to lyse (Cisek et al., 2017; Sabouri Ghannad and 
Mohammadi, 2012). Phages are considered to be the most numerous biological 
entities in the world (Sharma et al., 2017) and are common in the gastrointestinal tract 
(GIT) of mammals (Mills et al., 2013). Especially temperate phages are the important 
components of the mammalian intestinal flora (Ashelford et al., 2000; Gorski et al., 
2003; Merril, 1974). Studying on gut virome using metagenomic analysis has 
revealed that the potential functions of phages in the gut ecosystem (Breitbart et al., 
2003; Foca et al., 2015).  
Pathogen infections of the GIT are one of the major causes of morbidity and mortality 
in economically important animals (Oliveira et al., 2014). Following oral ingestion of 
pathogenic bacteria, proportions of intestinal microorganism survive in the stomach, 
some of them reach the ileum and the cecum, and disrupt the already established 
commensal microbial flora and induce inflammation (Mastroeni and Sheppard, 2004). 
They are carried from the intestine to the bloodstream. One of the effective way for 
treating GIT infections were oral administration of phages (Ahmed et al., 2016; 
Bradley et al., 1991; Hannu et al., 2002; Schattner et al., 2005). The role of intestinal 
phages is the potential capability to regulate the commensal bacteria populations 
(Lopetuso et al., 2016). Thus, gut phages may be responsible for defensing harmful 
bacteria and restricting their widespread transmission and repairing the resulting 
pathology (Gorski and Weber-Dabrowska, 2005), highlighting that phages play a key 
role in the gut. However, phage survival as well as gut colonization and distribution in 
the GIT is still poorly understood. In addition, most phage studies do not report if 
phages can penetrate the tissue of other organs. 
Phage preparations contain large amounts of bacterial endotoxin due to host cell lysis 
(Gu et al., 2011). It has been known for more than 100 years that Gram-negative 
bacteria contain a heat-stable toxin, the so-called endotoxin, which chemically 
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belongs to the lipopolysaccharides (LPS) (Yuan et al., 2012). Even small amounts of 
LPS from protein preparations (1ng/mL) can induce cytokine production, pyrogenic 
reactions and septic shock in humans and experimental animals (Abaev et al., 2013; 
Romanovsky et al., 1996). Therefore, efficient removal of LPS from phage 
preparations is an ongoing challenge in the application of phages. So far, various 
techniques including cesium chloride (CsCl) ultracentrifugation (Dufour et al., 2016), 
anion exchange and affinity chromatography (Boratynski et al., 2004), and 
ultrafiltration (Hashemi et al., 2013) have been investigated to remove LPS from 
recombinant protein solutions with varying degrees of success. 
This study intended to elucidate the abundance and distribution of phages in the GIT 
when mice were orally administrated the phage for 31 days. At the same time, the 
capabilities of phages to translocate to blood and spleen and the levels of IgG in sera 
and sIgA in ileum samples were determined. 
3.2 Materials and Methods 
3.2.1 Large scale preparation of phage suspensions 
Lytic phage PA13076 and temperate phage BP96115 were used in this study. Phage 
PA13076, originally isolated from chicken feces, was propagated by using 106 
CFU/mL of Salmonella enterica subsp. enterica serovar Enteritidis (Salmonella 
Enteritidis) ATCC 13076 and 108 PFU/mL of PA13076 in 1000 mL TSB broth at 37℃ 
without shaking for 6 h. The temperate phage BP96115, originally induced from the 
gut pathogen Salmonella enterica subsp. enterica serovar Pullorum (Salmonella 
Pullorum), was amplified using its host strain Salmonella Pullorum SPu-109 (1×108 
CFU/mL) and BP96115 (1×109 PFU/mL) in 1000 mL of TSB broth for 6 h at 37℃ 
without shaking. Crude phage lysates were obtained by centrifugation at 15,000×g for 
10 min at 4℃. After filtrating, phage particles were precipitated using NaCl and PEG 
8000 as described in chapter two. 
3.2.2 LPS removal 
Phage particles (1010 PFU/mL) in SM buffer were added on top of discontinuous 
cesium chloride gradients (CsCl) and centrifuged at 40,000×g for 4 h at 4℃ 
(Watanabe et al., 2007). The phage band was collected with a sterile syringe, dialyzed 
against sterile SM buffer overnight at 4℃ and changed one time during dialysis. 
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The CsCl-purified phages were treated with 1% deoxycholate detergent with shaking 
at 37℃ for 60 min. This was followed by ultrafiltration using Amicon Ultra-15 
Centrifugal Filter Devices with a 100 KDa nominal molecular weight cut-off 
membrane (Merck Millipore Ltd., Ireland) with centrifugation at 4,000×g for 5 min at 
4℃ (Jun et al., 2013), which was done five times with washing using SM buffer. 
Finally, the phage suspension obtained from ultrafiltration was filtered again.  
3.2.3 Endotoxin quantitation in phage solutions 
The endotoxin contents of the raw phage lysate and the purified phage suspensions 
were measured using a Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin 
Quantitation kit (Thermo Fisher, Sweden), according to the accessary protocol. 
3.2.4 Animals experimental treatments 
C57BL/6 female mice (6-8 week-old) were purchased from the Comparative Medical 
Centre of Yangzhou University (Yangzhou, China) and maintained under specific 
pathogen-free conditions in the experimental animal center in Jiangsu Academy of 
Agricultural Sciences (JAAS). The animal experiment was approved by the JAAS in 
accordance with the guidelines provided by the Animal Care and Ethics Committee 
and followed the ARRIVE (Animal Research: Reporting of in vivo Experiments) 
guidelines (Kilkenny et al., 2010). Mice were fed ad libitum with a commercial grain 
formulation (SHOOBREE Rat and Mouse Maintenance Diet, Jiangsu XieTong 
Organism Co., Ltd., Nanjing) and sterilized mineral water (Evian; pH 7.2; HCO3-, 489 
mg/L).  
After two weeks acclimation, mice were randomly assigned to three experimental 
treatments on the basis of body weight (~18g), the Control group (20 mice) was 
separated from phage-treated mice and received no phage in their drinking water,  
the Lytic group (20 mice) received purified lytic gut phage PA13076 in their drinking 
water at a concentration of ca. 1×108 PFU/mL (approx. 4×108 PFU) and the Temperate 
group (20 mice) were treated with 1×108 PFU/mL (approx. 4×108 PFU per mouse 
daily) of purified temperate phage BP96115 in sterilized mineral water daily. The trial 
was conducted for 31 days. 
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3.2.5 Sample collection 
After being weighed again, four mice in each group were “humanely” euthanized on 
day 16 and 31 after their first ingestion of phage. For each mouse, 0.2 mL of blood 
was taken from puncturing the orbital plexus with a plastic tube containing 20 μL 
heparin (1000 U/mL, Sigma), while simultaneously 0.2 mL of blood was added into a 
tube without any anti-agglutination additive to produce serum. Six different segments 
of the GIT with their contents including stomach, duodenum, jejunum, ileum, cecum, 
and colon, and, additionally spleen, were isolated from mice and weighed prior to 
phage enumeration. All samples were collected aseptically. In addition, fecal samples 
were obtained on day 16 and 31 from each mouse before being euthanized. 
3.2.6 Phage detection  
Freshly collected feces were weighted and homogenized in a sterile plastic tube after 
addition of sterile 10-fold SM buffer. Each segment of the GIT with its contents and 
spleen was homogenized in SM buffer with a tissue homogenizer (Shanghai 
Chemistry and Scientific Co. Ltd., Shanghai, China) making 10-fold diluted 
suspensions. The un-agglutinated blood (0.2 mL) was homogenized with SM buffer in 
a final volume of 1 mL. After centrifugation at 12,000×g for 10min at 4℃, these 
solutions were subjected to serial decimal dilution. The phage titers were determined 
using Salmonella Enteritidis ATCC 13076 or Salmonella Pullorum SPu-109 as host 
cells. The detection limits were 50 PFU/g. 
3.2.7 Determination of IgG in sera and secretory IgA in the ileum 
While IgG levels were tested in sera, secretory IgA (sIgA) levels were tested in ileum 
homogenates. Samples from day 31 were analyzed using a mouse IgG ELISA 
(88-50400) and a mouse IgA ELISA (88-50450) kit (eBioscience, San Diego, CA), 
according to the manufacturer’s protocol. The optical density (OD) was measured at 
450 nm with a plate reader (TECAN SUNRISE, Switzerland) and phage-treated 
samples were compared to the control group using one-way ANOVA. Significant 
differences were determined using Duncan’s test with significance set at p<0.01. All 
data were analyzed using SPSS 16.0 (SPSS Inc.). 
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3.3 Results 
3.3.1 The endotoxin concentration of purified phages 
The endotoxin levels in the crude phage lysate exceeded 700 EU/mL for both phages 
(Table 3.1). After the phage suspensions were dialyzed following CsCl- 
ultracentrifugation, still 16.72 and 20.25 EU/mL were detected. After detergent 
treatment and ultrafiltration, sufficiently low endotoxin levels were reached. Thus, the 
concentration of endotoxin was reduced to <1 EU/mL, which is an acceptable range 
for in vivo applications (Table 3.1).  
Table 3.1 Endotoxin levels after each purification (unit: EU/mL) 
Purification Step The phage solution PA13076 BP96115 
1 Crude phage lysate 748.54 912.20 
2 CsCl-ultracentrifugation 16.72 20.25 
3 Ultrafiltrated 0.86 0.91 
 Phage titer (PFU/mL) 1×1010 1×1010 
3.3.2 Distribution of the phages in the GIT 
The average body weight of the mice did not differ significantly between the three 
groups at the times of sampling. Mice were sacrificed for phage enumeration in the 
gastrointestinal tracts in the middle (day 16) and at the end (day 31) of the trial, 
indicating that a constant titer was reached at day 16 (Fig. 3.1). In comparison to the 
control group, significantly increased phage titers were detected in all of the examined 
segments of the GIT of treated mice for the lytic gut phage PA13076 (Fig. 3.1A) and 
the temperate phage BP96115 (Fig. 3.1B), indicating that both phages colonized the 
gastrointestinal tract. Phages were also detected in the ileum, colon, cecum and feces 
samples of control mice using Salmonella Pullorum SPu-109 as the host. More than 
102 PFU/g were detected in stomach samples of mice treated with phage PA13076 and 
BP96115 through drinking water. 
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Fig. 3.1 Phage titers in the GIT of mice. The phage titer is expressed as Log PFU/g 
in form of min to max with the mean for the specified gut segment (stomach, 
duodenum, jejunum, ileum, colon, cecum and feces) on the 16th and 31st day. Water 
and food were withdrawn 2 h before killing. A. The titer of phage PA13076 using 
Salmonella Enteritidis ATCC13076 as the host. B. The titer of phage BP96115 using 
Salmonella Pullorum SPu-109 as the host. Black and blue color represents the lytic (A) 
and lysogenic (B) and control group, respectively.  Represents phage titer values 
below the detection limit. 
3.3.3 Phage recovery from blood and spleen samples 
Phages were detected in blood and spleen samples on day 16 and day 31 (Fig. 3.2), 
and phage titers in the spleen were similar between PA13076 treated and BP96115 
treated mice (Fig. 3.2 A and B). The phage titers in whole blood samples ranged from 
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102 to 103 PFU/mL, thus lower than those detected in spleen samples wherein up to 
104 PFU/g were detected.  
     
Fig. 3.2 Quantification of phages in blood and spleen. Phage PA13076 and 
BP96115 (about 4×108PFU) were fed to mice via drinking water every day for the 
lytic and the temperate group. The phage titers were detected on day 16 and 31. A. 
The titer of phage PA13076 using Salmonella Enteritidis ATCC13076 as the host. B. 
The titer of phage BP96115 using Salmonella Pullorum SPu-109 as the host. Black 
and blue color represents the lytic (A) and lysogenic (B) and control group, 
respectively.  Represents phage titer values below the detection limit. 
3.3.4 The levels of IgG in sera and sIgA in ileum 
At day 31 of the phage treatment, slightly increased IgG (p=0.118) and sIgA (p=0.88) 
levels were detected in comparison to the control mice. However, no significant effect 
on the levels of sera IgG and ileal sIgA was observed, although IgG and sIgA levels 
were somewhat higher in the lytic than the temperate group. 
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Fig. 3.3 IgG serum and sIgA ileum levels in samples at the end of the experiment 
(day 31). Results are shown as mean values of pg/mL. The standard deviation of the 
mean is indicated by error bars (n=4). 
3.4 Discussion 
In recent years, researchers have increasingly focused on the regulatory role of phages 
in the gut (Abeles and Pride, 2014; Foca et al., 2015; Lusiak-Szelachowska et al., 
2017). However, poor understanding of the preferred distribution of phages in the gut 
remains a major problem. This study therefore analyzed the abundance and 
distribution of phages in the GIT when mice were exposed to phages for 31 days.  
Oral administration of phages may be a potential route for controlling gastrointestinal 
infections and systemic infections (Ryan et al., 2011). However, the environment of 
the stomach is a major challenge for phage stability (Atterbury et al., 2007; Ma et al., 
2008; Maura et al., 2012). The current study showed that the viability of phages was 
rapidly lost upon exposure to gastric acid, as the titers of phages in stomach were 
always ≤102 PFU/g, although the mice were administrated 4×108 PFU/day 
continuously for 31 days in the lytic and temperate groups. 
It has been confirmed that phages can migrate to peripheral blood and organs from the 
gut (Abeles and Pride, 2014; Gorski et al., 2006). Phages, such as E. coli phages, can 
translocate to the blood much more effectively from the intestinal tract than from the 
stomach (Dabrowska et al., 2005). Keller and Engley (1958) have shown that the oral 
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inoculation of Bacillus megaterium phages could be detected in mice blood in 5 min. 
Schubbert et al. (1994) demonstrated that orally ingested foreign DNA, phage M13 
and plasmid DNA, was able to persist in fragmented form in the GIT of mice, 
penetrated the intestinal wall and reached the nuclei of various cells. In this study, the 
presence of phages in spleen and whole blood samples also suggested that phages can 
cross the epithelial barrier and enter extraintestinal sites even when applied via the 
oral route. Highest phage titers were detected in the cecum as well as in feces with 104 
and 106 PFU/g in cecum for PA13076 and BP96115 treatment. Similar results showed 
that phage T3 preferentially absorbed in the higher or deeper sections of the intestine 
(Hoffmann, 1965). In the current study, the lysogenic phage using Salmonella 
Pullorum SPu-109 as the host was detected at up to 104 PFU/g in the cecum in the 
control mice, while low abundances were detected for the virulent phage using 
Salmonella Enteritidis ATCC13076 as the host in the mice gut. This matches a report 
by Dhillon et al. (1976), showing that temperate phages predominate in mammalian 
feces. 
However, despite exposing mice to phage over 31 days, the titer of phages in GIT and 
blood samples did not increase gradually. Phages are foreign invaders, so that they 
can induce immune response. Moreover, they can be rapidly eliminated by 
reticulo-endothelial system (Dabrowska et al., 2005). The production of anti-phage 
antibodies and the inhibitory effect due to adaptive immunity responses are key 
factors controlling phage colonization in the animal body. A long-term study of 
antibody induction in mice with T4 phage applied per os over 100 days showed that 
high levels of anti-phage antibodies (IgM, IgG, and secretory IgA), decreased the 
phage concentrations in the blood of mice (Majewska et al., 2015). In the present 
study, the numbers of both phages in blood did not exceed 103 PFU/mL, indicating 
that the mice immune response was active.  
The residual quantity of bacterial LPS is restricted during the administration of 
biotherapeutics and vaccines (Kabanov and Prokhorenko, 2010; Wang and Quinn, 
2010). Recent studies showed that high phage concentrations can induce 
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pro-inflammatory responses, and long-term exposure to phages induced an antibody 
response in spleen (Hodyra-Stefaniak et al., 2015; Majewska et al., 2015). These data 
highlight the need for an appropriate purification protocol in terms of acceptable 
endotoxin levels. In order to satisfy the requirements for phage clinical application 
(Simoliunas et al., 2015), it is necessary to quantify endotoxin levels in the final 
product prior to application (Merabishvili et al., 2009). An acceptable level of 
endotoxin, usually below 0.5 EU/mL of endotoxin in the phage solution, was 
achieved when using a protocol including concentration/washing by ultrafiltration and 
two CsCl ultracentrifugation steps (a step gradient followed by an isopycnic gradient) 
(Henry et al., 2013). A combination of ultracentrifugation and ultrafiltration was 
successfully used in the present study to remove bacterial LPS from prepared phage 
solutions before these solutions were used for animal experiments, thereby matching 
previous studies (Hudson et al., 2015; Williamson and Paul, 2006).  
The two phages, PA13076 and BP96115, were purified using ultracentrifugation and 
ultrafiltration methods. The endotoxin levels were reduced to <1 EU/mL. Overall, the 
current study demonstrated that the gut lytic and gut temperate phage would distribute 
and locate in the intestinal tract of mice by oral intake, preferentially colonizing the 
posterior of the gut. Moreover, the temperate phage was more numerous than the lytic 
phage in mammalian feces. This study therefore provides basis information for 
studying the impact of gut phage on the gut microbiota. 
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CHAPTER FOUR 
ALTERATIONS IN THE DIVERSITY AND COMPOSITION OF MICE GUT 
MICROBIOTA BY LYTIC OR TEMPERATE SALMONELLA GUT PHAGE 
TREATMENT 
4.1 Introduction 
The global overuse of antibiotics has led to the rapid emergence of multi-drug 
resistant bacteria, potentially endangering the efficacy of antibiotics and threatening 
public health (Ventola, 2015; WHO, 2014; Zaman et al., 2017; Zhang et al., 2006). 
Moreover, antibiotics alter the normal composition of mammalian gut microbiota 
resulting in short-term or even persistent dysbiosis (Iizumi et al., 2017; Lewis et al., 
2017; Namasivayam et al., 2017). Hence, there is increasing demand to find 
alternatives to antibiotics to tackle bacterial infections.  
As the gut contributes to animal health in many ways (Blaut and Clavel, 2007; 
Marchesi et al., 2016), the term ‘gut health’ of mammalia is increasingly popular 
(Bischoff, 2011). The mammalian gut is colonized by diverse microorganisms, 
including bacteria, phages and eukaryotic viruses and other microorganisms (fungi, 
protozoa and archaea) (Robinson et al., 2016; Rosshart et al., 2017). The intestinal 
commensal flora plays multifaceted roles in maintaining animal health, such as 
promoting metabolism, defensing pathogens, developing the immune system and 
maturation (Belkaid and Hand, 2014; Rampelli et al., 2015; Rosshart et al., 2017).  
Compared with traditional sequencing methods, high-throughput sequencing 
techniques such as Illumina sequencing are considered to be timesaving and more 
cost-effective and are thus now routinely used for microbial metagenome analysis 
(Heck et al., 2016). Comparative metagenomic analyses help us understand the 
composition and structure of gut microbiota in the complex gut ecosystem (Grossart 
et al., 2013; Norman et al., 2014). Moreover, the development of fecal transplantation 
is a promising method to treat dysbiosis diseases.  
Phages are the dominating species of the gut microbiota, with estimates of 1015 
particles in the gut ecosystem (Dalmasso et al., 2014), outnumbering bacteria at a 10:1 
ratio (Dabrowska et al., 2005). Further, the phages in the intestinal tract are dominated 
by temperate phages (Reyes et al., 2010). Also, gut phages may have an important 
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role in disease, such as chronic periodontitis (Gorski and Weber-Dabrowska, 2005) 
and inflammatory bowel disease (IBD) (Lepage et al., 2008). Moreover, oral 
prophylactic “phagebiotics” can kill specifically targeted bacterial pathogens in the 
gastrointestinal tract (GIT)(Volker, 2015). The influence of gut phages on animal 
health is manifold (De Paepe et al., 2014; Lusiak-Szelachowska et al., 2017; Mills et 
al., 2013) and phages may have the potential to exert selective pressure and regulate 
selected members of the mammalian intestinal microbiota. However, there are only 
few studies showing the impact of phages or phage cocktails on gut microbiota in 
healthy animals. The aim of this study was therefore to understand the regulating roles 
of lytic or temperate gut phage treatment on the microbial community and diversity in 
healthy mice. This information may guide further research on the evaluation of the 
prophylactic use of phages in livestock rearing. 
4.2 Materials and Methods 
4.2.1 Phage and antibiotic solutions 
The lytic gut phage PA13076 and the temperate gut phage BP96115 were prepared 
and purified as reported in Chapter Two and Three. The titer of each phage was 
adjusted to 1×108 PFU/mL in drinking water (sterilized mineral water, Evian, pH 7.2; 
HCO3-, 350 mg/L). The concentration of streptomycin sulfate (Solarbio Technology 
Co., Ltd., Shanghai, China; >98%) was adjusted to 10 mg/mL using the same drinking 
water. Mice without phage and streptomycin treatment were used as the control group. 
The phage or streptomycin solutions were prepared every day. 
4.2.2 Animals 
C57BL/6 female mice (6-8 week-old) were used in this study and they were reared 
under the same condition with Chapter Three and following the ARRIVE guideline 
(Kilkenny et al., 2010). Mice were fed ad libitum with a commercial grain 
formulation (SHOOBREE Rat and Mouse Maintenance Diet, Jiangsu Xietong 
Organism Co., Ltd., Nanjing, China) and sterilized mineral water. Groups: group A 
(10 mice) received no phage and no streptomycin in their drinking water and were 
separated from the other groups, group B (10 mice) received purified lytic gut phage 
PA13076 in drinking water at a concentration of 1×108 PFU/mL (approx. 4×108 PFU), 
group C (10 mice) were treated with 1×108 PFU/mL (approx. 4×108 PFU per mouse 
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daily) of purified temperate phage BP96115 in drinking water daily and group D (10 
mice) received streptomycin at a concentration of 10mg/mL (approx. 40mg per mouse 
daily). The experiment was conducted for 31 days.   
4.2.3 Feces collection 
At 31 days post-inoculation, feces (fresh weight: 0.5 g) were aseptically collected 
from all 40 individual mice using separate sterile tubes. 
4.2.4 16S rRNA gene amplicon sequencing  
A total of 15 fecal samples were randomly chosen, containing 4 samples from each of 
the control, the lytic and the temperate gut phage treated groups, and 3 samples from 
the streptomycin treated group. The total DNA of each fresh fecal sample was isolated 
using QIAamp® DNA stool Mini kit (MP Biomedicals, CA). The DNA quality was 
determined using 2% agarose gel electrophoresis and a Qubit® 3.0 fluorometer (Life, 
Madison, WI). The V3-V4 regions of the bacterial 16S ribosomal RNA genes were 
amplified using primers 341F 5’-(barcode) CCTACGGGNGGCWGCAG-3’ and 805R 
5’-GACTACHVGGGTATCTAATCC-3’ (Klindworth et al., 2013). However, there are 
eight-base barcode added to the primer 341F. The cycling was performed in triplicate 
using 15 μL of 2×Taq master Mix, 1 μL of Barcode-PCR primer 341F (10 μM), 1 μL 
of Primer 805R (10 μM) and 10ng of genomic DNA in a final volume of 20 μL using 
the following PCR cycling conditions (Klindworth et al., 2013).  
The second PCR based amplification using Ilumina bridge type primers was carried 
out. The PCR products were purified using the MagicPure Size Selection DNA Beads 
(Transgen Biosciences, Beijing, China), and quantified using the Qubit®3.0 DNA 
detection kit (Life, Madison, WI). The purified amplicon samples were analyzed by 
Sangong Biotechnology Co. Ltd. (Shanghai, China) using high-throughput 
sequencing (2×300 bp, paired-end sequence, equimolar amounts) on the Illumina 
Miseq platform (Illumina, CA, USA).  
4.2.5 Sequence analysis 
The data were arranged by changing files, demultiplexing and qualifying of acquired 
Illumina reads using QIIME (version 1.17) (Kuczynski et al., 2012). The data were 
further merged using FLASH software (v1.2.3) (Magoc and Salzberg, 2011), and 
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assigned to each sample according to the unique barcodes. Sequence analysis was 
performed by UPARSE software (v7.1, http://drive5.com/uparse/) using the 
UPARSE-OTU and UPARSE-OTUref algorithms. The Operational taxonomic units 
(OTUs) were aggregated at a 97% similarity level. Chao 1, which indicates the 
species abundance and Shannon, which tests the diversity indexes were the parameter 
to evaluate the α-diversity (Lemos et al., 2011). Rarefaction curves were generated 
and unweighted unifrac distance for Principal Coordinate Analysis (PCoA) were 
calculated. The accession no. is SRP142620, which was deposit in NCBI Sequence 
Read Archive. 
4.2.6 Statistical analysis  
To analysis differences in the abundances of individual taxonomic groups between the 
four groups, Metastats software (http://metastats.cbcb.umd.edu/) was used (Hess et al., 
2011). The differences of bacterial communities between the four groups, ANOSIM 
(Zerzucha et al., 2012) and MRPP (multi-response permutation procedure) (Anderson 
and Santana-Garcon, 2015) were performed. Significant differences were set at p<0.01.  
4.2.7 Extraction and quantitation of virus-like-particles (VLPs) in feces 
After the animal experiment, four fecal samples from each group were characterized 
for the presence of VLPs. VLPs were isolated and counted according to the previous 
method (Thurber et al., 2009). In brief, 0.5 g fresh fecal sample was dissolved with 10 
mL of sterilized SM buffer with vigorous shaking (300 rpm) for 4h in 4℃. The 
suspension was centrifuged and the supernatant was filtered. Then, the suspension 
was further separated using CsCl gradients (1.3, 1.5, and 1.7 g/cm3) with 
centrifugation at 40,000×g for 4 h at 4℃ according to Chapter three described. The 
VLPs samples were diluted, and VLPs were stained with 10×SYBR Gold (Thermo 
fisher, CA) for DNA viruses and 10×SYBR Green II (Solarbio, Shanghai, China) for 
RNA viruses for 15 min, washed once using Amicon® Ultra-15 Filter (100 KDa 
nominal molecular weight cut-off (NMWCO) membrane, Merck Millipore Ltd., 
Ireland), and visualized using a UltraVIEW VoX confocal microscope with 
NIS-elements (Nikon, Tokyo, Japan). If the background appeared milky or grainy, 
then samples were diluted further and another slide was created until individual 
virions became visible. VLPs were quantified from 20 to 30 slides. All fluorescence 
images were taken at 600×magnification with excitation at 488 nm. Stained particles 
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<0.22 μm in diameter were regarded as VLPs. 
4.3 Results 
4.3.1 Metagenomic sequence data summary 
In this study, 15 fecal samples were collected from 15 individual mice after a 
treatment experiment running for 31 days. A total of 672,406 16S rRNA gene 
comprising 310,655,582 bp were generated from the raw data, and 613,930 valid 
sequences remained after chimeras were filtered out and low-quality sequences were 
removed, which were mostly between 400 and 440 bp. A total of 2470 OTUs were 
authenticated from all samples. Rarefaction analysis was employed (Fig 4.1) to 
compare the taxon richness between samples and to determine if the diversity of fecal 
samples was sufficiently sampled. The numbers of OTUs of samples in group D is the 
lowest (around 200 OTUs at 4000 sequences), however, samples in the other three 
groups are higher than it (between 360 to 650 OTUs around 4000 sequences). 
Therefore, the result of rarefaction analysis show higher species richness of samples 
of group A, B, C than samples in group D. Furthermore, it also shows the amount of 
sequencing data in each group is reasonable for analysis. 
 
Fig. 4.1 Rarefaction curves for 15 metagenomic data sets established for the four 
treatment groups comparing phylotype richness at 97% similarity and the 
number of sequences analyzed. C1–C4, Lytic1–Lytic4, Lysogen1–Lysogen4 and 
SM1–SM3 indicate the 15 samples of group A (control), group B (lytic gut phage 
treatment), group C (temperate phage treatment) and group D (streptomycin 
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treatment). 
4.3.2 Alpha diversity of the gut microbiota 
The calculated alpha diversities for the analyzed samples based on Chao 1 and 
Shannon are shown in Fig.4.2. A significant difference was evident between group A 
(control) and group B (the lytic gut phage treatment) in terms of community richness 
using the Chao 1 index (p<0.01) (Fig.4.2). The temperate phage treatment (group C) 
apparently enhanced the diversity, but not to a statistically significant level (P=0.1135) 
as did the lytic phage treatment. However, the diversity of the gut microbiota was 
clearly reduced after streptomycin treatment in group D (p=0.0299) (Fig.4.2). The 
Shannon index indicated that group B (the lytic gut phage treatment) and group C (the 
temperate phage treatment) were not significantly different in comparison to groups A 
and D. Both groups had a higher bacterial diversity than the control group A, while 
the streptomycin treated group D showed the lowest community diversity of the 
analyzed samples (p=0.0122) (Fig. 4.2). 
 
Fig. 4.2 The alpha diversity of the gut microbiota based on the Chao 1 index (1) 
and the Shannon index (2) for the control group (A), the lytic group (B), the 
temperate group (C) and the streptomycin group (D) at the end of the 
experiment (31 days). ** Significant differed by p<0.01. 
4.3.3 Taxonomic diversity of the gut microbiota 
The taxonomic diversity of the gut microbiota at phylum level is shown in Table 4.1. 
Bacteroidetes was the most abundant phylum, accounting for 62.85% of the total 
reads, and the gut microbiota of all fecal samples were dominated by the phyla 
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Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria. However, while the 
abundance of the phylum Bacteroidetes declined after lytic or temperate gut phage 
and streptomycin treatment from 80.47% in the control group to 49.39% (group B), 
60.41% (group C) and 61.15% (group D), respectively, the proportion of the phylum 
Firmicutes increased to 42.36%, 31.97% and 22.25% in the same groups.  
Genus level diversity of gut bacteria in the four experimental groups is shown in 
Fig.4.3. The dominant bacterial genus in all samples was Barnesiella. Compared to 
the control group, the genera Barnesiella, Tannerella, Parabacteroides, Alistipes, 
Bacteroides, Klebsiella and Exiguobacterium declined in the lytic phage treatment 
group. Both phage treatments increased the abundance of members of the genera 
Lactobacillus, Allobaculum, Macellibacteroides, Odoribacter, Turicibacter, 
Akkermansia and Bifidobacterium, while all these genera decreased and even 
disappeared after streptomycin treatment except the genus Allobaculum. The 
abundance of members of the genus Barnesiella (33.08%), Tannerella (12.66%), 
Parabacteroides (1.44%), Alistipes (2.89%), Escherichia/Shigella (4.56%), 
Clostridium IV (0.80%) and Clostridium XlVa (1.91%) in the temperate phage treated 
group were higher than in the lytic phage treated group. Treatment with the lytic and 
the temperate gut phage for 31 days increased the two beneficial genera Lactobacillus 
(19.50% and 13.93%) and Bifidobacterium (1.51% and 0.12%), while the proportion 
of the genus Lactobacillus in the control group was only 7.09% and 3.20% in the 
streptomycin treatment group. Moreover, no Bifidobacterium was detected in groups 
A and D. The lytic phage treatment did not cause an apparent increase in potentially 
harmful pathogens. Nonetheless, streptomycin caused a clear increase of the genus 
Parabacteroides (5.70%), Bacteroides (4.95%), Klebsiella (9.66%) and 
Escherichia/Shigella (6.29%).  
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Table 4.1 The gut microbiota composition at the phylum level (unit, %) 
Group A B C D 
Bacteroidetes 80.47±4.57 49.39±7.06 60.41±6.42 61.15±9.50 
Firmicutes 15.43±4.52 42.36±4.79 31.97±8.45 22.25±3.67 
Proteobacteria 2.92±1.44 4.48±3.50 6.20±2.71 16.27±6.24 
Actinobacteria 0.95±0.61 2.27±0.81 0.99±0.16 0.31±0.05 
Verrucomicrobia ND 1.40±0.82 0.35±0.20 ND 
Candidatus Saccharibacteria 0.10±0.06 0.08±0.15 0.04±0.07 ND 
Tenericutes 0.12±0.15 ND 0.02±0.02 ND 
Thermotogae 0.02±0.01 0.02 0.02±0.01 0.01±0.01 
Fusobacteria ND 0.01±0.01 ND ND 
Atribacteria ND ND 0.01±0.01 ND 
Information of each group: A, the control group; B, the lytic group; C, the 
temperate group; D, the streptomycin group. 
ND= Not detected. 
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Fig. 4.3 Genus level diversity of gut microbiota in the four experimental groups. 
Shown are dominant bacterial genera based on OTUs from identified in samples each 
mouse, the average OTU coverage of each group is displayed as a pie plot. A, the 
control group; B, the lytic group; C, the temperate group; D, the streptomycin group. 
4.3.4 Comparative metagenomic among the bacterial communities 
β-diversity analysis using the hierarchical clustering algorithm UPGMA and 
dimensionality reduction using PCoA for all 15 fecal samples obtained in the study 
was done (Fig. 4.4 a and 4.4 b). Streptomycin treatment significant reduces the 
diversity and pattern of the gut microbiota. All groups of treated mice clearly 
88 
 
clustered in their own groups. However, while streptomycin treated mice were clearly 
separated from the control mice, the lytic and temperate phage treated groups did not 
show significant differences to the control group. 
 
 
Fig. 4.4 (a) Hierarchical clustering analysis for OTUs of all analyzed samples by 
UPGMA. (b) Principal coordinate analysis for the gut microbiota patterns 
depending on the abundances of OTU.  
In addition, the community structures within the microbiota were compared using 
UniFrac for paired comparisons on the distances between samples in regard to the 
89 
 
fraction of evolutionary history that separates the organisms (Fig. 4.5). While samples 
C1-C4 and Lysogen2, Lysogen3 and Lysogen4 formed clusters, Lysogen1 clustered 
with samples Lytic1-Lytic4. These three clusters formed a higher-level cluster clearly 
distant from the cluster of samples SM1- SM3. 
 
Fig.4.5 The heat map showing the similarity matrix based on hierarchical 
clustering analysis across the four groups using the weighted UniFrac distance.  
4.3.5 The VLPs of fecal samples 
Virus-like particles (VLPs) were detected and quantified in feces using confocal 
microscopy (Fig. 4.6 and 4.7). The average titer was 9.08 log±0.37 VLPs/g for DNA 
viruses and 8.8 log±0.43 VLPs/g for RNA viruses in the feces of normal C57BJ/6 
mice (Fig.4.8). After lytic gut phage or temperate phage treatment, fecal VLPs did not 
change significantly. However, fecal VLPs increased to 9.89 log ± 0.33 VLPs/g 
(p<0.05) for DNA viruses and 8.99 log ± 0.23 VLPs/g for RNA viruses compared to 
the control group, after streptomycin treatment.  
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Fig. 4.6 Confocal microscopy images demonstrating the detection of VLPs 
stained with SYBR Gold. VLPs were dim pinpoints. The yellow arrows refer to 
VLPs. A, B, C and D represent the control group, the lytic gut phage treated group, 
the temperate phage treated group and the streptomycin treated group. The 
representative dilution of each sample is shown at the bottom center of each photo. 
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Fig. 4.7 Confocal microscopy images demonstrating the detection of VLPs 
stained with SYBR GreenⅡ. Filtrates were diluted serially until numerable VLPs 
were counted in a view. VLPs were dim pinpoints. The yellow arrows refer to VLPs. 
A, B, C and D represent the control group, the lytic gut phage treated group, the 
temperate gut phage treated group and the streptomycin treated group.  
 
Fig. 4.8 Numbers of VLPs per g of feces of the four tested groups (One-way 
ANOVA, Duncan’s test, **p < 0.01).  
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4.4 Discussion 
Previous metagenomic analyses of feces demonstrated that phages were the most 
abundant replicating entities (Breitbart et al., 2003), outnumbering bacterial cells by 
10 times (Chibani-Chennoufi et al., 2004), with as many as 1015 individual phage 
particles present in the mammalian gut (Lepage, 2013; Mills et al., 2013). Lytic 
phages appear to perform the predation on sensitive bacteria using the “kill the winner” 
model (Letarov and Kulikov, 2009). However, research on the role of lytic or 
temperate gut phages impacting gut microbial populations, especially in healthy 
animals, is in its early days.  
This study indicated that regular, long-term (31 days) administration of lytic or 
temperate gut phages changed the composition and diversity of gut microbiota. 
However, previous phage therapy studies indicated that even high titers of lytic 
phages just reduced the concentration of pathogens but revealed no significant 
differences of the diversity of gut microbiota (Golomidova et al., 2007; Mai et al., 
2010; Tanji et al., 2005). The fundamentally different results in the present study 
might be due to the long-term treatment of mice instead of the usual short time 
treatment.  
The gut microbial diversity might enhance the host immune response enhancing 
susceptibility to allergy (Shreiner et al., 2008) and has been related to increase the 
stability of the ecological balance (Eisenhauer et al., 2012). High diversity of the gut 
microbiota was more propitious to the holistic health and productivity of animals such 
as weaned piglets (Zhang et al., 2016) and disease resistance in laboratory mice 
(Rosshart et al., 2017). Studies targeting the role of probiotic bacteria showed that 
they can enhance species richness and diversity in the fecal microbiota (Cox et al., 
2010; Grazul et al., 2016). The treatment results in this study showed that α-diversity 
of gut bacteria were higher in both phage treated groups of mice when compared to 
the control group using both Chao 1 and Shannon diversity indexes. However, in the 
present study streptomycin treatment significantly reduced the richness and diversity 
of the intestinal microbial community of mice, matching another recent study (Grazul 
et al., 2016) indicating that the broad-spectrum antibiotics reduced the gut microbiota 
of mice to two genera, Stenotrophomonas and Xanthomonas. These results indicated 
that the lytic and temperate gut phages used for treatment are beneficial as they 
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promote the diversity of gut microbiota such as probiotics treatments. The low 
diversity of microbiota by antibiotic treatment can increase susceptibility to pathogens 
such as Salmonella Typhimurium and Clostridium difficile (Barthel et al., 2003; 
Zhang et al., 2013).  
The dominant phyla detected in the distal gut of mice in the earlier study were 
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria (Clarke et al., 2012). 
They were also the dominant phyla in the GIT of mice after 31 days of phage 
treatments in our study. Nevertheless, the composition of gut microbiota might be 
influenced additionally by species, diet, water, husbandry, and age as was reported for 
pigs (Zhao et al., 2015).  
The most abundant genus Barnesiella (family Porphyromonadaceae, phylum 
Bacteroidetes) declined after the lytic phage or temperate phage treatment, but 
increased after the streptomycin treatment. Although other studies have detected 
Barnesiella as an abundant member of the gut community in mice (Cho et al., 2016), 
the role of Barnesiella and the meaning of their intestinal reduction is currently not 
clear.  
At the genus level, the most obvious difference between groups in this study was the 
abundance of members of the beneficial genus Lactobacillus. The level of these 
“probiotics” was greater in the lytic and temperate gut phage treated mice than in the 
other two groups. In addition, the genus Bifidobacterium was also enhanced after both 
phage administrations. This distinctive role of the lytic gut phage on the composition of 
gut microbiota was similar to the reported treatment with a probiotics cocktail, 
containing Lactobacillus, Bifidobacterium, Enterococcus and Pediococcus strains, 
which significantly increased the numbers of Bifidobacterium spp. and Lactobacillus 
spp. in cecal microflora of broilers (Mountzouris et al., 2007). Lactobacillus and 
Bifidobacterium species are two commonly used probiotic bacteria, enhancing 
resistance to pathogens or producing short-chain fatty acid (Kechagia et al., 2013; Rist 
et al., 2013). In addition, they play an important modulation role in the digestive and 
in the immune system (Ashraf and Shah, 2014). Mice given either one of the four 
riboflavin-producing probiotic strains showed that there were lower histologic 
damage, lower translocation of pathogens, significant iNOs+ cells and 
pro-inflammatory cytokines reduction in the large intestines (Levit et al., 2017). 
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Lactobacillus murinus treatment could prevent experimental autoimmune 
encephalomyelitis and salt-sensitive hypertension by modulating TH17 cells (Wilck et 
al., 2017), mice gavage-fed Lactobacillus rhamnosus GG increased expression of 
transmembrane Claudin protein (Cldn) 3 and 7 and accelerated maturation of gut 
barrier function (Ravi et al., 2011). Similarly, Bifidobacterium species provided 
benefits including the protection of animals from enteric pathogens (Fanning et al., 
2012; Fukuda et al., 2011) and prevention of inflammatory disorders of the GIT 
(Gareau et al., 2010). Moreover, in this study the lytic and temperate gut phages 
significantly decreased the abundance of the genus Klebsiella, containing potential 
pathogens, such as Klebsiella pneumoniae, when compared to the streptomycin 
treatment. Hence, the results demonstrate that lytic and temperate gut phages can 
regulate the composition and diversity of gut microbiota in mice, resulting in a 
significant probiotic effect. In contrast, the human norovirus directly induce acute gut 
inflammation (Basic et al., 2014) and increase the incidence of Crohn’s disease 
(Cadwell et al., 2010).  
However, after the temperate phage administration, some bacterial genera such as 
Esherichia/Shigella, including potential pathogens were increased; demonstrating that 
exposure to temperate phages may establish conditions promoting such organisms. 
These findings highlight the potential role of temperate phages increasing intestinal 
permeability (Dalmasso et al., 2104). 
This study further analyzed the effect of lytic or temperate phage and streptomycin 
treatment on the abundance of enteric viruses. VLPs are usually quite high in gut, 
ranging from 5×107 to 1×1010 particles/g (Letarov and Kulikov, 2009), thereby 
matching the data for mice feces, yet these values are probably underestimated. Viral 
communities and their encoding genes are highly diverse, with only 0.0002% of the 
global viral gene pool being sequenced (Rohwer, 2003). Deep sequencing of virus 
DNA/RNA purified from the environment typically yielded a majority of unidentified 
sequences (Breitbart et al., 2008; Minot et al., 2012; Minot et al., 2011; Reyes et al., 
2010). Thus, Mills et al. (2013) reported that 81% of VLP-derived metagenomic data 
is unknown. The enumeration results for VLPs showed that both phages did not cause 
a significantly alteration of the VLPs number in feces. However, streptomycin 
treatment resulted in significantly higher DNA VLP titers than seen in control mice 
possibly because of release of endogenous prophages (Allen et al., 2011). This is 
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consistent with fluoroquinolone treatment increasing the production of Clostridium 
difficile phages in mammalian feces (Davies et al., 2016). However, this result does 
not match a study reporting that an antiviral cocktail decreased enteric DNA and RNA 
viruses significantly in mice (Yang et al., 2016). 
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CHAPTER FIVE 
THE IMPACT OF PREADMINISTRATION OF LYTIC AND TEMPERATE 
SALMONELLA GUT PHAGE ON GUT MICROBIOTA COMPOSITION AND 
INTESTINAL INFLAMMATION IN A MOUSE MODEL 
5.1 Introduction 
Salmonella enterica serovar Typhimurium (Salmonella Typhimurium) is an important 
enteropathogen causing zoonotic diseases, and a serious factor affecting public health 
worldwide (Ebel et al., 2016). The primary habitat of Salmonella spp. is the intestinal 
tract of diverse animals such as chicken, birds, pigs, humans, and occasionally insects 
(Kubota et al., 2011). They can colonize the intestinal tract, causing serious infections 
in domestic animals (Park et al., 2015). The mouse model has been widely used to 
study the mechanisms of Salmonella spp. pathogenesis, immunity, and systemic 
salmonellosis (Mastroeni and Sheppard, 2004). Non-typhoidal Salmonella 
Typhimurium infections of streptomycin-pretreated mice resemble many aspects of 
the mammalian enteric salmonellosis (Barthel et al., 2003). 
The animal GIT is a very complex ecosystem because of the diverse interactions of 
invading pathogens, the host immune system, and symbiotic microorganisms 
colonizing the host (the microbiota) (McKenney and Pamer, 2015; Yurist-Doutsch et 
al., 2014). There are very limited options for reducing already established Salmonella 
spp. in the GIT (Atterbury et al., 2007). Antibiotics, which are used to treat bacterial 
infections, are considered to be not efficient for the treatment of gut pathogens 
(Stecher and Hardt, 2011). As a result of disrupting the balanced species composition 
in the intestinal system, antibiotic treatments can support the growth of pathogenic 
bacteria such as Clostridium difficile (Issa and Moucari, 2014). Additionally, the 
emergence of multi-drug resistant strains of Salmonella spp., pathogenic strains of E. 
coli, vancomycin-resistant Enterococcus spp., and fluoroquinolone-resistant 
Campylobacter spp. were all related to the use of antibiotic (Woodford et al., 2011). 
Probiotics, which can alleviate enteropathogen carriage, have received a substantial 
amount of public enthusiasm (Patterson and Burkholder, 2003). Many studies have 
described the efficacy of probiotics controlling pathogens. For example, when pigs 
were orally inoculated with the cocktail of two Lactobacillus strains, the counts of 
Enterobacteriaceae were decreased (Gardiner et al., 2004), and Salmonella enterica 
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serovar Typhimurium in the GIT were also reduced when pigs were treated with a 
five-strain probiotic combination (Casey et al., 2007). Although more attention has 
been paid to the use of probiotics as prophylactic and therapeutic preparation in 
animal husbandry (Neal-McKinney et al., 2012; Potocnjak et al., 2017; Wang, et al., 
2013), relatively few probiotic strains have demonstrated efficacy in vivo (Gardiner et 
al., 2004; Steinberg et al., 2014). As the exact mode of action of probiotics is still 
unknown (Mengheri, 2008), searching for new alternatives to treat gastrointestinal 
pathogen infections is an urgent matter.  
Phages are extremely abundant viruses, and are at least ten times of bacteria on the 
earth (Casjens, 2005). Interestingly, phage therapy is completely different from 
antibiotic treatment to prevent pathogenic infections. Prophylactic use of phages 
resembles that used for probiotics (Cisek et al., 2017). Smith et al. (1987) 
demonstrated that in orally treated calves, phage titers increased in feces over time 
with a concomitant decrease in pathogenic E. coli counts. Moreover, calves could no 
longer be infected once phages occupied the gastrointestinal tract, manifesting 
so-called “infectious protection”. A study by Bardina et al. (2012) indicated that the 
prophylactic administrations of phage to chickens for a long-term are able to reduce 
the concentration of Salmonella spp. significantly. Furthermore, phages were 
administered orally to eliminate diarrheic pathogens like Salmonella spp. (Toro et al., 
2005), Clostridium difficile (Ramesh, 1999) and E. coli O157: H7 (Raya et al., 2006). 
All of the successful phage therapy studies depended on using specific phages. 
However, phages inevitably encounter diverse enteric pathogens in the highly 
complex gut ecosystem (Olivo et al., 2016). The effects of non-specific lytic gut 
phages or temperate phages on infections caused by bacterial pathogens are still not 
well established. 
Results reported in chapter four confirmed that lytic gut phages potentially promote 
gut health through alteration of the composition of gut microbiota while temperate 
phages enhanced the diversity and changed the composition of gut microbiota. The 
question is whether phages can alleviate intestinal inflammation and improve 
mammalian health. In this study, the hypothesis that phage pretreatment causes 
changes in gut microbiota and that non-specific phages can prevent intestinal 
infections, was therefore examined. 
103 
 
5.2 Materials and Methods 
5.2.1 Phages and Salmonella enterica subsp. enterica serovar Typhimurium strain 
The lytic gut phage PA13076 and the temperate gut phage BP96115 were amplified 
and purified according to the methods described in chapter two, using their specific 
host. They were purified through CsCl gradient ultracentrifugation, dialysis and 
ultrafiltration. Solutions of lytic phage PA13076 or temperate phage Bp96115, at 
1×108 PFU/mL in drinking water, were prepared using the method described in 
chapter three. To confirm that the Salmonella enterica subsp. enterica serovar 
Typhimurium (Salmonella Typhimurium) strain used for the challenge was not 
infected by the lytic or the temperate gut phage, spot tests were employed. Salmonella 
Typhimurium 002 was chosen and grown overnight from a colony at 37℃ in TSB 
(Beijing Land Bridge Technology Co., LTD, Beijing). Cells were diluted by 1:20 in 
fresh sterile medium, and subcultured for 4 h at the same temperature, washed twice 
in ice-cold PBS (pH 7.2, Hyclone, Logan, Utah) and suspended in cold PBS to 2×108 
CFU/200 μL. 
5.2.2 Animals 
C57BL/6 female mice (6 to 8 weeks old) were purchased from the Comparative 
Medical Center of Yangzhou University (Yangzhou, China). For the experiments, 
mice were reared in groups of up to five animals and maintained under specific 
pathogen-free conditions in the experimental animal center in the Jiangsu Academy of 
Agricultural Sciences (JAAS). Experiments were done following the ARRIVE 
guidelines (Kilkenny et al., 2010). Mice were fed ad libitum with a commercial grain 
formulation (SHOOBREE Rat and Mouse Maintenance Die, Jinagsu xietong 
organism Co., Ltd., Nanjing) and sterilized mineral water (Evian; pH 7.2; HCO3-, 489 
mg/L), and allowed to acclimatize for two weeks before commencement of 
experiments. They were weighed before and after the experiments. Fresh fecal 
samples were collected after infection and treatment. 
5.2.3 Experimental design 
Two trials were done as follows. Trial 1 evaluated the regulating efficacy of 
pretreatment with lytic or temperate phage on gut microbiota diversity and 
composition after being challenged with Salmonella Typhimurium 002. Fifty mice 
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were randomly allocated into five groups (n=10): Group A (10 mice, the control group) 
was without any treatment; Group F (10 mice, the ST group) drank sterilized mineral 
water daily for 31 days before and after being challenged with Salmonella 
Typhimurium 002 (2×108 CFU) by oral gavage; Group G (10 mice, the LyticST group) 
was treated with 1×108 PFU/mL of lytic phage PA13076 (thus making approximately 
4×108 PFU/ mouse daily) for 31 days before and after being challenged with 2×108 
CFU of Salmonella Typhimurium 002 by oral gavage; Group H (10 mice, the 
LysogenST group) was treated with 1×108 PFU/mL of temperate phage BP96115 
daily (approximately 4×108 PFU/mouse), the same titer as for the lytic phage, for 31 
days before and after being challenged with 2×108 CFU of Salmonella Typhimurium 
002 by oral gavage and Group I (10 mice, the SMST group) received 10 mg/mL of 
streptomycin solution (approximately 40mg/mouse) daily for 31 days before and after 
being challenged with 2×108 CFU of Salmonella Typhimurium 002 by oral gavage. 
Trial 2 was conducted to evaluate the pretreatment of lytic or temperate phage to 
prevent intestinal inflammations. The preadministration of phages or the streptomycin 
solution were the same as for trial 1. However, after 31 days of preadministration, 
mice were gavaged with a single dose of 20 mg of streptomycin 24 hours before being 
challenged with 2×108 CFU of Salmonella Typhimurium 002. In this trial, each group 
matched a corresponding group from trial 1, thus, Group a (10 mice, the control 
group), Group f (10 mice, the ST group), Group g (10 mice, the LyticST group), 
Group h (10 mice, the LysogenST group), and Group i (10 mice, the SM group). 
5.2.4 Trial 1 
5.2.4.1 16S rRNA gene sequencing and analysis 
At 48h post bacteria challenge, a total of eighteen fecal samples from five groups 
(four samples of each group, except two samples of the SMST group) were chosen 
from trial 1. 16S rRNA gene sequencing was used to determine the composition of gut 
microbiota as described in chapter four. In brief, the DNA of each sample was 
extracted using QIAamp® DNA stool Mini kit (MP Biomedicals, CA). The DNA 
extractions were verified using a Qubit® 3.0 fluorometer (Life, Madison, WI), DNA 
integrity were assessed by gel electrophoresis, and amplified using universal primers 
targeting the V3-V4 regions of 16S rRNA of Bacteria (Klindworth et al., 2013). The 
amplicons were sequenced on the Illumina Miseq platform (2×300 bp) (Illumina, CA) 
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at Sangong biotechnology Co. Ltd. (Shanghai, China). The sequencing data from this 
study were processed and analyzed using the same method of chapter four, and 
uploaded to the NCBI Sequence Read Archive under accession no. SRP144014. 
5.2.4.2 Enumeration of members of the Enterobacteriaceae and Lactobacillus spp. 
in cecum samples 
After finishing feces collection, mice were sacrificed by CO2 asphyxiation, and cecal 
contents were tested for the presence of members of the Enterobacteriaceae and 
Lactobacillus spp. Each content was diluted (10-fold increments) in ice-cold PBS (pH 
7.2, Hyclone), and then a volume of 100 µL of appropriate decimal dilutions was 
plated on selective agars. Viable counts (CFU/g) were determined in duplicate using 
SS agar (Qingdao Hope Bio-Technology Co. Ltd., Qingdao, China) for members of 
the Enterobacteriaceae and MRS agar (Difco, BD science, USA) for Lactobacillus 
spp. The detection limit was 100 CFU/g. Each phage pretreated or streptomycin 
pretreated sample was compared to the control by one-way ANOVA. Significant 
differences were determined using SPSS 16.0 (SPSS Inc. CA) with Duncan’s test set at 
p<0.01.  
5.2.5 Trial 2 
At 24h post infection, mice were sacrificed by CO2 asphyxiation. Serum for LPS and 
DAO analysis was separated from the blood and tissue samples from the intestinal 
tracts and used for analysis.  
5.2.5.1 Histopathological analysis 
Representative portions of ileum and cecum were put in 4% paraformaldehyde, 
embedded in paraffin, and stained with hematoxylin-eosin (H&E) according to 
standard procedures (Cardiff et al., 2014). Based on an earlier study (Barthel et al., 
2003), the pathological scores of each tissue were determined. The scores ranged 
between 0 and 13, the numbers represented: 0, intestine intact without any signs of 
inflammation; 1~2, minimal signs of inflammation; 3~4, mild inflammation; 5~8, 
moderate inflammation; 9~13, serious inflammation.  
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5.2.5.2 Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted from jejunum tissues using TRIzol (Invitrogen, CA), and 
cDNA was synthesized using a PrimeScriptTM RT reagent kit with gDNA Eraser 
(Takara, Japan). The products were used as a template for real-time PCR. The 
targeting primers were designed using Primer 5.0 software, based on the published 
GenBank sequences (Table 5.1). q-PCR was performed using SYBR® Premix EX 
TaqTM kit (Takara, Japan) and LightCycler 480 (Roch, Basel, Switzerland). The 
program was followed by 40 cycles of 94°C for 10 s, 60°C for 20 s, and 68°C for 20 s. 
Melting curves were subsequently created, which consisted of 95°C for 15 s and 60°C 
for 20 min increasing by 0.5°C per minute to a final temperature of 95°C. Each 
experiment was performed in triplicate. The GADPH gene was used as an internal 
standard, and the values were calculated based on the 2-∆∆Ct method . 
Table 5.1 Primers used in this study 
Primer name Sequence (5′-3′) 
Amlicon 
size(bp) 
Gene ID 
GAPDH 
Forward 5’-TGAAGGGTGGAGCCAAAAG-3’ 
227 14433 
reverse 5’-AGTCTTCTGGGTGGCAGTGAT-3’ 
IL-10 
Forward 5’- GGTTGCCAAGCCTTATCGG-3’ 
191 16153 
reverse 5’- ACCTGCTCCACTGCCTTGC-3’ 
IFN-γ 
Forward 5’-GATGCATTCATGAGTATTGCCAAGT-3’ 
118 15978 
reverse 5’-GTGGACCACTCGGATGAGCTC-3’ 
IL-4 
Forward 5’-AGATGGATGTGCCAAACGTCCTCA-3’  
104 16189 
reverse AATATGCGAAGCACCTTGGAAGCC-3’ 
IL-1β 
Forward 5’- GGGCCTCAAAGGAAAGAATCT-3’ 
195 16176 
reverse 5’- GAGGTGCTGATGTACCAGTTGG-3’ 
TNF-α 
Forward 5’- CCCCAAAGGGATGAGAAGTT-3’ 
212 21926 
reverse 5’- TGGGCTACAGGCTTGTCACT-3’ 
IL-6 
Forward 5’- GAGGATACCACTCCCAACAGACC -3’ 
195 16193 
reverse 5`- AAGTGCATCATCGTTGTTCATACA -3` 
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5.2.5.3 Intestinal permeability analysis 
LPS were measured using LAL kit (Thermo Fisher, Sweden) and DAO Assay Kit 
(Jiancheng Bio-Technology Co., Ltd, Nanjing, China) according to the manufacturers’ 
instructions. Each sample was analyzed in triplicate. 
5.3 Results 
5.3.1 Gut microbiota analysis and comparison 
High-throughput sequencing of 16S rRNA gene amplicons was conducted to exploit 
the role of lytic and temperate gut phage on dysbiosis of gut microbiota caused by 
Salmonella Typhimurium 002 challenge. A total of 35,441 to 47,729 merged reads 
were obtained for each sample. As shown in Table 5.2, Bacteriodetes, Firmicutes and 
Proteobacteria was the top abundant phylum in the control group, accounting for 
80.47%, 15.43% and 2.92%, respectively. However, when administrating the lytic or 
the temperate phage for 31 days prior to the Salmonella Typhimurium 002 challenge, 
the Firmicutes became the most abundant phylum, accounting for 60.62% and 43.01% 
of reads, respectively. The abundance of Actinobacteria increased and Tenericutes 
reduced in group G and H compared to group A and F. Furthermore, the phylum 
Proteobacteria increased from 5.82% in group F (challenged with Salmonella 
Typhimurium 002) to 24.49% in group I (pretreated with streptomycin for 31 days 
before and after Salmonella Typhimurium 002 challenge). The number of phyla 
decreased in group I. Meanwhile, Bray-Curtis similarity cluster analysis indicated that 
group I was clearly separated from the other groups, and group G and group H were 
strongly correlated (Fig 5.1). Fig. 5.2 (1) Indicated that the diversity of bacterial 
communities in groups F, G and H was higher compared to the control group (A), and 
the diversity declined clearly in I group (p=0.083). The same trend was observed 
when comparing the Shannon index (Fig. 5.2 (2) with that using the Chao 1 diversity 
index. Principal coordinate analysis revealed differences based on relative OTU 
abundance at family level between groups. It showed that groups receiving 
pretreatment with streptomycin mostly differed from groups pretreated with phages 
and control samples (Fig. 5.3). The changes in bacterial composition at the genus 
level for selected members of the gut community are shown in Fig. 5.4. Pretreatment 
with the lytic and the temperate phage before Salmonella Typhimurium 002 challenge 
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increased two beneficial genera, Lactobacillus (14.73% and 21.02%) and 
Bifidobacterium (2.43% and 2.05%). While the genus Lactobacillus in group F was 
abundant at 14.04%, the genus Bifidobacterium was not detected. However, in group 
H an increased abundance of the genus Escherichia/Shigella (10.69%) is evident. The 
genus Allobaculum, belonging to the phylum Firmicutes, was also present in higher 
relative abundances after pretreatment with gut phage. On the other hand, the genus 
Klebsiella declined in groups G and H compared to groups F and I where it was high 
as 19.75%.  
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Table 5.2 Composition of the gut microbiota at phylum level (%) various 
experimental groups with or without challenged with Salmonella Typhimurium 
002 
Group A F G H I 
Bacteroidetes 80.47±4.94 58.99±11.07 30.29±5.29 30.78±15.17 55.08±0.40 
Firmicutes 15.43±5.43 33.19±10.19 60.62±3.88 43.01±23.75 20.14±3.93 
Proteobacteria 2.92±1.56 5.82±4.75 3.92±1.79 17.51±9.58 24.49±4.49 
Actinobacteria 0.95±0.61 0.49±0.21 4.17±1.20 2.98±2.22 0.27±0.14 
Verrucomicrobia ND 1.24±1.39 0.87±0.82 5.69±9.58 ND 
Candidatus  
Saccharibacteria 0.09±0.06 0.11±0.09 0.09±0.14 0.01±0.005 ND 
Tenericutes 0.12±0.15 0.11±0.16 0.01±0.01 0.003±0.005 ND 
Thermotogae 0.02±0.01 0.03±0.01 0.01±0.01 0.025±0.01 0.02±0.01 
Fusobacteria ND ND 0.01±0.02 ND ND 
Cyanobacteria ND ND ND ND 0.02±0.02 
Synergistetes ND 0.003±0.005 ND ND ND 
Euryarchaeota ND 0.003±0.005 ND ND ND 
Lentisphaerae ND 0.003±0.005 ND ND ND 
Planctomycetes ND 0.003±0.005 ND ND ND 
Note: Information of each group of trial 1: A, the control group, without any treatment; 
F, the ST group, drank sterilized mineral water daily for 31 days before and after 
being challenged with Salmonella Typhimurium 002; G, the LyticST group, treated 
with the lytic gut phage PA13076 for 31 days before and after being challenged with 
Salmonella Typhimurium 002; H, the LysogenST group, treated with the temperate 
phage BP96115 for 31 days before and after being challenged with Salmonella 
Typhimurium 002 and I, the SMST group, received streptomycin solution for 31 days 
before and after being challenged with Salmonella Typhimurium 002. 
ND=Not detected. 
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Fig. 5.1 Bray-Curtis similarity cluster analysis combined with the composition of 
gut microbiota at phylum level. A, the control group; F, the ST group; G, the 
LyticST group; H, the LysogenST group and I, the SMST group. 
  
Fig. 5.2 The alpha diversity of gut microbiota in the different groups based on 
the Chao 1 (1) and the Shannon index (2) of diversity. A, the control group; F, the 
ST group; G, the LyticST group; H, the LysogenST group and I, the SMST group. 
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Fig. 5.3 Principal coordinate analysis (PCoA) of 18 metagenomic samples at 
family level for the different groups. Points represent samples, and the color 
indicates group information. 
 
Fig. 5.4 Relative abundance of selected members of the gut bacterial community 
at genus level. A, the control group; F, the ST group; G, the LyticST group; H, the 
LysogenST group and I, the SMST group. 
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5.3.2 Enumeration of members of the Enterobacteriaceae and Lactobacillus spp. 
in cecal contents 
Phage pretreatment did not significantly change counts of the Enterobacteriaceae in 
cecal contents. However, streptomycin pretreatment reduced the viable counts for the 
Enterobacteriaceae to 4.32±0.12 log (cfu/g) in cecal samples (Fig. 5.5-1). In addition, 
pretreatment with the lytic and temperate gut phage for 31 days increased the 
Lactobacillus spp. counts (>8.0 cfu/g), even though the mice were challenged with 
Salmonella Typhimurium 002, while pretreatment with streptomycin decreased the 
Lactobacillus spp. counts to 6.16±0.41(cfu/g). 
 
Fig. 5.5 Viable counts of Enterobacteriaceae (1) and Lactobacillus spp. (2) in cecal 
content of mice after being challenged with Salmonella Typhimurium 002. 
Results are expressed as base-10 logarithm of colony-forming units per gram. Error 
bars represent standard deviations. A, the control group; F, the ST group; G, the 
LyticST group; H, the LysogenST group and I, the SMST group. 
5.3.3 Histopathological changes 
In order to characterize the regulatory role of phages in the process of intestinal 
inflammation, the mice were treated orally with the lytic or the temperate phage for 
31 days. Intestinal inflammation was induced via oral pretreatment with streptomycin 
before the Salmonella Typhimurium 002 challenge. Histologic changes of ileum and 
cecum were analyzed by bright field microscopy and representative pictures are 
shown (Fig. 5.6, 1-2). Compared with group f (the ST group) and group i (the SMST 
group), the phenomena of villus break and loss of crypts were absent in ileum samples 
of groups g (the LyticST group) and h (the LysogenST group). However, compared 
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with group a (the control group), pathophysiological changes (epithelial edema, villus 
break and thinner villi) were still present. In the cecum samples of group f, the 
destruction of the crypt structure, the decrease of goblet cells, epithelial erosion and 
PMN infiltration of the submucosa were observed. However, no signs of serious 
inflammation were observed in the cecum of groups g and h of mice. The histological 
severity of effects observed in treated mice was quantified by pathologic scoring 
(Fig.5.6-3). According to the analysis of pathological changes, preadministration of 
the lytic (group g) and the temperate (group h) gut phage reduced ileum and cecum 
inflammation.  
 
  
Fig. 5.6 Representative images of hematoxylin-eosin staining of ileum (1) and 
cecum (2) samples, n = 5 mice per group. Scale bar, 100 μm. (3) The cumulative 
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pathology scores from 5 mice per group (range, 0-13). ** differed by p<0.01. 
Information of each group of trial 2: Group a, the control group; group f, the ST group; 
group g, the LyticST group; group h, the LysogenST group and group i, the SMST 
group. 
5.3.4 Gene expression of inflammatory cytokines in Jejunum tissue 
To further assess pathologic changes, mRNA levels were analyzed for cytokines IL-1β, 
IFN-γ, TNF-α, IL-6, IL-4 and IL-10. The expression of each of these tested cytokine 
genes was elevated 3.85, 3.78, 3.92, 3.95,4.32, and 4.28 fold in average in the 
jejunum at 24h post challenge in the f group (ST group). Compared to the group f, the 
expression of all detected cytokine genes was not changed significantly in treated 
groups (Fig. 5.7). However, oral pretreatment with the lytic or the temperate gut 
phage resulted in lower gene expression of IL-1β, IFN-γ, TNF-α, IL-6 and IL-4 than 
in group f. 
 
Fig. 5.7 Effects of the pretreatment with the lytic or the temperate gut phage on 
expression levels of inflammatory cytokines in jejunum tissue. (1) IL-1β, (2) 
TNF-α, (3) IFN-γ, (4) IL-6, (5) IL-4, (6) IL-10. Group a, the control group; group f, 
the ST group; group g, the LyticST group; group h, the LysogenST group and group i, 
the SMST group.  
5.3.5 DAO and ET levels after phage treatment 
Serum Lipopolysaccharide (LPS) and diamine oxidase (DAO) levels can be used 
indicators for assessing intestinal injury and monitoring intestinal permeability 
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(Hartmann et al., 2012). Fig. 5.8 showed that pretreatment with the lytic or the 
temperate gut phage before intestinal inflammation resulted in slightly reduced DAO 
levels in serum compared to group f. In addition, the ET level was also reduced but 
the difference was statistically not significant. However, even pretreatment with 
streptomycin increased the levels of DAO and ET.  
 
Fig. 5.8 The concentration of DAO (1) and ET (2) in serum. Group a, the control 
group; group f, the ST group; group g, the LyticST group; group h, the LysogenST 
group and group i, the SMST group. Error bars represent standard deviations. 
5.4 Discussion 
Phages are the most abundant bacterial viruses on the earth and it was estimated that 
as many as 1015 individual phage particles are present in the mammalian gut 
(Dabrowska et al., 2005; Dalmasso et al., 2014). Several phage therapy studies 
indicated that phages minimally impact health-protecting bacteria of the normal gut 
flora (Galtier et al., 2016; Mai et al., 2010). The reasons were that they infected only a 
few strains of a particular bacterial species, and the short administration time and low 
repetitions safeguarded that no detrimental effects took place. The ability of phages to 
regulate dysbiosis of gastrointestinal microbiota caused by Salmonella Typhimurium 
challenge in a mouse model was explored in this study. As the challenged bacteria 
were not the specific host of the used phages and the phages were repeatedly 
preadministrated for an extended period, this study was different from previous 
studies evaluating phage therapy against bacterial pathogen infections in laboratory 
animals (Ahmadi et al., 2016; Fukuda et al., 2012; Tanji et al., 2005). The present 
study was based on a concept of probiotic intervention (Abedon et al., 2011), which 
would employ phage therapy prophylactically rather than therapeutically. Although 
phages are not considered to be probiotics, they actually conform to the definition of 
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probiotics by the Food and Agriculture Organization (FAO) of the United Nations 
(UN) and the World Health Organization (WHO) (Abedon et al., 2011): “live 
microorganisms which, when administered in adequate amounts, confer a health 
benefit on the host” (WHO, 2001). 
Several studies reported that phages may have a potential role in shaping the 
composition of the gut bacterial community (Gorski et al., 2003; Gorski and 
Weber-Dabrowska, 2005; Mills et al., 2013) and that phages are a good maker for 
health and disease (Dalmasso et al., 2014; Lepage et al., 2008). An earlier study in 
Chapter 4 confirmed that not only the lytic but also the temperate gut phage enhanced 
the diversity and altered the composition of gut microbiota when the mice were orally 
administrated with these phages over 31 days. In this study, the result of higher alpha 
diversity in phage pretreated mice was consistent with similar studies by Valeriano et 
al. (2017) from probiotic studies. However, this experiment results of higher alpha 
diversity are contrary to the experimental results of mice study of HPLCD diet (30% 
casein and 57% carbohydrate) (Kim et al., 2016), and the rat models of colorectal 
cancer and ulcerative colitis (Zhu et al., 2014). The diversity of intestinal microflora is 
related to some health deterioration and will be an indication of illness (Kim et al., 
2016). This suggests that the pretreated mice with phage may have good benefits on 
intestinal health by increasing the diversity of intestinal microflora. 
Furthermore, the lytic gut phage provided a healthy gut ecosystem, which matches 
probiotics (Valeriano et al., 2017). Probiotics are considered to modulate gut 
microbiota imbalances and modify population of the gut microbiota to improve the 
health of animal body (Rahmat Ullah et al., 2017; Stough et al., 2017). Similarly, 
results obtained in this study indicate that preadministration of phages for 31 days 
before the bacterial challenge can enhance the diversity of gut bacterial populations, 
increase the Firmicutes/Bacteroidetes ratio and specifically increase the beneficial 
genera Lactobacillus and Bifidobacterium. Lactobacillus and Bifidobacterium can 
lower the pH value of intestinal digesta and prevent pathogens colonization, so that, 
they have the potential ability to facilitate the development of intestinal functions 
(Dunkley et al., 2009; Haghighi et al., 2008) and enhancing animal immune functions 
(Haghighi et al., 2005). One probiotic study indicated that the application of 
Lactobacillus plantarum G83 not only increased genera Lactobacillus and 
Bifidobacterium, but also reduced the number of Bacteroidetes and 
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Enterobacteriaceae in the mice colon (Oliveira et al., 2016). Members of the genus 
Bifidobacterium, along with Lactobacillus, represent well-known probiotics and are 
the major bacterial genera making up the bacterial flora in healthy mammals (Unkauf 
et al., 2016). Probiotic Bifidobacterium spp. enhanced the abundance of 
Bifidobacterium, accompanied by reduced IL-10 and TNF-α levels in the elderly, 
demonstrating that Bifidobacterium could decrease the age-dependent inflammatory 
status (Ouwehand et al., 2008). Furthermore, using Bifidobacterium spp. as a 
probiotic in the conventional treatment of ulcerative colitis was associated with 
improved rates and maintenance of remission (Fernandez et al., 2017). 
Phage-based “probiotic products” do not carry pathogenic bacteria and can improve 
overall balance of the gastrointestinal tract. Moreover, a previous study verified that a 
phage cocktail as the additive in the dietary improved the growth performance of 
weaning pigs (Wang, et al., 2013). However, the broad-spectrum of antibiotics leads 
to microflora dysbiosis and overgrowth of pathogens, and potentially life-threatening 
secondary infections (Schokker et al., 2015). Feeding antibiotics particularly reduced 
the relative abundance of the beneficial genus Lactobacillus (Collier et al., 2003; 
Looft et al., 2012).  
Pretreatment of mice with streptomycin disturbs the microbiota community structure, 
and the Salmonella Typhimurium invasion into the gut tissue further triggers gut 
inflammation. Streptomycin-pretreated mice provide a mouse model for Salmonella 
Typhimurium colitis (Barthel et al., 2003; Miki et al., 2017; Pedicord et al., 2016). 
Intestinal microbial composition appears to benefit for systemic balance and even 
modulate inflammatory responses caused by diseases for mice (Kinross et al., 2011; 
Pedicord et al., 2016). Moreover, it has been shown that gut microbiota of the wild 
mice promoted host adaptability and alleviated inflammation (Rosshart et al., 2017). 
Microbiome-based therapeutics via the preadministration of phage may present a 
feasible approach to affect the microbial structure or activity of the gut microbiota 
(Pedicord et al., 2016). 
Inflammatory cytokines are usually expressed at elevated levels following infections 
with pathogens (Pinsky et al., 1993). However, it was shown that phages did not 
stimulate the production of inflammatory mediators in vitro and in mice 
(Weber-Dabrowska et al., 2000), but also played a strong anti-inflammatory roles, and 
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the mechanisms appear to be inconsistent with the antibacterial effects (Gorski et al., 
2017). It was also shown that alteration of the gut microbiota composition may play a 
role in ensuring immune response (Cho et al., 2016). In this study, oral pretreatment 
with the lytic or the temperate gut phage resulted in decreased expression of IL-1β, 
IFN-γ, TNF-α, IL-6 and IL-4 genes. These results match a study showing that phage 
can reduce inflammation and depress the cytokine levels of TNF-alpha and neutrophil 
in bronchoalveolar lavage fluid of mice (Carmody et al., 2010). 
The effects of phages on the immunologic system have been studied. Firstly, phages 
reduce bacterial numbers to relative lower levels, and then the immune systems help 
to scavenge bacteria together (Gorski and Weber-Dabrowska, 2005). The 
immunogenicity could be produced after phage causing repeated lytic infections of 
the normal bacterial flora (Biswas et al., 2002; Gorski and Weber-Dabrowska, 2005). 
In this study, histological analysis confirmed that the degree of ileum and cecum 
damage in groups of mice pretreated with phages was lower than that in groups of 
mice pretreated with streptomycin, which was confirmed by lower inflammatory 
scores. These observations are consistent with phage therapies ameliorating the 
histological damage in the colon (Jun et al., 2014) and in the vital organs: liver, kidney, 
lung, and spleen (Shivshetty et al., 2014). Intestinal pathogens usually alter the 
permeability of the mucosal barrier by destroying the tight junction and function and 
secreting proteases, so that they can translocate from gut to the other parts of the body 
(Berkes et al., 2003). The concentration of serum LPS was associated with 
inflammation and bacterial tissue invasion (Rosenfeld and Shai, 2006) and DAO was 
related to the capability of the mucosal barrier (Sun et al., 2013). Overgrowth of the 
gut community by Gram-negative bacteria and gut inflammation increase circulation 
of LPS, conversely, the increased LPS activates host immune cells to produce 
inflammatory factors and perpetuate the inflammatory cycle. Previous studies 
indicated that the activity of serum DAO was increased significantly in infected rats 
and the secretion of TNF-α, IFN-γ and IL-8 in the intestinal tissues were also higher 
compared to the healthy rats (Xin et al., 2016). 
In a word, phages can act as modulating agents regulating gut microbiota, showing 
that phage based prophylaxis can limit infection by bacterial pathogens. 
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CHAPTER SIX 
GENERAL OVERVIEW AND CONCLUSIONS 
6.1 Summary of findings 
The worldwide misuse of antibiotics in animal feed and particularly the rapid 
emergence of multi-drug-resistant Salmonella spp. due to antibiotic overuse have 
received global attention and raised concern (Martin et al., 2015; Park et al., 2017). 
Since 2005, many countries began to restrict the use of antibiotics as growth 
promoters for farm animals (EC, 2005). Currently, the most promising alternatives to 
antibiotics for controlling bacteria are bacteriophages (Cisek et al., 2017; Golkar et al., 
2014).  
Phages are probably the most diverse and abundant biological entities on earth. 
Furthermore, they are usually present in a very high concentration (approximately 
1015 phages) in the mammalian gut (Dalmasso et al., 2014). It is noteworthy that the 
majority of phages are prophages, which can be spontaneously induced as active 
phages (Kim and Bae, 2018). Furthermore, when lytic phages are orally used to treat 
pathogen infections in vivo, they encounter both pathogens and commensal 
microorganisms in the complex gut of the animal (Olivo et al., 2016). Except of 
phages being used as a lytic bio-bactericide, other beneficial impacts of phages on 
intestinal epithelial cells or even the animal body also can be exploited to help in the 
treatment of various diseases.  
Phages are diverse and largely unexplored in the animal gut, and most of the genome 
sequences of gut bacteriophages are still unknown (Rohwer, 2003; Ventura et al., 
2011). Lepage et al. (2008) suggested that gut phages likely have a strong influence 
on the diversity and population structure of bacterial communities in the intestinal 
tract; however, little is known of the role of abundant phages in the gastrointestinal 
tract (GIT) in shaping the mammalian gut microbiota and their relationships with 
health and disease. 
This thesis established that: 
 A lytic gut phage vB_SenM-PA13076 was isolated from fecal samples of chicken and 
characterized physiologically and genetically. This phage demonstrated a broad host 
range and contained no undesirable genes such as those for lysogeny, virulence 
126 
 
factors, and antimicrobial resistance genes. PA13076 is a virulent phage that has 
potential for treating animals to prevent infections by several Salmonella. In addition, 
a temperate gut phage designated as vB_SpuP-BP96115 was induced from 
Salmonella Pullorum strains using mitomycin C and characterized. Several lysogeny 
modules for phage lysogenization, such as cⅠ, cro, integrase, and Q, were identified 
from the genome of this phage. Furthermore, according to the comparative analysis of 
the putative proteins, many proteins showed high similarity to proteins from other 
temperate phages indicating that this phage is a real temperate phage (Zinno et al., 
2014). 
 The lytic phage PA13076, and the temperate phage BP96115, were purified using 
ultracentrifugation and ultrafiltration before phage administrations to mice. The 
endotoxin levels of lytic gut phage PA13076 and temperate phage BP96115 solutions 
were reduced to <1 EU/mL. Substantial phage titers were observed in the GIT after 
oral administration to mice, and both phages were mainly located in the cecum and 
feces, with titers reaching up to 104 and 106 PFU/g in cecum for PA13076 and 
BP96115, respectively. Simultaneously, the phages were detected in blood and spleen 
samples of mice. Overall, the current study demonstrated that a lytic and a temperate 
phage were distributed in the intestinal tract of mice and colonized it after oral intake, 
preferentially colonizing the posterior of the gut. 
 The metagenomic analyses of fecal samples showed that treatment of mice with the 
lytic and the temperate gut phage increased the gut bacterial diversity. Furthermore, 
the lytic gut phage significantly increased the alpha diversity and both phages 
changed the composition of the mice gut microbiota. Two beneficial genera, 
Lactobacillus and Bifidobacterium, were enhanced by treatment with the lytic and the 
temperate gut phage. While the lytic gut phage treatment did not cause an increase in 
potentially harmful bacterial pathogens, the temperate phage treatment of mice gave 
rise to the genus Shigella. Both phages did not change fecal VLPs significantly. 
Therefore, this study demonstrated that a long-term phage administration undoubtedly 
influences the dominant bacterial groups in the mammalian intestine and therefore 
health. The lytic gut phage promoted a beneficial gut ecosystem, while the temperate 
phage may promote conditions enabling diseases to occur. 
 Mice pretreated with the lytic and the temperate gut phage before Salmonella 
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Typhimurium challenge had an increased diversity of the gut microbiota not only at 
phylum but also at genus level. These results suggest that pretreatment of mice with 
lytic gut phage maintained a stable and healthy gut ecosystem, altered the 
composition of the bacterial community and enhanced the capability of mice to resist 
the pathogen challenge. The altered intestinal permeability and expression of 
inflammatory cytokines confirmed that the pretreatment of mice with the lytic or 
temperate gut phage reduced the pathogen induced intestinal inflammation. Hence, the 
use of a phage-based “probiotic product” affected the abundance and composition of 
gut microbiota as a regulatory therapy by increasing beneficial bacteria and thereby 
restricting intestinal inflammation. This study provides a first insight regarding the 
potential of phages as modulating agents for gastrointestinal microbial communities, 
potentially allowing for the development of phage-based strategies to prevent 
pathogen infection. 
6.2 Conclusions 
Due to the rapid emergence of multi-drug resistant Salmonella spp. causing infections 
of animal intestines and the overuse of antibiotics in animal feed, there is an urgent 
need to use phage-based bio-bactericides to promote animal health instead of 
antibiotics (Watts, 2017; Zelasko et al., 2017). Therefore, lytic phages seem to be a 
potential agent to improve the treatment of infections caused by bacterial pathogens 
(Cisek et al., 2017). However, unlike lytic phages, temperate phages are not suitable 
to kill bacterial pathogens (Cadwell, 2015). Nevertheless, temperate phages dominate 
in the animal gut, and perform a remarkable level of horizontal gene transfer and enter 
a preferred prophage life cycle upon infection (De Paepe et al., 2014). 
From an evolutionary perspective, phages will undoubtedly exert selective pressure 
on the commensal bacterial populations in the animal gut. However, so far there are 
limited numbers of studies, which have focused on the regulatory role of phages in the 
animal gut.  
To gain a better understanding of the governing capability of phages in the animal gut, 
One lytic and one temperate phage, which were originally isolated from animal gut 
were characterized and sequenced. The two genomes were analyzed using a 
comparative genomics approach. This is important as our knowledge of the genomes 
and the diversity of gut phages is very limited (Moreno Switt et al., 2013). Phage 
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PA13076 was confirmed as a virulent phage based on the absence of genes coding for 
integrase, repressor or transposase proteins and its high similarities to the genomes of 
lytic phage BP63 and UPF_BP2. Similarly, phage BP96115 shared a high degree of 
similarity with other temperate phages such as Salmonella phage P22 (Vander Byl and 
Kropinski, 2000), and enterobacteria phage ST104 (Tanaka et al., 2004). Additionally, 
the genomic elements, such as the functional serotype conversion cassette, integrase, 
excisionase, Abc1, and superinfection exclusion were found in BP96115, strongly 
suggesting that this phage is a temperate phage (Yoon and Chang, 2015). A better 
understanding of phage genomes is essential as gut phages may have an important 
role in protecting the host from pathogen infections and in regulating the bacterial 
population of the gut (Hurley et al., 2008; Lusiak-Szelachowska et al., 2017). 
Efficient removal of LPS from phage preparations is a key process to produce high 
quality phage formulations for clinical application. A combination of 
ultracentrifugation and ultrafiltration was efficient in removing bacterial LPS from 
prepared phage solutions, thereby matching previous studies (Dufour et al., 2016; 
Hashemi et al., 2013; Henry et al., 2013). Oral administration of phages is an 
important way to treat gastrointestinal infections and containing systemic infections 
(Ryan et al., 2011). However, phage survival as well as the preferred colonization and 
distribution in the GIT of treated animals are poorly understood. This study 
demonstrated that the lytic phage PA13076 and the temperate phage BP96115 can 
translocate across the gut mucosal barrier and migrate to peripheral blood and local 
tissues, which is in good agreement with previous studies (Gorski et al., 2006). In the 
present study, highest phage titers were detected in the cecum and in feces of mice. 
This result matches the report by Hoffmann (1965), showing that phage T3 
preferentially located in the higher or deeper sections of the intestine. Moreover, it 
was verified in this thesis that the temperate phage was more numerous than the lytic 
phage in mammalian feces, which matches the result of Dhillon et al. (1976). 
This study indicated that long-term (31 days) administration of the lytic or temperate 
gut phages in healthy mice changed the composition and diversity of gut microbiota. 
This result matched previous studies highlighting that phages have the potential to 
exert selective pressure upon and regulate selected members of the mammalian 
intestinal microbiota (De Paepe, et al., 2014; Lusiak-Szelachowska et al., 2017; Mills 
et al., 2013). The alpha diversity of gut microbiota was higher in both phage treated 
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groups of mice when compared to the control group. It has been shown that a high 
diversity of the gut microbiota is good for the overall health and productivity of 
animals such as weaned piglets and disease resistance in laboratory mice (Rosshart et 
al., 2017; Zhang et al., 2016). Furthermore, the abundance of members of two 
beneficial bacterial genera, Lactobacillus and Bifidobacterium, was higher in the lytic 
and temperate gut phage treated mice than in mice of control group. These enhanced 
beneficial gut probiotics can provide protection from enteric pathogen infection in 
animals (Fanning et al., 2012; Ravi, 2011). However, the abundance of the genus 
Escherichia/Shigella was higher in mice after temperate phage administration than in 
the control group. These results demonstrate that a long-term lytic gut phage 
administration promoted a beneficial gut ecosystem, while using the temperate phage 
may promote conditions enabling diseases to occur. 
The ability of phages to regulate dysbiosis of gut microbiota caused by Salmonella 
Typhimurium challenge in a mouse model was further explored. It was shown that the 
prophylactic use of phages for 31 days can prevent gut microbiota imbalances and 
improve gut health via modifying the gut microbial population based on a 
phage-based “probiotic product” (Abedon et al., 2011). Phage-based prophylaxis may 
therefore present a feasible approach to promote host fitness and limit pathogenic 
infection (Pedicord et al., 2016; Rosshart et al., 2017). Phages did not stimulate 
inflammatory mediator production in vitro, but can exert strong anti-inflammatory 
effects (Gorski et al., 2017). In addition, phage-based prophylaxis can reduce 
intestinal inflammation levels by ameliorating the histological damage in the ileum 
and cecum (Jun et al., 2014). In the present study, the mucosal barrier function was 
somewhat enhanced based on detecting LPS and DAO activity. This is closely related 
to the lower inflammatory level and the degree of damage of the intestinal mucosa 
(Xin et al., 2016). Therefore, phages can act as modulating agents regulating gut 
microbiota, showing that phage based prophylaxis can limit infection by bacterial 
pathogens. 
6.3 Further studies 
Gut health is very important for safeguarding animal health, performance, and welfare 
(Ohland and Jobin, 2015; Tuddenham and Sears, 2015). The results of this thesis 
indicated that long-term use of phages increased the diversity of gut microbiota and 
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enhanced the abundance of beneficial bacteria, thereby reducing the intestinal 
inflammation caused by bacterial infection. Hence, there is a need to expand our 
understanding of the diversity and abundance of phages as a large proportion of phage 
genes detected in the gut are unknown and cannot be assigned to known phages 
(Minot et al., 2011; Rohwer, 2003). This highlights the need for the application of in 
depth metagenomic studies to detect currently nonculturable phages (Breitbart et al., 
2003; Reyes et al., 2010). An improved understanding of the mechanisms by which 
gut phages shape the diversity and composition of commensal bacteria is also 
desirable, as this will provide a basis to develop new, more effective ways to control 
bacterial infections or to find new effective applications to promote the gut health of 
animals. 
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SUPPLEMENTARY MATERIAL 
Table S2.1 Host ranges of lytic phage PA13076   
 
No. Salmonella strains Serotype 
Lytic phage PA13076 
susceptibilitya Sources 
1 50336 Enteritidis + Ⅰ 
2 994 Enteritidis + Ⅰ 
3 T48 Enteritidis ++ Ⅰ 
4 T49 Enteritidis ++ Ⅰ 
5 T64 Enteritidis + Ⅰ 
6 CVCC1 Pullorun - Ⅰ 
7 S11-2 Pullorun - Ⅰ 
8 S11-3 Pullorun - Ⅰ 
9 S11-4-1 Pullorun + Ⅰ 
10 S11-4-2 Pullorun + Ⅰ 
11 S11-5 Pullorun + Ⅰ 
12 S12-2-1 Pullorun + Ⅰ 
13 S11-2-2 Pullorun + Ⅰ 
14 C1 Enteritidis + Ⅱ 
15 C2 Enteritidis + Ⅱ 
16 C5 Enteritidis + Ⅱ 
17 C7 Enteritidis + Ⅱ 
18 C8 Enteritidis - Ⅱ 
19 C11 Enteritidis + Ⅱ 
20 C12 Enteritidis + Ⅱ 
21 C14 Enteritidis + Ⅱ 
22 C15 Enteritidis + Ⅱ 
23 C16 Enteritidis + Ⅱ 
24 C17 Enteritidis + Ⅱ 
25 C18 Enteritidis + Ⅱ 
26 C19 Enteritidis ± Ⅱ 
27 C20 Enteritidis ± Ⅱ 
28 C21 Enteritidis ± Ⅱ 
29 C22 Enteritidis ± Ⅱ 
30 C23 Enteritidis ± Ⅱ 
31 C24 Enteritidis ± Ⅱ 
32 C25 Enteritidis ± Ⅱ 
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33 C26 Enteritidis - Ⅱ 
34 C27 Enteritidis + Ⅱ 
35 C29 Enteritidis + Ⅱ 
36 C30 Enteritidis + Ⅱ 
37 C31 Enteritidis + Ⅱ 
38 C32 Enteritidis + Ⅱ 
39 C36 Enteritidis + Ⅱ 
40 C39 Enteritidis + Ⅱ 
41 C40 Enteritidis + Ⅱ 
42 C41 Enteritidis + Ⅱ 
43 C43 Enteritidis + Ⅱ 
44 C44 Enteritidis + Ⅱ 
45 C46 Enteritidis + Ⅱ 
46 C53 Enteritidis + Ⅱ 
47 C56 Enteritidis + Ⅱ 
48 C57 Enteritidis + Ⅱ 
49 C58 Enteritidis - Ⅱ 
50 C59 Enteritidis - Ⅱ 
51 C60 Enteritidis - Ⅱ 
52 C61 Enteritidis - Ⅱ 
53 C63 Enteritidis + Ⅱ 
54 C65 Enteritidis + Ⅱ 
55 C71 Enteritidis + Ⅱ 
56 C72 Enteritidis + Ⅱ 
57 C76 Enteritidis + Ⅱ 
58 C79 Enteritidis + Ⅱ 
59 C80 Enteritidis + Ⅱ 
60 C83 Enteritidis + Ⅱ 
61 C88 Enteritidis + Ⅱ 
62 C89 Enteritidis + Ⅱ 
63 C94 Enteritidis + Ⅱ 
64 C96 Enteritidis + Ⅱ 
65 C99 Enteritidis + Ⅱ 
66 C102 Enteritidis + Ⅱ 
67 C105 Enteritidis + Ⅱ 
68 C106 Enteritidis + Ⅱ 
69 C110 Enteritidis + Ⅱ 
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70 C118 Enteritidis + Ⅱ 
71 C124 Enteritidis + Ⅱ 
72 C125 Enteritidis + Ⅱ 
73 C128 Enteritidis + Ⅱ 
74 C130 Enteritidis + Ⅱ 
75 C133 Enteritidis - Ⅱ 
76 C135 Enteritidis + Ⅱ 
77 C137 Enteritidis - Ⅱ 
78 C138 Enteritidis + Ⅱ 
79 C139 Enteritidis + Ⅱ 
80 C144 Enteritidis + Ⅱ 
81 C145 Enteritidis + Ⅱ 
82 C146 Enteritidis + Ⅱ 
83 C149 Enteritidis + Ⅱ 
84 C150 Enteritidis + Ⅱ 
85 C152 Enteritidis + Ⅱ 
86 C154 Enteritidis + Ⅱ 
87 C155 Enteritidis + Ⅱ 
88 C156 Enteritidis + Ⅱ 
89 C158 Enteritidis + Ⅱ 
90 C161 Enteritidis + Ⅱ 
91 C164 Enteritidis + Ⅱ 
92 C165 Enteritidis + Ⅱ 
93 C167 Enteritidis + Ⅱ 
94 2 Enteritidis - Ⅱ 
95 4 Enteritidis - Ⅱ 
96 8 Enteritidis + Ⅱ 
97 21 Enteritidis + Ⅱ 
98 31 Enteritidis + Ⅱ 
99 32 Enteritidis + Ⅱ 
100 34 Enteritidis + Ⅱ 
101 36 Enteritidis + Ⅱ 
102 37 Enteritidis + Ⅱ 
103 42 Enteritidis + Ⅱ 
104 43 Enteritidis - Ⅱ 
105 59 Enteritidis + Ⅱ 
106 71 Enteritidis + Ⅱ 
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107 SM-1-KDE Enteritidis + Ⅱ 
108 SM-3-KDE Indiana + Ⅱ 
109 SM-4-KDE Typhimurium - Ⅱ 
110 SM-5-KDE Typhimurium - Ⅱ 
111 SM-6-KDE Typhimurium - Ⅱ 
112 SM-7-KDE Typhimurium - Ⅱ 
113 SM-8-KDE Typhimurium + Ⅱ 
114 SM-10-KDE Enteritidis + Ⅱ 
115 SM-12-KDE Typhimurium - Ⅱ 
116 SM-14-KDE Enteritidis + Ⅱ 
117 SM-16-KDE Enteritidis + Ⅱ 
118 SM-17-KDE Enteritidis + Ⅱ 
119 SM-22-KDE Newport + Ⅱ 
120 SM-23-KDE Enteritidis + Ⅱ 
121 SM-27-KDE Sanftenberg + Ⅱ 
122 SM-28-KDE Indiana + Ⅱ 
123 SM-29-KDE Kottbus + Ⅱ 
124 SM-30-KDE Indiana + Ⅱ 
125 SM-31-KDE Choleraesuis + Ⅱ 
126 SM-32-KDE Enteritidis + Ⅱ 
127 SM-34-KDE Enteritidis + Ⅱ 
128 SM-38-KDE Enteritidis + Ⅱ 
129 SM-39-KDE Enteritidis ++ Ⅱ 
130 SM-41-KDE Enteritidis - Ⅱ 
131 SM-46-KDE Enteritidis + Ⅱ 
132 SM-49-KDE Enteritidis + Ⅱ 
133 SM-52-KDE Enteritidis + Ⅱ 
134 SM-53-KDE Enteritidis + Ⅱ 
135 SM-54-KDE Enteritidis + Ⅱ 
136 SM-55-KDE Enteritidis + Ⅱ 
137 SM-56-KDE Indiana + Ⅱ 
138 SM-57-KDE Indiana + Ⅱ 
139 SM-58-KDE Typhimurium - Ⅱ 
140 SM-61-KDE Newport ++ Ⅱ 
141 SM-SC-XT-1 Enteritidis - Ⅱ 
142 SM-SC-XT-2 Enteritidis - Ⅱ 
143 SM-SC-XT-3 Enteritidis + Ⅱ 
139 
 
144 SM-SC-XT-4 Enteritidis + Ⅱ 
145 SM-SC-XT-5 Enteritidis - Ⅱ 
146 SM-SC-XT-6 Enteritidis - Ⅱ 
147 SM-SC-XT-7 Enteritidis + Ⅱ 
148 SM-SC-XT-8 Enteritidis + Ⅱ 
149 SM-SC-XT-9 Enteritidis + Ⅱ 
150 SM-SC-XT-10 Enteritidis + Ⅱ 
151 SM-SC-XT-11 Enteritidis + Ⅱ 
152 SM-SC-XT-12 Enteritidis - Ⅱ 
153 SM-SC-XT-13 Enteritidis + Ⅱ 
154 SM-SC-XT-14 Enteritidis - Ⅱ 
155 SM-SC-XT-15 Enteritidis - Ⅱ 
156 SM-SC-XT-16 Enteritidis - Ⅱ 
157 SM-SC-XT-17 Enteritidis - Ⅱ 
158 SM-SC-XT-18 Enteritidis - Ⅱ 
159 SM-SC-XT-19 Enteritidis + Ⅱ 
160 SM-SC-XT-20 Enteritidis - Ⅱ 
161 SM-SC-XT-21 Enteritidis - Ⅱ 
162 SM-SC-XT-22 Enteritidis - Ⅱ 
163 SM-SC-XT-23 Enteritidis - Ⅱ 
164 SM-SC-XT-24 Enteritidis - Ⅱ 
165 SM-SC-XT-25 Enteritidis - Ⅱ 
166 SM-SC-XT-26 Enteritidis - Ⅱ 
167 SM-SC-XT-27 Enteritidis + Ⅱ 
168 SM-SC-XT-28 Enteritidis + Ⅱ 
169 SM-SC-XT-29 Enteritidis + Ⅱ 
170 SM-SC-XT-30 Enteritidis - Ⅱ 
171 SM-SC-XT-31 Enteritidis - Ⅱ 
172 SM-SC-XT-32 Enteritidis + Ⅱ 
173 SM-SC-XT-33 Enteritidis + Ⅱ 
174 SM-SC-XT-34 Enteritidis + Ⅱ 
175 SM-SC-XT-35 Enteritidis - Ⅱ 
176 SM-SC-XT-36 Enteritidis + Ⅱ 
177 SM-SC-XT-37 Enteritidis + Ⅱ 
178 SM-SC-XT-38 Enteritidis + Ⅱ 
179 SM-90-1 Enteritidis - Ⅱ 
180 SM-90-2 Enteritidis - Ⅱ 
140 
 
181 SC-81 Enteritidis - Ⅱ 
182 SC-91 Typhimurium ++ Ⅱ 
183 SC-131 Enteritidis - Ⅱ 
184 L3 Enteritidis - Ⅱ 
185 L5 Enteritidis + Ⅱ 
186 L6 Enteritidis + Ⅱ 
187 L7 Enteritidis - Ⅱ 
188 L10 Enteritidis - Ⅱ 
189 L11 Enteritidis - Ⅱ 
190 L13 Enteritidis + Ⅱ 
191 L20 Enteritidis - Ⅱ 
192 L24 Enteritidis - Ⅱ 
193 L35 Enteritidis + Ⅱ 
194 L40 Enteritidis + Ⅱ 
195 L43 Enteritidis - Ⅱ 
196 L44 Enteritidis + Ⅱ 
197 L56 Derby - Ⅱ 
198 L80 Indiana + Ⅱ 
199 L98 Indiana + Ⅱ 
200 L333 Enteritidis +++ Ⅱ 
201 205 Enteritidis + Ⅱ 
202 206 Enteritidis + Ⅱ 
203 213 Enteritidis - Ⅱ 
204 225 Indiana + Ⅱ 
205 228 Enteritidis - Ⅱ 
206 230 Indiana + Ⅱ 
207 234 Enteritidis - Ⅱ 
208 243 Indiana - Ⅱ 
209 269 Enteritidis + Ⅱ 
210 275 
not belonging to 
A-f group ++ Ⅱ 
211 283 Indiana + Ⅱ 
212 300 Indiana + Ⅱ 
213 307 Indiana + Ⅱ 
214 312 Enteritidis - Ⅱ 
215 315 Indiana + Ⅱ 
216 324 Enteritidis - Ⅱ 
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217 325 Enteritidis - Ⅱ 
218 334 Enteritidis + Ⅱ 
219 342 Indiana + Ⅱ 
220 343 Indiana + Ⅱ 
221 354 Enteritidis + Ⅱ 
222 359 Indiana + Ⅱ 
223 360 Enteritidis + Ⅱ 
224 365 Enteritidis - Ⅱ 
225 404 Indiana + Ⅱ 
226 407 Typhimurium - Ⅱ 
227 410 Enteritidis + Ⅱ 
228 414 Indiana + Ⅱ 
229 415 Indiana + Ⅱ 
230 418 Enteritidis + Ⅱ 
231 420 Indiana + Ⅱ 
232 421 Enteritidis + Ⅱ 
233 431 Enteritidis - Ⅱ 
234 433 Enteritidis + Ⅱ 
235 450 Enteritidis + Ⅱ 
236 457 Enteritidis - Ⅱ 
237 460 Indiana + Ⅱ 
238 462 Indiana + Ⅱ 
239 470 Enteritidis + Ⅱ 
240 472 Enteritidis + Ⅱ 
241 505 Enteritidis + Ⅱ 
242 507 Enteritidis + Ⅱ 
243 508 Enteritidis - Ⅱ 
244 513 Enteritidis + Ⅱ 
245 515 Enteritidis + Ⅱ 
246 517 Enteritidis ++ Ⅱ 
247 521 Typhimurium + Ⅱ 
248 SPu-109 Pullorum - Ⅲ 
249 SPu-13 Pullorum - Ⅲ 
250 SPu-102 Pullorum - Ⅲ 
251 SPu-45 Pullorum - Ⅲ 
252 SPu-115 Pullorum - Ⅲ 
253 SPu-116 Pullorum - Ⅲ 
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254 SPu-905 Pullorum - Ⅲ 
255 SPu-27 Pullorum - Ⅲ 
256 SPu-01 Pullorum - Ⅲ 
257 SPu-49 Pullorum - Ⅲ 
258 SPu-103 Pullorum - Ⅲ 
259 SPu-85 Pullorum - Ⅲ 
260 E2 Typhimurium ++ Ⅲ 
261 E6 Typhimurium + Ⅲ 
262 E10 Typhimurium + Ⅲ 
263 E12 Typhimurium + Ⅲ 
264 E16 Typhimurium + Ⅲ 
265 E17 Anatum + Ⅲ 
266 D9 London + Ⅲ 
267 S3 Typhimurium + Ⅲ 
268 S8 Typhimurium + Ⅲ 
269 S9 Typhimurium + Ⅲ 
270 S20 Enteritidis + Ⅲ 
271 DHLM-1 Typhimurium + Ⅲ 
272 DHLM-2 Typhimurium + Ⅲ 
273 JKSen Enteritidis + Ⅲ 
274 C50041 Enteritidis - Ⅲ 
275 CYR1 Enteritidis +++ Ⅲ 
276 CYR2 Enteritidis + Ⅲ 
277 CYR3 Enteritidis + Ⅲ 
278 CYR4 Enteritidis + Ⅲ 
279 CYR5 Enteritidis + Ⅲ 
280 ATCC13076 Enteritidis +++ Ⅳ 
281 ATCC13311 Typhimurium - Ⅳ 
282 ATCC50073 Paratyphi A - Ⅳ 
283 CVCC2184 Enteritidis + Ⅲ 
284 CMCC533 Pullorum - Ⅲ 
285 HNER027 Derby + Ⅴ 
286 HNER121 Enteritidis + Ⅴ 
287 HNER055 Derby + Ⅴ 
288 HNER127 Derby + Ⅴ 
289 HNER004 Derby + Ⅴ 
290 HNER067-1 Derby ++ Ⅴ 
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291 HNER067-2 Derby + Ⅴ 
292 HNER117 Derby ++ Ⅴ 
293 HNER102 Derby + Ⅴ 
294 HNER047 Derby + Ⅴ 
295 HNER178 Typhimurium + Ⅴ 
296 HNER086 Derby ++ Ⅴ 
297 CDER157 O:10, H:1,w - Ⅴ 
298 CDER160 Derby + Ⅴ 
299 CDER188 Derby + Ⅴ 
300 DBER023 Typhimurium + Ⅴ 
301 DLJR01 Arizonae - Ⅴ 
302 DBJR151 Enteritidis + Ⅴ 
303 DBJR193-2 Derby + Ⅴ 
304 DBJR236 Enteritidis + Ⅴ 
305 1769 Derby + Ⅵ 
306 1401 Pullorum - Ⅵ 
307 1402 Pullorum - Ⅵ 
308 1403 Pullorum - Ⅵ 
309 1404 Pullorum - Ⅵ 
310 1405 Pullorum - Ⅵ 
311 1406 Pullorum - Ⅵ 
Sources: Ⅰ Guo-qiang Zhu (Yangzhou University, Yangzhou, China); Ⅱ Yu-qing Liu (Shandong 
Academy of Agricultural Sciences, Jinan, China); Ⅲ Lab stock;  IV Guo-xiang Cao (Chinese 
Academy of Agricultural Science, Yangzhou, China); ⅤYan-bin Zeng (Jiangxi Academy of 
Agricultural Sciences, Nanchang, China);Ⅵ Jian-sen Gong(Poultry institute, Chinese Academy of 
Agricultural Sciences, Yangzhou, China, Yangzhou, China) 
a  +++ , complete lysis;  ++, lysis; +, turbid lysis; -, no plagues. 
  
144 
 
Table S2.2 Host range of temperate phage BP96115 
No. 
Salmonella 
strains 
Serotype 
Temperate phage BP96115 
susceptibilitya 
Sources 
1 S11-2 Pullorum - Ⅰ 
2 SPu-115 Pullorum - Ⅲ 
3 SPu-109 Pullorum +++ Ⅲ 
4 SPu-01 Pullorum - Ⅲ 
5 S11-3 Pullorum ++ Ⅰ 
6 SPu-905 Pullorum + Ⅲ 
7 SPu-45 Pullorum ++ Ⅲ 
8 S11-5 Pullorum - Ⅰ 
9 SPu-13 Pullorum - Ⅲ 
10 SPu-103 Pullorum - Ⅲ 
11 SPu-116 Pullorum + Ⅲ 
12 SPu-27 Pullorum ++ Ⅲ 
13 SPu-85 Pullorum - Ⅲ 
14 CYR1 Enteritidis - Ⅲ 
15 CYR2 Enteritidis - Ⅲ 
16 CYR3 Enteritidis - Ⅲ 
17 CYR4 Enteritidis - Ⅲ 
18 CYR5 Enteritidis - Ⅲ 
19 D9 London - Ⅲ 
20 SPu-102 Pullorum - Ⅲ 
21 SPu-49 Pullorum - Ⅲ 
22 SPu-95 Pullorum ++ Ⅲ 
145 
 
23 DHLM-2 Typhimurium - Ⅲ 
24 HNER 067-2 Derby - Ⅴ 
25 HNER 178 Typhimurium ++ Ⅴ 
26 SM-SC-XT-35  Enteritidis ++ Ⅱ 
The information of the bacteria is the same with the bacteria’s in table S2.1. 
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Table S2.3 ORF features, database matches and functional assignments of coding 
sequences (cds) of the lytic phage PA13076 genome for which homologies (e-value 
< 0.01) to known proteins could be found 
ORF# Start Stop Strand Predicted product 
Organism, 
gene or 
product 
Coverag
e 
E value Identity 
Accession 
no 
Predicted Domain 
1 <2 106 - 
Hypothetical protein 
BP63_38 
Salmonella 
phage BP63 
100% 
3.00E-1
5 
100% 
YP_009302
957.1 
Uncharacterized 
protein 
2 106 2682 - 
Hypothetical protein 
BP63_36 
Salmonella 
phage BP63 
64% 0 98% 
YP_009302
955.1 
Uncharacterized 
protein 
3 2845 3273 - 
Hypothetical protein 
BP63_34 
Salmonella 
phage BP63 
100% .00E-99 100% 
YP_009302
953.1 
Uncharacterized 
protein 
4 3292 3723 - 
Hypothetical protein 
BP63_33 
Salmonella 
phage BP63 
100% 
5.00E-1
01 
100% 
YP_009302
952.1 
Uncharacterized 
protein 
5 3735 4874 - 
Hypothetical protein 
BP63_32 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
951.1 
Uncharacterized 
protein 
6 4961 7090 - 
Cell wall/surface 
repeat-containing 
protein 
Salmonella 
phage BP63 
100% 0 98% 
YP_009302
950.1 
Cell wall/surface 
repeat-containing 
protein 
7 7102 7740 - 
Ig domain protein 
group 2 domain 
protein 
Salmonella 
phage BP63 
100% 
2.00E-1
39 
99% 
YP_009302
949.1 
Ig domain protein 
group 2 domain 
protein 
8 7808 10765 - Tail protein 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
948.1 
Tail-associated 
protein 
9 10765 11388 - 
Putative tail fiber 
protein 
Salmonella 
phage BP63 
100% 
1.00E-1
44 
99% 
YP_009302
947.1 
Putative tail fiber 
protein 
10 11388 11696 - 
Hypothetical protein 
BP63_27 
Salmonella 
phage BP63 
100% 
7.00E-6
8 
99% 
YP_009302
946.1 
Uncharacterized 
protein 
11 11696 11839 - Unkown 
     
leucine-rich repeat 
and death 
domain-containing 
protein 1-like 
12 11839 12216 - 
Hypothetical protein 
BP63_26 
Salmonella 
phage BP63 
100% 
5.00E-9
0 
100% 
YP_009302
945.1 
Uncharacterized 
protein 
13 12216 12704 - 
Hypothetical protein 
BP63_25 
Salmonella 
phage BP63 
100% 
2.00E-1
15 
99% 
YP_009302
944.1 
Uncharacterized 
protein 
14 12704 13204 - 
Hypothetical protein 
BP63_24 
Salmonella 
phage BP63 
100% 
2.00E-1
16 
97% 
YP_009302
943.1 
Virion protein 
15 13309 14286 - Major capsid protein 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
942.1 
Uncharacterized 
protein 
16 14290 15003 - Scaffold protein 
Salmonella 
phage BP63 
100% 
3.00E-1
71 
100% 
YP_009302
941.1 
Scaffold protein 
17 15181 16569 - Portal protein Salmonella 100% 0 100% YP_009302 Portal protein 
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phage BP63 940.1 
18 16745 18193 - 
Terminase large 
subunit 
Salmonella 
phage BP63 100% 0 99% 
YP_009302
939.1 
Putative phage 
terminase large 
subunit 
19 18197 18487 - 
Hypothetical protein 
BP63_19 
Salmonella 
phage BP63 
100% 
8.00E-6
2 
99% 
YP_009302
938.1 
no hits 
20 18665 18955 - 
Hypothetical protein 
BP63_18 
Salmonella 
phage BP63 
100% 
1.00E-6
5 
99% 
YP_009302
937.1 
Uncharacterized 
protein 
21 18955 19647 - 
Fibrous sheath 
CABYR-binding 
protein 
Salmonella 
phage BP63 100% 
2.00E-1
58 
91% 
YP_009302
936.1 
fibrous sheath 
CABYR-binding 
protein 
22 19644 20150 - Thymidylate kinase 
Salmonella 
phage BP63 
100% 
5.00E-1
20 
99% 
YP_009302
935.1 
thymidylate kinase 
23 20147 20821 - 
Hypothetical protein 
BP63_15 
Salmonella 
phage BP63 
100% 
1.00E-1
64 
98% 
YP_009302
934.1 
PHIKZ004 
24 20814 21299 - 
Hypothetical protein 
BP63_14 
Salmonella 
phage BP63 
98% 
1.00E-1
13 
98% 
YP_009302
933.1 
Uncharacterized 
protein 
25 22121 22423 + unknown 
     
No hits 
26 22519 23088 + 
Hypothetical protein 
BP63_11 
Salmonella 
phage BP63 99% 
5.00E-1
17 
93% 
YP_009302
930.1 
Uncharacterized 
protein 
VR7ORF147c 
27 23153 23311 + 
Hypothetical protein 
BP63_10 
Salmonella 
phage BP63 
100% 
2.00E-2
8 
100% 
YP_009302
929.1 
TPR repeat protein 
28 23317 23574 + 
Hypothetical protein 
BP63_09 
Salmonella 
phage BP63 
100% 
3.00E-5
2 
96% 
YP_009302
928.1 
Uncharacterized 
protein (Fragment) 
29 23571 23744 + 
Hypothetical protein 
BP63_08 
Salmonella 
phage BP63 
100% 
8.00E-3
2 
100% 
YP_009302
927.1 
Uncharacterized 
protein 
30 23818 24207 + 
Hypothetical protein 
BP63_07 
Salmonella 
phage BP63 
100% 
2.00E-8
8 
96% 
YP_009302
926.1 
All3346 protein 
31 24207 24407 + 
Hypothetical protein 
BP63_06 
Salmonella 
phage BP63 
100% 
3.00E-4
0 
94% 
YP_009302
925.1 
Uncharacterized 
protein 
32 24520 24645 + 
TPR repeat:Kinesin 
light chain 
Salmonella 
phage BP63 
100% 
4.00E-1
9 
93% 
YP_009302
924.1 
TPR repeat:Kinesin 
light chain 
33 24657 24824 + 
Hypothetical protein 
BP63_04 
Salmonella 
phage BP63 
100% 
8.00E-3
1 
100% 
YP_009302
923. 
Uncharacterized 
protein 
34 24880 25059 + 
Hypothetical protein 
BP63_03 
Salmonella 
phage BP63 
100% 
2.00E-3
6 
98% 
YP_009302
922.1 
Predicted protein 
35 25238 25669 - 
Hypothetical protein 
BP63_01 
Salmonella 
phage BP63 
100% 
3.00E-1
04 
100% 
YP_009302
920.1 
Uncharacterized 
protein 
36 26149 28683 - Primase 
Salmonella 
phage BP63 
100% 0 98% 
YP_009302
995.1 
Putative 
primase/helicase 
37 28658 28990 - 
Hypothetical protein 
BP63_75 
Salmonella 
phage BP63 100% 
3.00E-7
5 
100% 
YP_009302
994.1 
Putative 
transcriptional 
regulator 
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38 29144 29581 + 
Hypothetical protein 
BP63_74 
Salmonella 
phage BP63 
100% 
3.00E-1
00 
96% 
YP_009302
993.1 
Unplaced genomic 
scaffold 
CY34scaffold_122, 
whole genome 
shotgun sequence 
(Fragment) 
39 29863 30312 + 
Putative DNA 
binding protein 
Salmonella 
phage BP63 
100% 
3.00E-1
05 
100% 
YP_009302
991.1 
Putative DNA 
binding protein 
40 30468 30659 + 
Hypothetical protein 
BP63_71 
Salmonella 
phage BP63 
93% 
3.00E-3
0 
88% 
YP_009302
990.1 
Uncharacterized 
protein 
41 30750 31040 + 
Hypothetical protein 
BP63_70 
Salmonella 
phage BP63 
100% 
8.00E-6
2 
97% 
YP_009302
989.1 
Uncharacterized 
protein 
42 31037 31327 + 
Hypothetical protein 
BP63_69 
Salmonella 
phage BP63 
100% 
3.00E-6
5 
100% 
YP_009302
988.1 
Uncharacterized 
protein 
43 31442 32347 + PAS domain S-box 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
987.1 
PAS domain S-box 
44 32396 32842 + 
Hypothetical protein 
BP63_67 
Salmonella 
phage BP63 
100% 
3.00E-1
05 
99% 
YP_009302
986.1 
Uncharacterized 
protein (Fragment) 
45 32903 33133 + 
Hypothetical protein 
BP63_66 
Salmonella 
phage BP63 
100% 
5.00E-4
9 
99% 
YP_009302
985.1 
Regulator of 
chromosome 
condensation, 
RCC1 
46 33133 34017 + 
Nucleotide-binding 
protein 
Salmonella 
phage BP63 100% 0 98% 
YP_009302
984.1 
Phage 
nucleotide-binding 
protein 
47 34125 34670 + 
Hypothetical protein 
BP63_64 
Salmonella 
phage BP63 
100% 
1.00E-1
28 
98% 
YP_009302
983.1 
Uncharacterized 
protein 
48 34732 35217 + 
Deoxycytidylate 
deaminase 
Salmonella 
phage BP63 
100% 
5.00E-1
16 
99% 
YP_009302
982.1 
Uncharacterized 
protein 
49 35201 36079 + 
Hypothetical protein 
BP63_62 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
981.1 
Exonuclease 
50 36138 37808 + DEAD box helicase 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
980.1 
Superfamily II 
DNA/RNA helicase 
51 38123 38590 + 
Hypothetical protein 
BP63_59 
Salmonella 
phage BP63 
100% 
2.00E-1
01 
100% 
YP_009302
978.1 
50S ribosomal 
protein L19 
52 39268 39666 + 
Hypothetical protein 
BP63_57 
Salmonella 
phage BP63 
100% 
2.00E-9
1 
98% 
YP_009302
976.1 
No hits 
53 39653 40246 + 
Hypothetical protein 
BP63_56 
Salmonella 
phage BP63 
100% 
2.00E-1
44 
99% 
YP_009302
975.1 
Uncharacterized 
protein 
54 40246 41130 + 
Thymidylate 
synthase 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
974.1 
Thymidylate 
synthase 
55 41161 42156 + 
DNA polymerase 
beta subunit 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
973.1 
DNA polymerase 
beta subunit 
56 42156 44123 + DNA polymerase Salmonella 100% 0 99% YP_009302 DNA polymerase A 
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phage BP63 972.1 
57 44139 44414 + 
Hypothetical protein 
BP63_52 
Salmonella 
phage BP63 
100% 
1.00E-5
6 
97% 
YP_009302
971.1 
Uncharacterized 
protein 
58 44414 44638 + 
Zinc finger protein 
729 
Salmonella 
phage BP63 
100% 
9.00E-4
6 
97% 
YP_009302
970.1 
Zinc finger protein 
729 (Fragment) 
59 44856 45185 - 
Hypothetical protein 
BP63_49 
Salmonella 
phage BP63 
100% 
1.00E-6
8 
96% 
YP_009302
968.1 
Uncharacterized 
protein 
60 45164 45670 - Lysozyme 
Salmonella 
phage BP63 
100% 
2.00E-1
23 
99% 
YP_009302
967. 
Lysozyme 
61 45684 45944 - 
Hypothetical protein 
BP63_47 
Salmonella 
phage BP63 
100% 
1.00E-5
4 
100% 
YP_009302
966.1 
Uncharacterized 
protein 
62 46047 46550 - 
Putative tail fiber 
assembly protein 
Salmonella 
phage BP63 
100% 
2.00E-1
18 
98% 
YP_009302
965.1 
Putative tail fiber 
assembly protein 
63 46554 47096 - 
Putative tail fiber 
assembly protein 
Salmonella 
phage BP63 
100% 
1.00E-1
31 
99% 
YP_009302
964.1 
Putative tail fiber 
assembly protein 
64 47106 48440 - 
Phage tail fiber 
protein 
Salmonella 
phage BP63 
100% 0 99% 
YP_009302
963.1 
Phage tail fiber 
protein 
65 48433 49086 - 
Hypothetical protein 
BP63_43 
Salmonella 
phage BP63 
100% 
2.00E-1
56 
99% 
YP_009302
962.1 
Uncharacterized 
protein 
66 49079 50251 - 
Hypothetical protein 
BP63_42 
Salmonella 
phage BP63 100% 0 99% 
YP_009302
961.1 
Putative 
bacteriophage 
protein 
67 50251 50622 - 
Hypothetical protein 
BP63_41 
Salmonella 
phage BP63 
100% 
5.00E-8
6 
100% 
YP_009302
960.1 
Uncharacterized 
protein 
68 50633 51280 - 
Hypothetical protein 
BP63_40 
Salmonella 
phage BP63 
100% 
2.00E-1
58 
100% 
YP_009302
959.1 
Uncharacterized 
protein 
69 51280 52260 - 
Hypothetical protein 
BP63_39 
Salmonella 
phage BP63 
97% 0 99% 
YP_009302
958.1 
Uncharacterized 
protein 
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Table S2.4 The ORFs characteristics of temperate phage BP96115, functional 
assignments of coding sequences (cds) for which homologies (e-value< 0.01) to 
known proteins could be found 
 
ORF# start stop Strand 
Predicted 
functions 
Organism, gene or 
product 
E value identity Accession no 
Predicted 
domains 
1 1 108 + Orf232 
Salmonella phage 
ST64T 
7.00E-08 86% AAL15494.1 
serine-rich adhesin 
for platelets-like 
2 246 440 - Ral 
Salmonella virus 
P22 
2.00E-37 97% NP_059603.1 
Ral 
3 681 1241 + 
Superinfection 
exclusion protein 
B 
Salmonella phage 
SPN9CC 
6.00E-113 95% YP_006383855.1 
Superinfection 
exclusion protein 
B 
4 1254 1556 - Gp24 
Enterobacteria 
phage ST104 
7.00E-69 100% YP_006377.1 
Probable 
regulatory protein 
N 
5 1920 2123 + unknown 
    
Uncharacterized 
protein 
6 2162 3205 - ORF23 
Enterobacteria 
phage ST104 
0 100% YP_006378.1 
ORF23 
7 3406 4095 - CI 
Enterobacteria 
phage ST104 
2.00E-169 100% YP_006379.1 
CI 
8 4206 4421 + cro 
Escherichia phage 
HK639 
4.00E-23 74% YP_004934081.1 
cro 
9 4532 4813 + 
transcriptional 
activator 
Salmonella phage 
ST64T 
5.00E-63 100% NP_720301.1 
C1 
10 4848 5009 + Gp53 
Escherichia virus 
HK97 
1.00E-31 100% NP_037738.1 
Uncharacterized 
protein 
11 4996 5817 + 18, partial 
Enterobacteria 
phage ST104 
0 100% YP_006383.1 
DNA replication 
protein O 
12 5814 7190 + Gp55 
Escherichia virus 
HK97 
0 97% NP_037740.1 
DnaB helicase 
13 7187 7456 + ORF30 
Enterobacteria 
phage ST104 
6.00E-62 100% YP_006385.1 
Uncharacterized 
protein 
14 7453 7533 + NinA 
Enterobacteria 
phage UAB_Phi20 
8.00E-10 100% YP_009279781.1 
NinA protein 
15 7530 7967 + NinB 
Salmonella virus 
P22 
6.00E-101 99% NP_059612.1 
NinB protein 
16 8283 8624 + NinX 
Enterobacteria 
phage ST104 
3.00E-82 100% YP_006389.1 
NinX protein 
17 8617 8793 + NinF 
Enterobacteria 
phage ST104 
2.00E-36 100% YP_006390.1 
NinF protein 
18 8786 9397 + NinG protein 
Enterobacteria 
phage HK446 
1.00E-145 99% YP_007112004.1 
NinG protein 
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19 9394 9618 + NinY 
Enterobacteria 
phage ST104 
4.00E-51 100% YP_006392.1 
NinY protein 
20 9799 9978 + NinZ 
Enterobacteria 
phage ST104 
4.00E-37 100% YP_006394.1 
NinZ protein 
21 9975 10748 + 
late gene regulator 
Q 
Enterobacteria 
phage HK225 
6.00E-90 66% YP_007112198.1 
Antitermination 
protein 
22 11179 11382 + Gp13 
Enterobacteria 
phage ST104 
4.00E-43 100% YP_006396.1 
Class II holin 
23 11387 11857 + Lysozyme 
Salmonella enterica 
bacteriophage SE1 
5.00E-113 100% YP_002455881.1 
Lysozyme 
24 11854 12321 + endopeptidase 
Enterobacteria 
phage HK620 
1.00E-94 92% NP_112070.1 
Rz lysis protein 
25 12534 13064 + ORF45 
Enterobacteria 
phage ST104 
2.00E-129 100% YP_006400.1 
Uncharacterized 
protein  
26 13287 13529 + ORF46 
Enterobacteria 
phage ST104 
1.00E-48 100% YP_006401.1 
Uncharacterized 
protein 
27 13533 13922 + ORF47 
Enterobacteria 
phage ST104 
6.00E-95 100% YP_006402.1 
Uncharacterized 
protein 
28 13922 14326 + ORF48 
Enterobacteria 
phage ST104 
1.00E-93 100% YP_006403.1 
Phage Tail Collar 
Domain 
29 14330 14818 + 
terminase small 
subunit 
Salmonella phage 
ST64T 
2.00E-119 100% NP_720325.1 
Terminase, small 
subunit 
30 14796 16295 + 
terminase large 
subunit  
Salmonella phage 
ST64T 
0 99% NP_720326.1 
Terminase, large 
subunit 
31 16295 18472 + portal protein 
Salmonella phage 
SEN22 
0 99% YP_009191457.1 
Portal protein 
32 18486 19397 + 
Scaffolding 
protein 
Salmonella phage 
c341 
0 99% YP_003090221.1 
Scaffolding 
protein 
33 19397 20689 + capsid protein 
Salmonella phage 
SEN22 
0 100% YP_009191459.1 
Major capsid 
protein 
34 20730 21290 + ORF54 
Enterobacteria 
phage ST104 
2.00E-135 100% YP_006409.1 
Uncharacterized 
protein 
35 21274 21774 + 
head completion 
protein 
Salmonella phage 
vB_SemP_Emek 
8.00E-122 98% YP_006560557.1 
Peptidoglycan 
hydrolase gp4 
36 21734 23152 + 
Tail accessory 
protein 
Salmonella phage 
epsilon34 
0 100% YP_002533467.1 
Packaged DNA 
stabilization 
protein gp10 
37 23156 23857 + 26 
Enterobacteria 
phage ST104 
1.00E-166 100% YP_006413.1 
Tail needle protein 
gp26 
38 23857 24312 + 14 
Enterobacteria 
phage ST104 
1.00E-111 100% YP_006414.1 
Head assembly 
protein 
39 24315 25004 + 7 
Enterobacteria 
phage ST104 
7.00E-157 99% YP_006415.1 
DNA transfer 
protein 
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40 25015 26451 + 
DNA transfer 
protein 
Salmonella phage 
ST64T 
5.00E-161 71% NP_720336.1 
DNA transfer 
protein 
41 26451 28427 + 
DNA transfer 
protein 
Salmonella phage 
ST64T 
0 100% NP_720337.1 
DNA transfer 
protein 
42 28880 29128 - regulatory protein 
Salmonella phage 
ST64T 
2.00E-53 100% NP_720338.1 
Transcriptional 
repressor Mnt 
43 29264 31267 + tail protein 
Salmonella phage 
A1 
0 100% AAY43004.1 
Tailspike protein 
44 31326 32783 - 
O-antigen 
conversion protein 
C 
Enterobacteria 
phage ST64T 
0 100% NP_720275.1 
GtrC 
45 32773 33705 - 
O-antigen 
conversion protein 
B 
Salmonella phage 
ST64T 
0 100% NP_720276.1 
GtrB 
46 33702 34064 - 
bactoprenol-linked 
glucose 
translocase 
Cronobacter phage 
ENT47670 
7.00E-58 89% YP_007237579.1 
Bactoprenol-linked 
glucose 
translocase 
47 34413 35576 - integrase 
Enterobacteria 
phage UAB_Phi20 
0 99% YP_009279828.1 
Integrase 
48 35806 35943 - 
formate 
dehydrogenase N 
alpha subunit 
Salmonella phage 
SEN22 
3.00E-23 100% YP_009191477.2 
Tetratricopeptide 
TPR_4 
49 36015 36299 - 
phage-related 
protein 
Escherichia phage 
TL-2011a 
2.00E-62 99% AEW24508.1 
Uncharacterized 
protein 
50 36292 36576 - 
hypothetical 
protein 
ECRS218_0060 
Enterobacteria 
phage CUS-3 
2.00E-61 96% ABQ88440.1 
Uncharacterized 
protein 
51 36576 37367 - ORF8 
Enterobacteria 
phage ST104 
0 100% YP_006364.1 
Uncharacterized 
protein 
52 37437 37946 - ORF9 
Enterobacteria 
phage ST104 
1.00E-121 100% YP_006365.1 
Eae protein 
53 37943 38113 - ORF10 
Enterobacteria 
phage ST104 
1.00E-35 100% YP_006366.1 
Uncharacterized 
protein 
54 38124 38417 - Abc2 
Enterobacteria 
phage ST104 
4.00E-66 100% YP_006367.1 
Anti-RecBCD 
protein 2 
55 38464 38748 - Abc1 
Salmonella virus 
P22 
8.00E-64 99% NP_059595.1 
Anti-RecBCD 
protein 1 
56 38748 39455 - Erf 
Salmonella phage 
vB_SemP_Emek 
2.00E-173 99% YP_006560590.1 
Erf 
57 39452 39595 - Arf protein 
Salmonella phage 
vB_SosS_Oslo 
5.00E-25 96% YP_006560849.1 
Arf 
58 39585 39773 - Kil 
Enterobacteria 
phage ST104 
6.00E-41 100% YP_006370.1 
Kil 
59 39997 40311 - protein gp17 Enterobacteria 1.00E-64 94% AAD04642.1 Superinfection 
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phage H-19B exclusion protein 
60 40462 40587 - 
Enterobacter 
protein of 
unknown function 
Salmonella phage 
c341 
7.00E-21 100% YP_003090253.1 
Uncharacterized 
protein 
61 40587 40874 - ORF18 
Enterobacteria 
phage ST104 
2.00E-66 100% YP_006373.1 
Uncharacterized 
protein 
62 40908 41264 - Orf-232 
Salmonella phage 
ST64T 
4.00E-73 94% AAL15494.1 
Uncharacterized 
protein 
 
 
 
 
 
 
 
